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Abstract 
 
Background 
Transient cerebral microemboli detected by transcranial Doppler (TCD) have been demonstrated to be a 
reliable biomarker for short term stroke risk in two clinical settings; patients with carotid artery stenosis 
and those following carotid endarterectomy. Suppressing cerebral microemboli using TCD-directed anti-
platelet treatment reduces risk of recurrent stroke. The association between classical cardiovascular risk 
factors and cerebral microemboli has not been studied. Furthermore, standard TCD method to detect 
cerebral microemboli is limited by lack of acoustic temporal bone window which is not available in 
approximately 1 in 7 patients. TCD is the only real-time imaging modality for detecting microemboli. The 
demonstration of the kinetic of the microemboli is invaluable in assessing the efficacy of antiplatelet agents. 
 
Hypotheses 
1. Whether Pocock cardiovascular risk score and ABCD2 risk score are able to predict the presence of 
cerebral microemboli. 
2. The feasibility of using transorbital Doppler as an alternative to transcranial Doppler. 
3. The effectiveness of Tirofiban in suppressing cerebral microemboli. 
 
Methods 
1. Pocock score was assessed for the newly developed Carotid Surgery Registry of 670 patients 
managed between January 2002 and December 2012. 
2. ABCD2 score was determined in 206 patients with hyper-acute symptomatic critical carotid artery 
stenosis in which 102 of these patients were from Registry. A further 104 consecutive patients 
were recruited between February 2011 and May 2013 within a new prospective observational 
study.  
3. The feasibility of using transorbital Doppler was assessed based on the Registry data. Further new 
prospective validation study of transorbital Doppler against standard TCD method involving 100 
consecutive patients undergoing elective carotid endarterectomies were undertaken. 
4. From the Registry, patients who had microembolic signals acutely following carotid surgery were 
assessed to evaluate the effectiveness of Tirofiban in suppressing microemboli. 
 
Findings 
1. A high Pocock score (≥ 0.8%) predicts presence of cerebral microemboli acutely following carotid 
endarterectomy (Area Under Curve (AUC) 0.582 95% CI 0.507 – 0.658, P = 0.038). It also showed a 
high sensitivity for the presence of microemboli in patients with hyper-acute symptomatic carotid 
artery disease.  
2. The ABCD2 score did not predict presence of cerebral microemboli ((AUC 0.49 95% CI 0.41 – 0.57, P 
= 0.860), or carotid disease in over one-quarter of patients with symptomatic critical carotid artery 
stenosis.  
3. Transorbital Doppler imaging appears a valid alternative to transcranial Doppler for detecting 
microembolic signals in patients with no suitable temporal acoustic window (sensitivity 80 %, 
specificity 86 %. Bland and Altman analysis revealed no significant bias [bias 0.11 microemboli 
(95% CI: -0.52 to 0.74), P = 0.81]).  
4. Tirofiban has been shown to be more effective in treating microemboli in comparison to other 
most commonly used antithrombotic agents. The time for complete microemboli resolution 
(Tirofiban 68 minutes (53-94); dextran 113 (79-146); or in controls 53(49-68); P<0.001, KW) were 
shorter with tirofiban. 
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Introduction 
 
The risk of recurrent stroke following first transient ischaemic attack (TIA) or minor stroke is 
highest during the first 7 – 14 days1. Atherosclerotic carotid artery disease, whether symptomatic 
or asymptomatic is a major contributor to recurrent stroke. Thromboembolism is the primary 
mechanism of recurrent stroke in carotid artery disease. Transcranial Doppler detected 
microemboli have been shown as a reliable short term stroke risk biomarker in acute carotid 
syndrome. The context of my thesis is the clinical prediction, detection and suppression of 
transcranial Doppler detection of microemboli in symptomatic critical carotid artery disease 
patients. Transient cerebral microemboli associated with carotid disease detected by transcranial 
Doppler commonly occurred in 2 clinical settings which comprised the research cohorts in my 
thesis: 
1- Hyper-acute symptomatic critical carotid artery stenosis patients – defined as patients 
who presented with acute symptoms of stroke or transient ischaemic attack with 
evidence of carotid stenosis within 2 weeks of the index symptoms2. 
2-  Patients who underwent carotid endarterectomy. 
Background chapters cover an overview of symptomatic carotid atherosclerosis artery disease 
which includes the mechanism, cardiovascular risk factors, ABCD2 risk score, principles of carotid 
duplex and carotid endarterectomy. The association between cardiovascular risk factors, ABCD2 
risk score and carotid artery disease were reviewed.  This will be followed by detailed description 
of the establishment of microemboli detected by transcranial Doppler as the short term stroke 
risk in carotid artery disease patients and post carotid endarterectomy patients. In this thesis, the 
terms ‘microembolic signals’ detected by the transcranial Doppler and ‘microemboli’ were used 
interchangeably. 
The process of establishing the carotid Registry and prospective observational studies was 
described in the methods section. The process of data collection was explained in great detail. The 
same data definitions were used for the Registry and the prospective observational studies. The 
15 
 
technical aspects of transcranial Doppler and carotid endarterectomy were also described in the 
chapter. 
The results chapters were divided within the context of Registry, hyper-acute prospective 
observational study of minor stroke/TIA, transorbital imaging and antiplatelet treatment. The 
analysis of association between Pocock risk score, ABCD2 risk score and microemboli were 
covered in Registry, hyper-acute prospective observational study of minor stroke/TIA. Transorbital 
imaging explained the development of transorbital Doppler in detecting microemboli and the 
antiplatelet treatment chapter covers the relevance of tirofiban as the treatment of choice for 
microemboli. 
The thesis concludes with an overall discussion of the presented data in the context of other 
studies and an outlook for future studies.  
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CHAPTER ONE 
 
1 Background 
 
1.1 Symptomatic Carotid Artery Disease 
1.1.1 Risk and mechanism of recurrence stroke 
Stroke is the third leading cause of death in developed countries and a leading cause of long term 
disability3.  It is also the most frequent neurological diagnosis that requires hospitalisation4. Data 
from Northern America showed that approximately 88% of all strokes are ischaemic, 9% are 
intracerebral haemorrhages and 3% are subarachnoid haemorrhages5-7. It has been estimated 
that approximately 20% of all ischaemic strokes are preceded by transient ischaemic attack or 
minor ischaemic stroke8. Approximately 46 000 people in the UK each year have first transient 
ischaemic attacks (TIA)9. The risk of recurrent stroke following first TIA or minor stroke is highest 
during the first 7 – 14 days1. It has been estimated that risk of recurrent ischaemic stroke was 
8.0% (95% CI 2.3% to 13.7%) at seven days, 11.5% (95% CI 4.8% to 18.2%) at one month, and 
17.3% (95% CI 9.3% to 25.3%) at three months after a TIA or minor stroke10.  
Extra-cranial cerebrovascular disorders affect the carotid and vertebral arteries which supply the 
cerebral tissue and is an important cause of stroke and TIA. The major cause of carotid artery 
stenosis results from atherosclerotic disease. However, other causes include dissection, arteritis, 
cystic medial necrosis, trauma, radiation and fibromuscular dysplasia. Atherosclerosis is a 
systemic disease and develops insidiously over a period of time. Stroke is unsurprisingly, the first 
clinical manifestation of symptomatic carotid artery disease. Symptomatic carotid artery disease 
patients are typically at high risk of developing other cardiovascular adverse events such as 
stroke, myocardial infarction and complications related to peripheral artery disease11. The 
pathophysiology of atherosclerosis in the carotid artery is similar to the atherosclerosis that 
affects other artery beds. The process starts with the initiation of the lipoprotein accumulation in 
the intima layer of the artery. This is followed by the oxidative and inflammatory processes12 
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aided by cytokines. This causes the migration of monocytes to the intimal area and release of 
additional cytokines, oxidants and matrix metalloproteinases which is then followed by the 
accumulation of lipid-laden macrophages and migration of smooth muscle from the media to the 
intima. Extracellular lipid then accumulates in the central core surrounded by a fibrous cap which 
is a layer of connective tissue. Some of these advanced plaques will be calcified and continue to 
grow causing carotid stenosis. These plaques often develop at the flow divider where there is 
turbulence and low shear stress such as at the carotid bifurcation area. Previous experimental 
study demonstrated that the carotid plaque is consistently found along the outer wall of the 
internal carotid artery, opposite the flow divider, which corresponds to an area of low shear 
stress13. Plaque disruption and the formation of subsequent thrombosis worsens the narrowing of 
the arterial lumen causing further stenosis or an acute occlusion which lead to the clinical events. 
This mechanism is similar to those proposed for the coronary arteries14. 
Atherosclerotic carotid artery stenosis is the most common underlying cause in patients who have 
had an earlier TIA15. The Cardiovascular Health Study evaluated the prevalence of extracranial 
carotid atherosclerosis assessed by carotid Duplex in men and women aged ≥ 65 years16. Overall, 
detectable carotid stenosis was present in 75% of men and 62% of women16. They also found that 
7% of men and 5% of women had 50%-74% carotid stenosis and severe stenosis (>74%) was 
detected in 2.3% of men and 1.1% of women16. The findings are similar to the more recent 
Framingham Heart Study population which showed that the prevalence of >50% carotid stenosis 
was 7% in women and 9% in men ranging in age from 65 onwards17. Olin et al18 reviewed the 
natural history and progression of 465 patients with asymptomatic moderate carotid artery 
stenosis (60% – 79%). They reported that the incidence of ipsilateral stroke were higher in cohort 
of patients who demonstrated a progression of carotid stenosis than those who did not progress 
(12.5% vs. 3.1%). A similar study by Rockman et al19 also demonstrated that, in moderate 
stenosed carotid artery the occurrence of ipsilateral stroke is patients with increasing stenosed 
carotid lesion than static carotid lesion. More recent study by Nicolaides et al20 reported that 
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those patients who demonstrated progressively increasing carotid stenosis were at twice the risk 
of ipsilateral stroke compared with those without stenosis progression. 
Currently, clinically significant carotid artery stenosis contributed up to 20% of all ischaemic in 
comparison with other subgroups such as cardioembolic and small vessel stroke15, 21, 22. In carotid 
disease, the main mechanisms of ischaemic stroke and TIA may be attributed to several 
mechanisms such as thromboembolism originating from the unstable atherosclerotic plaque, 
embolism of cholesterol crystals or other atheromatous debris, acute thrombotic occlusion of the 
carotid resulting from plaque rupture, disintegration of the arterial wall following dissection or 
subintimal haematoma and reduced cerebral perfusion secondary to reduce blood flow. Caplan et 
al further suggested that the reduced blood flow at sites of narrowed arteries promotes 
formation of thrombi and thus increases the quantity of arterial thromboemboli23. 
In recent years, emphasis has dramatically changed to embolism as the predominant mechanism 
of brain infraction23. In carotid disease, thromboembolism is the predominant mechanism of 
recurrent stroke and was first established by Miller Fisher in the 1950s24, 25. Subsequently, further 
evidence supporting thromboembolism as the predominant mechanism emerged from different 
clinical sources. Microthromboemboli are often found at autopsy within an acute brain infarct26. 
Post-mortem and radiological studies have shown that thromboembolism appears to be the main 
mechanism of middle cerebral artery territory infarction in patients with carotid artery disease27, 
28. Diffusion-weighted magnetic resonance imaging based studies29, 30 have demonstrated that 
carotid artery originated microemboli cause the development of an ischaemic area in the deep 
layers of the cortex in the distribution of the middle cerebral artery. Direct evidence for the role 
of embolisation has been provided by transcranial Doppler detection of circulating microemboli. 
Transcranial Doppler ultrasound studies show that the presence of microemboli in symptomatic 
carotid artery disease is associated with increased risk of stroke31-33. These cerebral microemboli 
predict risk of future ischemic stroke events in patients with symptomatic or asymptomatic 
carotid stenosis, after controlling for other cardiovascular risk factors, degree of stenosis, 
symptoms, and use of aspirin or anticoagulant34. They can be used reliably as a biomarker of short 
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term stroke risk both following acute symptomatic carotid artery stenosis and carotid 
endarterectomy35, 36. Randomised controlled trial have shown that antiplatelet treatment, which 
suppresses microemboli, also reduces stroke risk37 in carotid artery disease patients.  
The severity of the stenotic lesion of the carotid artery remains the major prognostic factor in 
symptomatic patients38 that indicates the likelihood of future development of ischaemic stroke 
and therefore influences the decision regarding carotid revascularisation. Other potential markers 
of carotid plaque vulnerability and its stroke risk association have been explored. The 
Framingham Heart Study showed fewer than half of the stroke events which affected the cerebral 
hemisphere ipsilateral to the bruit and carotid stenosis6. Whilst carotid bruit is clearly an indicator 
of increased stroke risk and a general sign of advanced atherosclerotic disease, it is not 
necessarily an indicator of carotid stenosis preceding cerebral infarction. Carotid plaque 
vulnerability characteristics such as ulceration, echolucency, intraplaque haemorrhage and high 
lipid content, and its association with stroke risk in symptomatic patients, has been studied39, 40. 
Park et al41 evaluated the correlation between carotid plaque characteristics and patients 
presenting symptoms by examining carotid plaque intraoperatively during carotid surgery. Plaque 
ulceration correlated with symptomatic carotid stenosis compared with patients operated on for 
asymptomatic disease41. The presence of intraplaque haemorrhage was associated with more 
advanced stenosis of the internal carotid artery. Further histological analysis by Fisher et al 
demonstrated that microscopic morphology of plaque ulceration is more common in symptomatic 
patients regardless of the side of carotid symptoms, whereas thrombus is associated with 
ipsilateral symptoms and plaque ulceration40. Contrast-enhanced magnetic resonance imaging 
and computed tomography has been used to study the characteristics of unstable carotid plaque. 
Preliminary data demonstrated an association between fibrous caps, intraplaque haemorrhage, 
lipid rich or necrotic core with stroke risk of asymptomatic patients with more than 50% carotid 
stenosis42. The development of carotid plaque in symptomatic patients has been associated with 
an inflammatory process14. The increased uptake of 18F-fluorodeoxyglucose, demonstrated by 
positron emission tomography (PET) imaging is believed to reflect the inflammation process43. 
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Biomarkers indicating carotid plaque instability such as C-reactive protein44 have also been 
investigated. In a small cohort of patients, Alvarez et al45 found that metalloproteinase-2 and 
metalloproteinases-9 was associated with carotid plaque instability with higher serum levels in 
symptomatic carotid patients than asymptomatic patients. The reliability of these biomarkers to 
predict high risk symptomatic carotid patients has not been established. 
Despite extensive research studies on other modalities to predict carotid plaque instability, the 
degree of stenosis defined by ultrasound Duplex remains the main determinant of disease 
severity and the basis for clinical decision making. The higher degree of stenosis reflects the 
greater volume of carotid which may embolise, causing thrombotic ischaemic stroke46. Data from 
North American Symptomatic Carotid Endarterectomy Trial (NASCET)47 and the European Carotid 
Surgery Trial (ECST)38 have confirmed that plaque size and degree of lumen obstruction represent 
an important risk of stroke associated with carotid artery stenosis. Furthermore, Streifler et al48 
and Norris et al49, 50 found increasing cumulative rates of TIA or stroke in relation to increasing 
degree of arterial stenosis, and the incidence of ischaemic events also correlated with progression 
of stenosis. The pooled analysis of the major randomized carotid endarterectomy (CEA) trials 
showed that a stenosis exceeding 70 % was detected in 21 % of patients who experienced TIA or 
stroke, and a moderate stenosis (50 - 69%) in 25 % of patients51. The prevalence rates of clinically 
significant carotid artery stenosis in populations above 65 years of age have been 5-7 % in women 
and 7-9 % in men, and for the age group of 70 years or more, the prevalence rates were 12.5 % 
for men and 6.9 % for women16, 17, 52.  
Symptomatic carotid artery disease has a high recurrent risk of stroke and this cohort of patient 
would achieve maximum benefit from carotid revascularisation within 2 weeks after the last 
cerebrovascular symptoms53. Therefore, guidelines recommend that CEA should be performed 
within a time frame of 2 weeks54.  
Table 1 below shows the summaries of the evidence of recurrent stroke rate within 14 days 
following recent symptomatic critical carotid artery stenosis (≥ 50% lumen narrowing) for the last 
10 years. As an example, I performed a literature search which only included prospective studies 
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focussing only on symptomatic haemodynamically significant ≥ 50% carotid stenosis. Stroke 
recurrence was defined as new developing focal neurological deficit lasting > 24 hour following 
the initial TIA or minor stroke. 
 
Table 1 Risk of recurrent stroke in symptomatic carotid disease  
Year Authors Research 
Method 
No. of patient Risk of recurrent stroke 
rate within 14 days 
2013 Al-Khaled et al55 Registry 597 5% 
2013 Johansson et al56 Prospective 230 11.2% 
2011 Marnane et al57 Prospective 36 8.3% 
2009 Ois A et al58 Prospective 163 25% 
2006 Kastrup A et al Prospective 131 12% 
2005 Fairhead JF et al59 Registry 120 21% 
 
A population-based study59 focusing on patients with symptomatic carotid artery stenosis (≥ 50%) 
reported the risk of stroke prior to carotid endarterectomy was 21% at 2 weeks and 32% at 12 
weeks, in half of which strokes were disabling or fatal. A more recent study showed that patients 
presenting with symptomatic carotid artery stenosis (≥ 50%) incurred a 17% risk of recurrent 
stroke at 72 hour, 22% at 7 days and 25% at 14 days58. Johansson et al found that despite being 
on optimal best medical therapy, the recurrent stroke risk in this cohort was high ~ 11% within 14 
days of the last cerebrovascular symptoms. 
Transcranial Doppler detected microemboli has provided direct evidence of thromboembolism as 
the main mechanism of carotid disease. Cerebral microemboli has also been established as a 
surrogate biomarker for short term stroke risk60. In my thesis, I attempted to clinically predict the 
presence of microemboli. This in turn could potentially be used as a clinical tool to identify 
cerebral microemboli in 2 clinical: following acute symptomatic carotid artery disease patients 
and acutely post carotid endarterectomy. 
 
1.1.2 Cardiovascular risk factors in carotid disease 
Patients with symptomatic atherosclerotic carotid disease typically have clusters of classical 
cardiovascular risk factors61. Patients with carotid artery disease frequently have atherosclerosis 
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in other arterial beds such as aorta, coronary and peripheral areas62. Several classical and non-
classical cardiovascular risk factors have been associated with the development and severity of 
carotid atherosclerotic disease63. Recognition of these systemic risk factors is important because 
the long term management of symptomatic carotid disease is the control of these cardiovascular 
risk factors. 
Population-based studies have consistently demonstrated that increasing age and male gender 
remain the main risk factors for carotid artery disease16, 64-66; even with advancing age, carotid 
artery disease is more common in males than females64. In a large population study, Joakimsen et 
al showed that until the age of 50 years, a higher proportion of males have carotid artery disease 
and thereafter it declines so that the prevalence of atherosclerosis is similar in elderly men and 
women67. This suggests that events related to the menopause may promote the development of 
atherosclerosis in elderly women. 
Both active and passive smoking are associated with the severity of carotid artery stenosis68. 
Smoking has also been identified as a strong predictor of atherosclerosis in men65 and elderly 
women64. The Framingham study demonstrated the development of carotid artery stenosis with 
the quantity of cigarettes smoked over time69. Increased exposure to smoking is significantly 
related to increased carotid artery intima media thickness and carotid artery stenosis70-72. The 
associations included thicker walls and higher degrees of stenosis from never-smokers to former 
smokers to current smokers71. Tell et al71 found smaller degrees of carotid wall thickening in 
former smokers than current smokers. This may suggest that smoking cessation slows the 
progression of the atherosclerosis.  
Epidemiology studies have established an association between hypertension and the 
development of carotid artery disease69, 73. Su et al demonstrated that hypertensive patients are 
five times more likely to develop critical artery stenoses in comparison to the normotensive 
cohort74. Whilst systolic hypertension has been closely associated with the severity of carotid 
artery disease in population-based studies64, 65, diastolic blood pressure has a weak association 
with the severity of carotid disease16. In the Systolic Hypertension in the Elderly Program study75, 
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systolic blood pressure of > or = 160 mmHg was the strongest predictor of carotid stenosis. In the 
longitudinal Framingham Heart Study69, a twice greater risk of developing carotid artery stenosis 
was demonstrated with each increase of 20 mmHg in systolic blood pressure (odds ratio 2.11 
(95% CI 1.51 - 2.97). Atherosclerosis may lead to arterial rigidity and cause a rise in systolic blood 
pressure. The strongly positive association between high systolic pressure and the development 
of carotid stenosis is a reminder of the importance of systolic pressure in determining the risk of 
cardiovascular disease. 
The prevalence of critical carotid stenosis has been reported in up to 33% of patients in different 
high risk groups investigated for either ischaemic heart disease or peripheral arterial disease76-78. 
Patients with carotid artery disease have been shown to be at an increased risk of myocardial 
infarction and death related to ischaemic heart disease11. Many of them face a greater risk of 
death from myocardial infarction than stroke11. An autopsy study demonstrated that the 
prevalence of coronary atherosclerosis and myocardial infarction (MI) was significantly higher in 
patients with stroke than patients with other neurologic diseases79. The prevalence of coronary 
plaques, coronary stenosis, and MI was 79.0%, 42.9%, and 46.0%, respectively, in the presence of 
plaques in any segment of the extracranial and intracranial brain arteries, and 50.8%, 17.9%, and 
23.9%, respectively, in the absence of plaques79. This showed that in stroke patients, the mortality 
related to the ischaemic heart disease is more frequent when atherosclerosis is present in the 
carotid and cerebral arteries. 
The presence of diabetes mellitus increases the risk of atherosclerosis and its complications such 
as carotid artery disease66, 80. The Cardiovascular Health study reported that diabetes was 
associated with the development of increasing carotid intima-media thickness and the severity of 
carotid artery stenosis16. The Insulin Resistance Atherosclerosis Study (IRAS), an observational 
cohort study,81 demonstrated that diabetes and high level of fasting glucose were associated with 
two fold higher progression of carotid artery disease than in non-diabetic patients. The Rotterdam 
study82 demonstrated that diabetes predicted progression to severe carotid artery obstruction. 
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Some studies have found an independent association between hypercholesterolaemia and carotid 
atherosclerosis66. For 34 years, the Framingham study69 observed the surviving members of 
participants of the original cohort of the Framingham Heart Study who had carotid ultrasound 
performed. These long term serial observations were thought to be better than a single 
contemporaneous measurement. They demonstrated that the risk ratio of carotid artery stenosis 
> 25% development was approximately 1.1 for every 10 mg/dL increase in total cholesterol69. The 
Multi-Ethnic Study of Atherosclerosis (MESA) cohort study showed that carotid plaque lipid core 
detected by MRI scan was strongly associated with total cholesterol level83. 
Carotid artery intima-media thickness has been shown to be a marker of systemic 
atherosclerosis11 and is associated with cardiovascular risk factors. The measurement is obtained 
by an ultrasonographic technique. A positive association between carotid-artery intima–media 
thickness and the incidence of new myocardial infarction and stroke in adults 65 years of age or 
older who did not have a history of cardiovascular disease has been reported84. However, the use 
of carotid artery intima-media thickness to assess atherosclerotic risks has not yet become 
routine or part of the carotid artery disease assessment. Recent evidence suggests a prominent 
genetic influence for the presence of carotid artery disease85-87. Hunt et al found a statistically 
significant heritability for focal carotid artery plaque that may represent advanced stage of 
atherosclerosis after accounting for age and sex effects86. Systemic inflammation has been 
associated with atherosclerosis plaque formation and stroke risk88,89. Recently, there is an 
emerging interest in the diagnostic potential of biological markers of inflammation and 
thrombosis and their association with the presence and severity of atherosclerotic disease. A 
previous cross-sectional study by Selhub et al90 showed high plasma homocysteine concentrations 
and low concentrations of folate and vitamin B6, through their role in homocysteine metabolism, 
are associated with an increased risk of extracranial carotid artery stenosis. The Rotterdam 
study91 found that while C-reactive protein showed increased level in patient with carotid artery 
disease, the results were less consistent with inflammatory mediators compared with Interleukin-
6 and soluble intracellular cell adhesion molecules such as sICAM-1. 
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Symptomatic atherosclerosis carotid disease patients typically present with clusters of systemic 
cardiovascular risk factors, hence the long term management of these patients relies on the 
control of all the cardiovascular risk factors. A number of composite risk scores have been 
developed to estimate the risk of patients developing cardiovascular disease, based on the 
presence of cardiovascular risk factors and established clinical vascular disease. The estimated 
cardiovascular disease (CVD) risk score has been widely advocated92 as a tool to introduce medical 
intervention on patients such as prescribing antiplatelet, antihypertensive and lipid lowering 
agents. The reasons for estimating total cardiovascular disease risk based on the major risk factors 
are93 : atherosclerotic disease is multifactorial and systemic in origin; risk factors tend to cluster; 
and co-existent risk factors tend to increase the risk even further and therefore it is important to 
take into account all the risk factors. 
The three most commonly used cardiovascular risk scores in the UK are the Framingham risk 
score, the Joint British societies risk score and the ASSessing cardiovascular risk using SIGN 
(ASSIGN) score. The Framingham risk score was the first composite cardiovascular risk score, 
which was initially developed to estimate the 10-year risk of developing coronary heart disease 
based on the Framingham Heart Study94. It was subsequently updated to predict the 10-year 
cardiovascular disease (CVD) risk95, which included the combined end point of coronary heart 
disease (fatal and non-fatal myocardial infarction and new angina) plus stroke (fatal and non-fatal 
stroke and cerebral haemorrhage) and transient cerebral ischaemia. The risk calculation algorithm 
used sex, age, systolic blood pressure, total cholesterol, HDL cholesterol, smoking status and 
presence of left ventricular hypertrophy as the equation variables. The risk score is an integer, 
which adds points for each cardiovascular risk factor. The score is sex-specific and the calculated 
points are categorised to the probability (expressed as percent chance) of developing CVD in 10 
years. A risk score of more than 18, which is equivalent to 20% risk of developing CVD, is 
considered as high risk. However, a UK based multicentre cohort study has shown that the 
Framingham risk score significantly overestimates the risk assigned to individuals in the United 
Kingdom96.  
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The Joint British Societies’ Guidelines on Prevention of Cardiovascular Disease in Clinical Practice 
(JBS 2)93 has been recommended for use in the UK population. It is an update from the previous 
version which only assessed the risk of coronary heart disease93. It was developed by the British 
Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care 
Cardiovascular Society, and The Stroke Association. It is recommended as a screening tool for all 
adults from 40 years onwards, who have no history of CVD or diabetes, and who are not already 
on treatment for blood pressure or lipids. It uses the same risk calculation algorithm principles as 
the Framingham risk score, and a risk score resulting in 20% risk of developing CVD is considered 
as high risk and requires medical and lifestyle interventions. The ASSessing cardiovascular risk 
using SIGN (ASSIGN) score was developed in Scotland97 to include the effect on cardiovascular risk 
of social deprivation. Studies from Scotland observed that classic cardiovascular risk factors 
inadequately explain social variation in disease and suggested that the Framingham risk score 
assigned preventive treatment that might lead to relative under-treatment of the socially 
deprived population98. The ASSIGN score is an evolution of the Framingham score, by 
incorporating social deprivation and family history and suitable for the Scotland population. It also 
used a 20% cut off to be considered as high risk. The Framingham, JBS 2 and ASSIGN risk scores 
were designed for healthy individuals at risk of developing symptomatic atherosclerotic disease93, 
95, 97. Therefore, these risk scores are meant to help the decision making on initiation of the long 
term medical therapy in the context of CVD prevention in asymptomatic patients. 
The Pocock score was developed to predict the 5-year risk of death from cardiovascular disease in 
a population with established cardiovascular risk factors. The score was derived from 47088 
participants of 8 randomised controlled trials of antihypertensive treatment99. The risk score is an 
integer, with points added for each cardiovascular risk factor. The risk score was developed based 
on age, sex, systolic blood pressure, serum total cholesterol, height, creatinine, smoking, diabetes, 
left ventricular hypertrophy, history of stroke and history of myocardial infarction99. The Pocock 
score has the advantage of including weightings for the presence of clinical vascular disease. The 
5-year risk of death from cardiovascular disease for scores of 10, 20, 30, 40, 50, and 60 was 0.1%, 
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0.3%, 0.8%, 2.3%, 6.1%, and 15.6% respectively99. The risk score was based on the large cohort of 
randomised controlled trials in different countries with reliable follow up. Therefore, the risk 
estimates are more precise than the other risk scores99. It is therefore a suitable CVD risk score 
with which to assess the cardiovascular risk factor burden of symptomatic carotid artery disease 
patients. 
While recent evidence showed some promising approaches beyond the presence of classical 
cardiovascular risk factors in predicting risk of CVD, the clinical application of these approaches 
remains within research realms. Clinically, classical cardiovascular risk factors remain the only 
practical clinical tool to identify high risk carotid artery disease. There is no current evidence on 
whether composite cardiovascular risk scores are associated with the presence of microemboli. In 
this thesis, I attempted to evaluate individual cardiovascular risk factor and also the composite 
Pocock cardiovascular risk score to predict the presence of transcranial Doppler detected 
microemboli in symptomatic carotid artery stenosis patients. 
 
1.1.3 ABCD2 risk score in carotid disease 
The ABCD2 (an updated version of ABCD risk score100) risk prognostic scoring system 101 predicts 
who is likely to be at increased risk of suffering a recurrent early stroke following onset of the 
initial TIA101, irrespective of the mechanism for TIA. The ABCD2 stroke risk score101 supports 
triaging of the priority with which patients with TIA or minor stroke are assessed. The ABCD2 risk 
score uses clinical features and standard CVD risk factors such as history of diabetes, and blood 
pressure to determine a patient’s short term risk of stroke. The ABCD2 score ranges from 0 – 7101. 
Age ≥60 years scores 1 point; blood pressure ≥140/90 mmHg scores 1 point; clinical features of 
arm/leg weakness scores 2 points, while speech disturbance scores 1 point; duration of symptoms 
score 2 points for ≥60 minutes and 1 point for 10-50 minutes; diabetes scores 1 point. An ABCD2 
risk score ≥ 4 predicts a 90-day stroke risk between 8% and 22%; ABCD2 risk score <4 predicts a 
90-day stroke risk of <3%101.   
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The score was derived from prospective population-based studies of TIA with a high level of 
ascertainment and detailed assessment by neurologists100. It was designed to allow primary care 
clinicians, emergency department physicians and specialist physicians to triage patients suffering 
a suspected TIA or minor stroke, according to their predicted risk of suffering recurrent stroke101. 
Since the initial publication, the ABCD2 risk score has been independently validated and has 
performed well in different clinical settings102. The strengths of the ABCD2 risk score includes 
external generalisability and simplicity of the application for primary care physicians and 
specialists. The ABCD2 risk score has now been recommended for triaging patients with suspected 
TIA/minor stroke by several major clinical guidelines103-105. The National Institute for Health and 
Care Excellence (NICE) guidelines103 recommends that patients with an ABCD2 risk score ≥4 should 
be assessed within 24 hours and those with an ABCD2 risk score <4  should be evaluated within a 
week of the onset of symptoms.  
There was concern that an ABCD2 risk score <4 may miss high risk TIA patients106-109. Data from the 
SOS – TIA registry, which was based on a specialist neurology clinic which provided round-the-
clock access (24 hours), which showed an ABCD2 risk score <4 missed 1 in 5 TIA patients who were 
at a very high risk of recurrence stroke106. These included patients with symptomatic critical artery 
stenosis, atrial fibrillation, cardiac source of embolism and symptomatic intracranial artery 
disease. Amarenco et al recently demonstrated that in a high risk TIA cohort, ABCD2 risk score <4 
had a 90-day stroke risk similar to patients with ABCD2 risk score ≥4, and recommended that 
additional investigations such as carotid ultrasound and electrocardiogram should be performed 
immediately, regardless of the ABCD2 risk score106, 107. 
Currently, the association between ABCD2 risk score and severity of structural carotid artery 
disease is unclear. This is an important issue to clarify as Ois et al58 reported that patients 
presenting with symptomatic critical carotid artery stenosis incur a 17% risk of recurrent stroke at 
72 hours, increasing to 22% at 7 days58. These patients are reported to benefit from carotid 
endarterectomy within 2 weeks53.  
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Based on the same population studies that were used to derive the ABCD2 risk score, Rothwell et 
al110 reported that ABCD2 risk scores appeared to be able to identify patients with ≥50% carotid 
stenosis requiring carotid endarterectomy or atrial fibrillation, which made them at high risk of 
recurrent stroke. Sheehan et al111 also suggested that high ABCD2 risk score may identify patients 
with significant carotid artery disease. This should be expected as many important elements of 
the score such as age, hypertension and diabetes are independent risk factors for carotid 
stenosis16, 66, 74. Weakness and speech disturbance are also related to the distribution of middle 
cerebral artery, which is the main branch of the internal carotid artery. 
Amarenco et al106 reported that an ABCD2 risk score <4 would miss 9% (62/679) of patients with 
symptomatic critical carotid artery stenosis. Walker et al112 found that the ABCD2 risk score was 
not predictive of patients with symptomatic carotid stenosis requiring urgent carotid 
endarterectomy. Schrock et al113 evaluated the ability of the ABCD2 risk score to predict positive 
diagnostic test results in patients being acutely evaluated for TIA. They found that, even though 
an ABCD2 risk score ≥4 was associated with an increased likelihood of carotid stenosis, 15% of 
patients with significant carotid artery stenosis would have been missed113. 
As both ABCD2 risk score and cerebral microemboli predict short term stroke risk, I attempted to 
explore whether the ABCD2 risk score predicted the likelihood of finding spontaneous cerebral 
microemboli using the data from the newly developed Carotid Registry and the hyper-acute 
TIA/minor stroke study. 
 
1.1.4 Carotid duplex ultrasound – Measuring carotid stenosis 
Conventional intra-arterial angiography has been established as the gold-standard for diagnosing 
and measuring carotid stenosis and was reference standard against which the non-invasive 
imaging studies have been compared. Both the North American Symptomatic Carotid 
Endarterectomy Trial (NASCET)47 and the European Carotid Surgery Trial (ECST)38 used intra-
arterial angiography at the baseline. However, intra-arterial angiography has been associated with 
1% - 2% procedure related neurological complications114. Stroke remains the most feared 
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complication and the periprocedural incidence is <1%, even in the hands of experienced 
radiologists115. While angiography is not the first line of imaging to evaluate carotid stenosis, it is 
increasingly used for planning the feasibility of deployment of a carotid stent. 
Carotid duplex ultrasound modalities combines 2-dimensional real-time imaging (B-mode) with 
Doppler waveform analysis in order to evaluate the anatomy of the artery and to assess blood 
flow velocity. It has been evaluated and validated since the 1970s as a means of assessing carotid 
stenosis and identifying patients at risk of stroke116. Since then, it has replaced intra-arterial 
carotid angiography as the main imaging method for diagnosing carotid artery stenosis117, 118 in 
routine clinical practice. It has been shown that with a well-defined protocol, when the carotid 
duplex ultrasound technique is performed by experienced practitioners, the results obtained 
compare extremely well with intra-arterial angiography118. In comparison to angiography, the 
sensitivities and specificities of carotid duplex ultrasound for detecting stenosis from 50% up to 
near occlusion internal carotid artery stenosis ranging from 90 - 95%. Current trends show 
increased dependence on carotid duplex scanning in recommending patients 
for stroke prevention surgery. Carotid duplex scan was used in the landmark Asymptomatic 
Carotid Surgery Trial (ACST) at baseline119. 
There are three methods of measurement of carotid artery stenosis on angiography: North 
American Symptomatic Carotid Endarterectomy Trial (NASCET); European Carotid Surgery Trial 
(ECST); and Common Carotid (CC) methods (Figure 1). 
The NASCET method compared the diameter of the residual lumen of the stenosis to the diameter 
of the distal internal carotid artery. This method underestimates stenosis in near occlusions with 
collapse of the distal carotid artery. The ECST method compared the diameter of the stenosis to 
the estimation of the diameter of the carotid bulb at the level of stenosis. The ECST method 
typically leads to higher percentages of stenosis compared to the NASCET method, which could 
produce an underestimation of percentage and cannot be applied in cases of near-occlusion. The 
ECST and Common carotid methods had almost identical results. The common carotid method 
compared the residual luminal diameter within the stenosis against the diameter of a normal 
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segment of proximal common carotid artery. Despite being easy to use, consistently the most 
reproducible of the three methods (particularly for stenosis in the clinically important range of 
50% to 90%), and to have lower intra- and inter observer variability than the NASCET and ECST 
methods, is not commonly used120. 
Re – analysis of the ESCT trial data using the measurement used in the NASCET trial showed that a 
50% NASCET stenosis was equivalent to 70% ECST, while a 70% NASCET stenosis equated to an 
85% ECST121. In order to avoid confusion when grading carotid stenosis between centres, the 
Vascular Society and Society of Vascular Technology of Great Britain and Ireland118 recommended 
criteria based on the NASCET method of grading carotid bulb disease. 
 
Figure 1 Methods of measurement of carotid artery stenosis 
 
 
 
Carotid duplex ultrasound does not directly measure the stenosis of the artery; instead, increasing 
blood flow velocity is used as an indicator of increasing degrees of stenosis. Based on the early 
intra-arterial angiography studies122-125, angiographic estimates of the carotid stenosis were used 
A = narrowest point of ICA stenosis  
B = normal-width artery distal to ICA stenosis  
C = estimated original width at the narrowest point of stenosis     
D = normal CCA proximal to the bulb  
  
NASCET method: stenosis = (B-A)/B × 100 %   
ECST method:  stenosis = (C-A)/C × 100 % 
Common Carotid method = (D-A)/D x 100 %. 
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as reference standard to generate numerous carotid duplex ultrasound parameters to diagnose 
and measure carotid stenosis. Most laboratories rely on one or more of the three following 
measurements: Peak systolic velocity (PSV), End diastolic velocity (EDV), and ratio of the PSV in 
the internal carotid artery (ICA) to the ipsilateral distal common carotid artery (CCA) 
(PSVICA/PSVCCA). Duplex criteria for carotid stenosis evaluation were standardised in 1987 at the 
University of Washington126. Based on duplex criteria, the percentage of stenosis could be reliably 
predicted as 0-15%, 16-49%, 50-79%, 80-99% or complete occlusion. 
Table 2 shows the recent consensus of the ultrasound criteria for diagnosing carotid artery 
stenosis, which can be applied in most situations127, 128. 
 
Table 2 Society of Radiologist in Ultrasound Criteria for the diagnosis of internal carotid artery stenosis127 
Degree of 
Stenosis (%) 
Primary Parameters Additional Parameters 
ICA PSV (cm/s) Plaque estimate 
(%)a 
ICA/CCA Ratio ICA EDV (cm/s) 
Normal <125 None <2.0 <40 
<50 <125 <50 <2.0 <40 
50 – 69 125 – 230 ≥50 2.0 – 4.0 40 – 100 
≥70 but less 
than near 
occlusion 
230 ≥50 >4.0 >100 
Near occlusion low, or 
undetectable 
Visible Variable Variable 
Total occlusion Undetectable Visible, no 
detectable 
lumen 
Not applicable Not applicable 
a Plaque estimate (diameter reduction) with grey-scale and colour Doppler ultrasound 
 
The disadvantage of this velocity based estimation of carotid artery is in women where the blood 
flow velocities is higher than men and abnormally elevated blood flow velocities in the presence 
of contralateral carotid artery occlusion129, 130. Severe calcification, arterial tortuosity, high carotid 
bifurcation level and obesity may also reduce the accuracy of Duplex ultrasound. 
Even though duplex ultrasound shown to be accurate and reliable imaging for assessing degree of 
stenosis, it is not reliably sensitive to differentiate near occlusion and total occlusion of the 
diseased carotid artery. Differentiation between near occlusion and total occlusions is clinically 
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important. Patients with near occlusion remain at high risk for embolic stroke and are surgically 
treated, while those with an occluded ICA are at minimal risk for embolic phenomena and are 
treated medically for hypoperfusion. In both North American Symptomatic Carotid 
Endarterectomy Trial (NASCET)47 and the European Carotid Surgery Trial (ECST)38, these patients 
had low risk stroke on medical treatment. This is more likely to be due to the presence of a good 
circulation. The benefit from surgery in near occlusion based on NASCET data131 had been 
minimal. ECST data121 suggested no benefit of surgery in this group in terms of preventing stroke. 
Due to its lack of sensitivity of duplex ultrasound, Magnetic Resonance (MR) Angiography or 
Computed Tomography (CT) Angiography should be used to confirm its presence. 
CT angiography provides an alternative carotid artery disease imaging technique. It is the only 
imaging modality which provides direct imaging of the arterial lumen suitable for evaluation of 
stenosis132. It is less user dependant and has been shown to accurately detect large intracranial 
and extracranial arterial stenosis and occlusion132. It compared favourably with conventional 
intra-arterial angiography with agreement of 96% (95% CI, 90 to 99%) vessels. The sensitivity of 
CTA was 100%, with a specificity of 63% (95% CI, 25 to 88%), and 100% negative predictive value 
in patients with <70% carotid stenosis133. Even though it tends to underestimate arterial stenosis, 
it does provide multiple viewing angles and three-dimensional reconstruction that allows us to 
identify calcium deposits separately from vessel lumen134. The requirement of a large dose of 
iodinated intravenous contrast to outline the arterial lumen restricts its use in patients with 
inadequate renal function. 
MR angiography without contrast relies on the radiofrequency signal characteristics of flowing 
blood flow which amplify the relative signal intensity of flowing blood allowing more detailed 
evaluation of the arteries. It is a safe and non-invasive alternative for carotid stenosis imaging. 
However, it tends to have problems with flow voids at the point of stenosis and overestimates the 
degree of stenosis135. The image quality and reproducibility of measurement of stenosis are 
significantly improved with contrast-enhanced MR angiography135. Compared with intra-arterial 
angiography, the sensitivity of MRA ranges from 97% to 100%, while specificity ranges from 82% 
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to 96%136. The main disadvantages of MRA are overestimation of the stenosis and inability to 
discriminate between subtotal and complete arterial occlusion. The technique is also restricted in 
patients with metal devices and claustrophobia. 
Using from both published and unpublished research and audit studies in the United Kingdom, 
Chappell et al137 evaluated the accuracy of non-invasive imaging; duplex ultrasound, CT 
angiography, MR angiography and contrast-enhanced MR angiography against intra-arterial 
angiography as the reference standard. They found that contrast-enhanced MR angiography had 
the highest sensitivity and specificity for 70% - 99% carotid stenosis, followed closely by duplex 
ultrasound137 and data for CT angiography were particularly lacking for analysis. All the non-
invasive imaging modalities performed poorly for 50% - 69% carotid stenosis137. 
Every non-invasive vascular imaging modality has its limitations as to when it can be accurately 
and reliably used to measure carotid stenosis. With a well-defined protocol, duplex ultrasound is a 
reliable diagnostic tool that has an important role in the cost-effective diagnosis and grading of 
carotid disease118. It remains the most widely used imaging, both as a screening tool and as a 
stand-alone modality, to make a decision to proceed to surgery.  
 
1.1.5 Carotid endarterectomy for prevention of recurrent stroke 
The primary management of all carotid artery disease is aggressive medical therapy with 
cardiovascular risk factors modification. In symptomatic carotid artery stenosis, the effective 
management of stroke prevention includes best medical therapy and urgent carotid 
endarterectomy for those with a haemodynamically significant carotid stenosis ≥50%. Best 
medical therapy (BMT) utilises medications to optimise the control of cardiovascular risk factors 
that contribute to atheroma development, as well as antiplatelet therapy, to reduce 
thromboembolic risk. In carotid endarterectomy, the removal of the atherosclerotic lesion allows 
the correction of reduced blood flow and also eliminates the source of emboli. 
The benefit of urgent treatment of TIA/minor stroke aimed at preventing recurrent stroke has 
been demonstrated in the prospective, population-based SOS-TIA Study138 and the Early Use of 
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Existing Preventive Strategies for Stroke (EXPRESS)139 studies. In the EXPRESS study, urgent 
treatment of TIA and minor stroke was associated with a significant 80% reduction in the risk of 
early recurrent stroke compared with standard treatment in primary care139. Similar findings were 
demonstrated in the SOS-TIA study138 which was based in Paris. Following the initiation of 24-hour 
a day emergency TIA clinics in Paris, the prognosis of TIA or minor stroke patients has improved. 
The recurrence of stroke within 7 days and three months follow-up were 0.3% and 1.9% 
respectively138.   
There is increasing evidence that aggressive use of antiplatelet therapy is effective in preventing 
recurrent stroke. In MATCH (Management of ATherothrombosis with Clopidogrel in High-risk 
patients)140, CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid 
Stenosis)37 and FASTER (Fast assessment of stroke and transient ischaemic attack to prevent early 
recurrence)141 randomised controlled trials, patients with recent TIA or symptomatic critical artery 
stenosis were randomised to a combination of aspirin and clopidogrel versus aspirin alone. These 
studies, suggest that a dual-antiplatelet therapy was better than monotherapy in reducing the risk 
of early recurrent stroke. 
The landmark level 1 evidence for intervening in patients with symptomatic extra-cranial carotid 
artery disease came from the North American Symptomatic Carotid Endarterectomy Trial 
(NASCET)47, European Carotid Surgery Trial (ECST)38 and The Veteran Affairs Trial142. Veteran 
Affairs Trial was prematurely stopped after interim results of ECST were published142. 
Both the European Society for Vascular Surgery (ESVS) and the Society for Vascular Surgery (SVS) 
issued updated guidelines on the management of carotid disease143 (Figure 2). These take into 
consideration the current literature and their recommendations are graded according to the 
levels of evidence.  
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Figure 2 Decision tree for carotid disease (NASCET criteria)143, 144 
 
 
North American Symptomatic Carotid Endarterectomy Trial (NASCET)47 and the European Carotid 
Surgery Trial (ECST)38, have shown that carotid endarterectomy vs. BMT is highly effective in 
reducing the risk of further strokes in moderate (5-year stroke risk; 15.7 vs 22.2% NASCET and 
marginal difference in ECST) to severe (2-year stroke risk; 9 vs 26% NASCET and 6.8 vs 20.6% ECST) 
symptomatic carotid artery stenosis. Surgery in carotid near-occlusion and stenosis less than 50% 
conferred with no benefit at al121. Pooled analysis of data from the major randomised controlled 
trials (ECST, NASCET and Veteran Affairs trials) of surgery for symptomatic carotid stenosis 
showed surgery reduced the 5-year absolute risk of any stroke or death by 15% in patients with 
70-99% stenosis, and by 7.8% in patients with 50-69% stenosis51. The analysis also showed the 
benefit of surgery was greatest in men, elderly (age >75) and when performed within 2 weeks 
after the last ischaemic event51. 
In order to maximise the benefit of carotid endarterectomy, it should be performed within 2 
weeks after the last ischaemic event and at the same time minimise the operative stroke and 
death complication rates. However, there has been a concern regarding the safety of the surgery 
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if performed too early. In general, the risk of endarterectomy for emergency surgery in patients 
with unstable symptomatic carotid disease is high145, 146, especially in patients with crescendo 
transient ischaemic attacks and stroke-in-evolution147. Otherwise, there was no evidence of any 
increase in operative risk in neurologically stable patients operated within 2 weeks of the last 
ischaemic event based on the 2 major randomised controlled trials (Table 3)53, 148 data. Table 3 
showed there was no significant difference of operative risk when between surgery performed 
within 2 weeks of last ischaemic event and beyond 2 weeks. 
 
Table 3 The operative risk (95% CI) due to trial surgery in relation to the time between the last symptomatic 
ischaemic event and surgery in the European Carotid Surgery Trial (ECST) and the North American 
Symptomatic Carotid Endarterectomy Trial (NASCET)53, 148 
 
 Time between last symptomatic ischaemic event and surgery 
<2 weeks 2-4 weeks 4-12 weeks >12 weeks P value 
Any stroke or death within 30 days after trial surgery 
ECST 6.5% (1.0–12.0) 6.4% (3.4–9.5) 7.4% (5.5–9.3) 8.0% (5.9–10.0) 0.86 
NASCET 7.1% (4.1–10.1) 5.0% (2.4–7.5) 6.5% (4.4–8.4) 7.4% (4.4–10.4) 0.64 
Total 6.9% (4.5–10.1) 5.7% (3.9–8.0) 7.0% (5.7–8.5) 7.8% (6.2–9.7) 0.48 
 
Disabling operative stroke or death within 30 days after trial surgery 
ECST 2.6% (0.3–9.1) 2.4% (0.9–5.2) 4.1% (2.8–5.8) 3.5% (2.2–5.2) 0.61 
NASCET 3.2% (1.5–6.0) 2.5% (1.0–5.1) 1.6% (0.7–3.1) 1.0% (0.2–2.9) 0.23 
Total 3.1% (1.5–5.4) 2.5% (1.3–4.2) 3.1% (2.2–4.1) 2.7% (1.8–4.0) 0.89 
 
Despite clear evidence of benefit if carotid endarterectomy is performed within 2 weeks of the 
last ischaemic event, it is still undermined in healthcare systems by delays in investigation and 
intervention148. For an example, an Oxfordshire Study found that the median time from transient 
ischaemic attack or stroke to imaging was over four weeks and that the median delay to surgery 
was 14 weeks59. In a recent national survey, only 20% of symptomatic patients had carotid 
endarterectomy within the two week target time set by the National Institute for Health and 
Clinical Excellence (NICE)149.  
Kerber et al150 performed the first carotid artery angioplasty in a human in 1980. Since then, the 
development of the carotid stent has evolved rapidly and has emerged as a potential alternative 
to carotid endarterectomy. It has an advantage of being performed under local anaesthesia. It 
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reduces the risk of myocardial infarction and pulmonary embolism. It also avoids the effect of 
general anaesthetic agents and promotes a more rapid recovery, thereby potentially reducing 
length of hospital stay. Since the 1990s, investigators have compared the effectiveness of carotid 
endarterectomy and carotid stenting. The first clinical trial of carotid stenting was a single centre 
study based in Leicester151. Since then, 14 clinical trials152 and 21 clinical registries153 comparing 
surgery and carotid stent effectiveness have been reported. These produced conflicting results 
due to differences in patient population, trial design, outcome measures, endovascular devices 
used and operator skills152. The two most recent international multi-centre randomised controlled 
trials comparing carotid endarterectomy and carotid stenting in symptomatic carotid stenosis 
have been published154-156. The International Carotid Investigators Stenting Study (ICSS) which is 
based in Europe, showed that surgery is superior to carotid stenting in symptomatic patients, 
especially in terms of stroke risk reduction and death rate in patients >70 years of age154, 155. 
Further meta-analysis of individual patient data from three randomised controlled trials from the 
same ICSS investigators concluded that carotid stenting for symptomatic carotid stenosis should 
be avoided in older patients (age ≥70 years)154. The Carotid Revascularisation Endarterectomy vs. 
Stenting trial (CREST), based in North America, demonstrated similar major complications for 
surgery and stenting in symptomatic and asymptomatic patients156. Both the European Society for 
Vascular Surgery (ESVS) and the Society for Vascular Surgery (SVS) issued updated guidelines 
indicate that carotid endarterectomy remains the better option144. 
Whilst the definitive management of the symptomatic carotid stenosis has been the subject of 
good quality medical research, further research is needed to identify the clinical method that 
enable us to identify these high risk patients which will benefit from urgent carotid 
endarterectomy. One option is to use transcranial Doppler microembolic signals as a surrogate 
biomarker of short term stroke risk. In my thesis, I aimed to study the clinical vascular disease 
characteristic and radiological detection of the TCD-detected microembolic signals. 
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1.2 Carotid artery disease associated cerebral microemboli 
1.2.1 Transcranial Doppler imaging and cerebral microemboli detection 
The Doppler effect is the basis upon which ultrasound provides information on blood flow 
velocity. Pulsed wave ultrasound is reflected by moving red blood cells. The frequency shift 
between the transmitted and reflected ultrasound wave correlates directly with blood flow 
velocity. The first transcranial Doppler (TCD) ultrasound recordings were performed in 1981 in 
Germany157 to assess the velocity of cerebral blood flow. Since then, TCD has been used to study 
cerebral arteries flow velocities, cerebral CO2 reactivity and microembolic signals (MES).  
The technique is highly operator dependent and relies on sufficient ultrasound transmission 
through the skull to allow the recording of intracerebral blood flow using a low frequency 
transducer. A number of different acoustic windows of the skull have been used to monitor 
different intracerebral arteries. The terminal internal carotid artery, middle cerebral artery, 
anterior and posterior cerebral arteries can be accessed via the temporal window which is the 
thinnest area of the skull157. The occipital window can be used to insonate the vertebral and 
basilar arteries. The orbital area can be used to insonate the distal internal carotid artery and 
ophthalmic artery. 
Various flow velocity parameters can be used to identify cerebral artery stenosis. For example, 
high flow velocity parameters have been strongly associated with middle cerebral artery 
stenosis158, 159. The cerebral reactivity measures the change of blood flow velocity in in response 
to the inhalation of CO2 or the administration of acetazolamide. Reduced cerebral reactivity 
suggests that the patient has little haemodynamically reserve which has been associated with 
cardiovascular risk factors and severe carotid disease160. Whilst blood flow velocity calculation 
relies on the frequency of the reflected ultrasound signal, the intensity of the reflected signal 
provides information on the material which reflects the ultrasound signal. The amount of 
ultrasound reflected is proportionate to the intensity of the received signal. The intensity of the 
reflected signal relies on the type of tissue through which the signal is passed. This is the basis of 
the transcranial Doppler detection of microemboli. The unique scattering of the reflected 
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ultrasound signal, compared with the homogenous background of red blood cell signals, allows 
microemboli to be detected as they pass through the intracerebral arterial circulation. The 
microembolic material can be both gaseous and solid within the intracerebral vessels. They 
appear as a short duration high intensity signal within the Doppler arterial waveform (Figure 3). 
The low frequency of transducer used (2MHz) for TCD increases the embolic-to-background blood 
signal ratio, hence making them easier to detect161. Sources of microemboli include symptomatic 
or asymptomatic carotid stenosis32, 162, atrial fibrillation163, prosthetic cardiac valves164 and 
cardiopulmonary bypass165. In carotid disease, TCD – detected microemboli were first described in 
a study evaluating blood flow velocity in the middle cerebral artery of nineteen patients during 
carotid endarterectomy166. At that time, the detected microemboli were thought to be harmless 
air microbubbles166. A study by Spencer et al161 published in 1990 provided the first evidence of 
the potential of TCD-detected microemboli as a biomarker of early stroke. Spencer et al161 
described the accumulation of thrombus on the endarterectomy site in patients who developed 
immediate post-operative stroke. Since then, TCD – detected microemboli have been identified as 
a potentially useful surrogate marker for selection of high risk carotid disease patients for 
intervention32, 162, perioperative monitoring167 in carotid endarterectomy and assessing the 
effectiveness of novel antiplatelet therapies168.  
Transcranial Doppler is a blind ultrasonic technique and microemboli detection requires a certain 
level of expertise.  Even though high inter-observer reproducibility of identifying microemboli has 
been reported in multi-centre studies32, 169, care needs to be taken in order to differentiate 
clinically relevant solid microemboli from artefact. Sufficiently specific and sensitive automated 
embolic signal detection is also needed for wider clinical application170. In order to avoid 
discrediting these techniques, experts around the world in this field gathered in 1997 and set out 
the recommendations of microembolic signal identification for appropriate use in clinical practice 
and scientific investigations171. The recommendations are based on distinct ultrasonic and audio 
characteristics of the relevant microembolic signals. They are characterised by: (1) high intensity 
transient signal; (2) short duration range of 10 - 100ms; (3) detection threshold range between 3 
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to 9 Db for discriminating embolic signal from the background noise;  (4) produce characteristic 
‘chirp’ sound and (5) unidirectional signal occurs randomly within the cardiac cycle to discriminate 
embolic signal from artefact171. 
Experimental studies have demonstrated that TCD has a very high sensitivity and specificity for 
detecting solid microemboli including platelet aggregates, thrombus and atheromatous debris172. 
The application of TCD relies on the clinical context as current technology does not reliably 
differentiate between cholesterol emboli, thrombus and platelet microemboli.  
In carotid disease, the ultrasound probe is placed on the acoustic temporal window to insonate 
the middle cerebral artery which is in continuation with the distal internal carotid artery. Carotid 
disease associated microemboli appear to be primarily platelet aggregates60.  A recent study by 
Kinsella et al173 has shown that patients with symptomatic carotid disease had higher platelet 
counts (potentially reflecting increased platelet production, mobilization or reduced clearance) 
and platelet activation status than asymptomatic patients. Microemboli were more frequently 
detected in recently symptomatic than asymptomatic cohorts173. Studies have shown that the 
microemboli detected in carotid disease were almost completely abolished by an inhibitor of 
platelet adhesion and aggregation174 and various antiplatelet agents such as aspirin, clopidogrel 
and tirofiban175 37, 176. In contrast, heparin has been shown to be less effective in abolishing the 
microemboli177, 178. These findings are consistent with trials which have shown that antiplatelet 
agents are more effective than anticoagulants in preventing stroke recurrence179. 
 
 
 
 
 
 
 
 
43 
 
Figure 3 Middle cerebral artery Doppler waveform. The typical MES appearance can be seen as a spike 
within the arterial waveform. 
 
 
 
1.2.2 Prevalence and prognostic impact of cerebral microemboli 
 
Microembolic signals following TIA/non-disabling stroke 
Tanaka et al suggest a ratio of middle cerebral artery (MCA) to anterior cerebral artery (ACA) 
blood flow of approximately 75:25 from the internal carotid artery180. A recent in vitro study by 
Chung et al181 showed that embolus trajectory favours the middle cerebral artery, especially large 
emboli. This preference of emboli to enter the MCA is consistent with the high ratio of MCA–ACA 
infarcts reported by the Harvard182 and Lausanne183 stroke registries. In carotid disease, cerebral 
infarcts occur more frequently in the territory of the middle, compared with that of the anterior, 
cerebral artery and occurrence of cerebral microembolism follows a similar distribution184.  
Microembolic signals (MES) have been detected in approximately 40% of symptomatic carotid 
artery stenosis patients35, 185. The presence of microembolic signal has been associated with 
recently symptomatic carotid stenosis, degree of stenosis185, intraluminal thrombosis and 
unstable carotid plaque characteristics162, 186-188.  
Typical MES seen as a spike 
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Forteza et al189 reported a higher occurrence of microembolic signals in patients presenting within 
4 days of their index symptoms, as compared to those who presented with 12 days of their most 
recent symptoms. Valton et al190 prospectively studied the association of microembolic signals in 
the ipsilateral middle cerebral artery and early ischaemic recurrence in 73 consecutive patients 
with anterior circulation, stroke or TIA in whom the TCD examination was performed within 7 
days from the onset of symptoms. A further report has shown that patients with MES are at a 
nine-fold increased risk of stroke190. In the more recent Clopidogrel and Aspirin for Reduction of 
Emboli in Symptomatic Carotid Stenosis (CARESS trial)37, the presence of MES was associated with 
a markedly increased risk of recurrent stroke and TIA at day 7 following the initial symptoms. This 
is also consistent with an epidemiological study demonstrating a high risk of early recurrent stroke 
or TIA at 7 days from the index symptom10. Ritter et al reported an increased prevalence of 
patients with MES with a higher degree of carotid stenosis185. Valton et al187 demonstrated that 
microembolic signals were associated with the appearance of plaque ulceration on angiography. 
The analysis of endarterectomy specimens by Sitzer et al186 demonstrated that microembolism 
before carotid surgery is closely related to surface thrombus and ulceration of the carotid plaque. 
These observations suggest that unstable ulcerated carotid plaque and surface thrombus are the 
source of the MES in acute symptomatic carotid disease patients. A more recent study by Van 
Lemmeren et al188 showed that spontaneous MES were detected in a quarter of symptomatic 
carotid disease patients scheduled for CEA and were associated with unstable carotid plaque 
characteristics such as luminal thrombus. 
Early work by Valton et al190 on symptomatic carotid stroke and TIA presenting within 7 days of 
index symptoms showed patients with MES had significantly higher ischaemic recurrence than 
without MES (33% vs. 5%, P = 0.008). They demonstrated the daily incidence of ischaemic 
recurrence was 4.3% per 100 patients with MES and only 0.5% without MES.190 A more recent 
prospective observational study by Mackinnon et al36 provided more conclusive evidence that 
showed that MES predicts short-term ipsilateral stroke risk in symptomatic critical carotid artery 
stenosis patients (stenosis > 50%). In the same study Mackinnon et al36 prospectively monitored 
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200 consecutive, recently symptomatic patients with 50 – 99% stenosis who underwent TCD 
evaluation. They found a significant association between microembolic signal (MES) and both 
recurrent stroke alone (P = 0.001) and the combined endpoint of stroke and TIA (P = 0.00001)36. 
The association between MES and stroke or stroke/TIA remained significant after taking into 
account the relevant clinical risk factors such as age, sex, smoking, hypertension, time from the 
last symptoms and degree of stenosis with an odds ratio of 4.67 (95% CI, 1.99 – 11.01, P < 
0.0001)36.  
Ritter et al185 report a systematic review investigating the prognostic impact of MES in 
symptomatic patients with carotid artery disease. They found that the daily risk of recurrent 
stroke or TIA was 1.3% in MES-positive patient, compared with 0.3% in MES-negative patients185. 
The overall 30-day risk of recurring stroke or TIA was 21% in symptomatic carotid artery disease 
patients185. Ritter et al185 calculated from the pooled data that symptomatic carotid artery disease 
patients with MES have about a sevenfold increased risk of future events compared with patients 
without MES (OR 7.5, 95%CI 3.6 – 15.4, P < 0.0001). A more recent meta-analysis by King et al35 
confirmed that the presence of MES in symptomatic carotid artery stenosis patients predicted 
both stroke alone (OR 9.57, 95% CI 1.54 – 59.3, P = 0.02) and the combined end point of stroke or 
TIA (OR 6.36, 95% CI 2.9 – 13.96, P < 0.00001). 
Mackinnon et al demonstrated that the presence or absence of microembolic signal rather than 
the rate of MES predicted the risk of recurrent stroke and TIA191. Using a higher rate or threshold 
of MES did not increase the predictive power of TCD. Ritter et al185 also recommended that the 
stroke risk stratification in symptomatic carotid artery disease is dependent on the detection of 
one single MES. The predicted risk of recurrent ipsilateral TIA/stroke based on the presence or 
absence of MES was also used in a more recent prospective, multicentre, international study 
looking at the association between MES and risk of recurrent ipsilateral TIA/stroke in 
asymptomatic carotid disease patients32. 
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Microembolic signals following carotid endarterectomy 
Carotid endarterectomy reduces the risk of future stroke in patients with symptomatic critical 
artery stenosis38, 47. However, the procedure itself carries a significant peri-procedural risk of 
stroke192. Current national guidelines103 recommend that carotid endarterectomy should be 
performed within 2 weeks of index TIA/minor stroke. Few studies have shown that early carotid 
endarterectomy confer higher risk of perioperative stroke146, 193. Reducing the risk of 
perioperative stroke improves the risk–to–benefit ratio for carotid endarterectomy. 
The mechanisms of stroke following carotid endarterectomy are numerous. Early work on the 
pathogenesis of stroke from internal carotid artery occlusion showed that both 
haemodynamically induced and embolic infarction could be distinguished based on the 
anatomical distribution194. Thromboembolism generally give rise to infarcts within the territory of 
a main arterial branch, whereas low-flow states are associated with watershed infarcts195. Early 
work by Steed et al suggested thromboembolism as the principal mechanism of peri-operative 
stroke196. Morphological study of a cerebral infarct on CT scan following carotid endarterectomy 
strongly suggested thromboembolism as the principal mechanism of ischaemic perioperative 
stroke195. Subsequent work showed that thromboembolism from the thrombogenic 
endarterectomised media zone was the principal of mechanism of perioperative ischaemic 
stroke195, 197, 198. Recent clinical and radiological studies have confirmed that perioperative cerebral 
microembolisation originating from the endarterectomised zone is strongly associated with 
thrombotic stroke following carotid endarterectomy199-201. Excision of the carotid plaque removes 
the endothelium creating a thrombogenic surface on which platelet aggregation occurs. Human 
and experimental studies have shown that platelet deposition is increased at the site of carotid 
endarterectomy202, 203, reaching a maximum within 20 - 60 minutes and potentially giving rise to 
microemboli causing thrombotic stroke. The platelet nature and origin of embolism in this group 
was further confirmed when the endarterectomised site was re-explored31, 204, 205 and by its 
response to antiplatelet agents.  
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Microemboli detected during the dissection phase (before carotid arteriotomy) are believed to be 
associated with thrombotic stroke risk35. In the dissection phase, the fragile carotid plaque has not 
yet been removed. The exposure to the blood flow will potentially give rise to the emboli. 
Meta-analysis by Markus et al35 has shown that the absence or presence of microemboli during 
dissection phase of carotid endarterectomy did not predict intraoperative stroke. However, a high 
rate of microembolic signals during dissection phase predicted stroke (Odds Ratio 14.79, 95%CI 
5.15 – 42.47, P < 0.00001)206. 
Increasing high rate of detected microembolic signals acutely following carotid endarterectomy 
have been demonstrated to be associated with post-operative thrombotic stroke31. 
Approximately up to 5% of patients developed persistent high rate of postoperative microembolic 
signals207 . Unfortunately, about 50% of these patients with high rate microembolic signals suffer a 
thromboembolic stroke207. A previous study has shown that the early microemboli were detected 
approximately 10 minutes following carotid artery flow restoration46. Work by Abbott et al 
showed that most of the patients who developed high microembolic signal rates, who were at risk 
of developing postoperative stroke, were identified during a 30 minute TCD study in the first post-
operative hour207. More recent work by Sharpe et al208 showed that a high risk cohort of patients 
who would go on to develop high rate embolization that require treatment with Dextran could be 
identified by measuring the magnitude and rate of embolization in the first 30 minutes after 
arriving in theatre recovery. The vast majority of patients (85%) require no further monitoring208. 
A meta-analysis by Markus et al35 showed that the absence or presence of microemboli did not 
predict postoperative stroke. However, it did predict the combination of postoperative stroke and 
TIA (OR 3.56, 95%CI 1.37 – 9.22, P = 0.009). Further analysis has confirmed that high microembolic 
signals rate acutely after surgery predicted stroke alone and also stroke/TIA (OR 32.04, 95%CI 
11.36 – 90.39, P < 0.00001)35. 
Currently, there is no consensus on the definitive threshold of MES rate which is associated with 
adverse neurological events following carotid endarterectomy due to variable outcomes between 
centres31, 199, 200, 209. The variation of the clinically significant threshold of MES rates could be 
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explained by the brain microcirculation which has considerable reserve capacity for microemboli. 
This capacity may be influenced by variables such as microembolus size, blood rheology, collateral 
flow and preoperative antiplatelet treatment31. Laman et al200 evaluated the relationship between 
the rate of microemboli (MES/min) and stroke complications following carotid endarterectomy. 
They found that a rate of 0.9 MES/min was associated with fourfold increase in the rate of early 
post-operative stroke following carotid endarterectomy200. Based on a prospective study by Levi 
et al, 31 a threshold of MES rate > 50/hr (0.83 MES/min) has been shown to correlate with stroke 
occurrence within a time frame of approximately 60 minutes following their detection. Levi’s 
group found that the positive predictive value for cerebral ischaemia of detecting MES rate > 
50/hr was 0.71, and the negative predictive value of < 50/hr was 0.9831. Naylor et al33 started 
Dextran therapy in patients with 25 or more emboli in any 10 minute period of monitoring (2.5 
MES/min). Cantelmo et al199 identified that MES rate of 0.33 MES/min was associated with 
clinically silent MRI ischaemic changes. Despite this variation of the MES rate threshold associated 
with thrombotic stroke between centres, a trend of increasing rates of embolisation carotid 
endarterectomy is strongly predictive of a high risk of progressing on to thrombotic stroke.  
1.2.3 Treatment for cerebral microemboli 
The evidence relating to the benefits and risks of antiplatelet treatment in symptomatic carotid 
artery stenosis is evolving. Historically, we relied on data extrapolated from global ischaemic 
stroke/TIA studies to guide us on the optimal antiplatelet treatment for carotid artery stenosis210. 
Combination therapy with dipyridamole or clopidogrel has greater efficacy but fails to prevent 
many stroke recurrences211. TCD-based studies37, 212  have allowed us to use MES as a surrogate 
marker of short term stroke risk to assess the optimal antithrombotic and antiplatelet agents in 
both patients with symptomatic carotid artery disease and following carotid endarterectomy. 
Microemboli following acute stroke/TIA or carotid endarterectomy are much more common than 
the actual recurrent clinical event. The main advantage of this technique is to be able to evaluate 
antiplatelet, anticoagulant and antithrombotic effect of treatments in a much smaller number of 
patients than those required with the use of a clinical end point such as stroke37. The efficacy of 
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using TCD-detected microemboli as the surrogate marker to evaluate the effectiveness of 
treatment pertinent to carotid artery disease has been reflected with the increasing published 
data as summarised by the Table 4 below: 
 
Table 4 Antiplatelet and antithrombotic agents evaluation based on TCD-based studies 
Year Authors Research 
method 
Clinical setting Agents evaluated 
2013 Saedon et al176 Registry Carotid endarterectomy Tirofiban vs. 
Dextran-40 
2011 King et al212 RCT Symptomatic carotid 
stenosis 
Clopidogrel & aspirin 
vs. Dipyridamole & 
aspirin 
2011 Markus et al168 RCT Carotid endarterectomy Von Willebrand 
Inhibitor ARC1779 
2008 Vogten et al213 Prospective Carotid endarterectomy Clopidogrel vs. 
aspirin 
2008 McMahon et al178 RCT Carotid endarterectomy Un-fractionated 
heparin vs. low 
molecular weight 
heparin 
2008 Van Dellen et al214 Case series Carotid endarterectomy Tirofiban 
2007 De Borst et al215 RCT Carotid endarterectomy Dipyridamole & 
aspirin vs. 
dipyridamole & 
aspirin & clopidogrel 
vs. Dipyridamole & 
aspirin & dextran 
2005 Markus et al37 RCT Symptomatic carotid 
stenosis 
Clopidogrel & aspirin 
vs. aspirin 
2005 Tytgat et al216 RCT Carotid endarterectomy Aspirin 
2004 Payne et al217 RCT Carotid endarterectomy Clopidogrel & aspirin 
vs. aspirin 
2003 Lennard et al218 Case series Symptomatic carotid 
stenosis 
Dextran-40 
2001 Goertlet et al219 Prospective Symptomatic carotid 
stenosis 
Aspirin 
2000 Hayes et al220 Prospective Carotid endarterectomy Dextran-40 
1998 Molloy et al221 RCT Carotid endarterectomy S-Nitrosoglutathione 
 
 TCD – directed antithrombotic treatments have been shown to reduce the risk of thrombotic 
stroke acutely in the context of carotid surgery33. Dextran was one of the earliest antithrombotic 
agents evaluated and used to treat microemboli. It has been extensively studied in the context 
carotid surgery, where it has been used to treat patients with high levels of postoperative 
embolisation since the late 1990s167, 222. The previous studies suggested a number of potential 
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modes of action involving platelets223, von Willebrand factor224, and the fibrinolytic system225. The 
most probable explanation comes from the Noorman et al study which showed that Dextran 
increases tissue – plasmin activator (t-PA) plasma concentration225. T-PA is a protein which 
activates fibrinolysis by converting plasminogen to plasmin. Noorman et al225 demonstrated that 
in rats, dextran inhibits mannose receptor-mediated t-PA clearance. The inhibition of t-PA 
clearance during dextran infusion results in increased endogenous t-PA plasma concentrations. A 
recent laboratory study in Leicester exploring the potential modes of action  of dextran involving 
platelets, von Willebrand factor and fibrinolytic system further supported the theory that dextran 
enhances fibrinolysis through blockade of the uptake of t-PA in vivo226 . This study also clarified 
other potential mechanisms of dextran such as the breakdown effect of von Willebrand factor 
leading to a reduction of platelet adhesion to the vessel wall and also the dextran effect in causing 
thrombus instability. In a consecutive carotid endarterectomy series by Naylor et al167, the use of 
perioperative dextran in 500 consecutive operations resulted in no postoperative strokes. More 
recent findings from a group of vascular surgeons based in New England found that dextran was 
not associated with a significant decrease in the incidence of postoperative ipsilateral stroke, all 
stroke, and stroke or death227. The use of dextran in their series was also associated with a 
significantly increased risk of myocardial infarction and congestive heart failure227. Hayes et al 
studied the association between microembolisation and platelet activity based on the hypothesis 
that the magnitude of postoperative embolisation reflected an enhanced state of platelet 
activation and aggregation in susceptible patients228. The platelet response to adenosine 
diphosphate was significantly higher in patients who developed high rates MES and these cohorts 
of patients may respond to the P2Y12 ADP receptor antagonist clopidogrel228. Further randomised 
controlled trials37, 217 of combined platelet inhibition with aspirin plus clopidogrel vs. aspirin in 
both patients with symptomatic carotid stenosis and undergoing carotid endarterectomy showed 
a significant reduction of frequency of MES and stroke recurrence. The use of TCD technique has 
made it clinically practical and feasible for us to evaluate novel antiplatelet agents or multiple 
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antiplatelet treatments such as S-nitroso-glutathione 221, tirofiban214, von Willebrand inhibitor 168, 
high dose aspirin175 and a combination of aspirin, dipyridamole and clopidogrel 37, 215, 217.  
Despite extensive studies, there is no consensus on which antiplatelet therapy or combination is 
most effective in abolishing TCD-detected microemboli, with both the aims of preventing post-
carotid endarterectomy thrombotic stroke and recurrent stroke in acute symptomatic carotid 
artery disease patients. 
 
1.3 Medical Registry – establishing Warwick Carotid Surgery Registry 
1.3.1 Background 
Medical registries have become increasingly significant in recent years229 and are firmly 
established as part of the nation’s public health system in measuring the delivery, effectiveness 
and efficiency of healthcare. Medical registry follows the principles of observational studies by 
focusing on the actual patient populations. The word registry came from the Latin word 
registrum, meaning ‘list’ or ‘catalogue’. Brooke230, writing for the World Health Organisation 
(WHO) in 1974, defined registry as “a file of documents containing uniform information about 
individual persons, collected in a systematic and comprehensive way, in order to serve a 
predetermined purpose”. Solomon et al defined medical registry as “a systematic collection of a 
clearly defined set of health and demographic data for patients with specific health 
characteristics, for a predefined purpose231. A more recent definition is “an organised system that 
uses observational study methods to collect uniform data to evaluate specified outcomes for a 
population defined by a particular disease, conditions, interventions or exposure, and that serves 
one or more predetermined scientific, clinical, or policy purposes”232. Based on the recent 
document by the Agency for Healthcare Research and Quality232, registry data criteria are the 
following: 
 
1. The data are collected in a natural manner. The registry should not influence the standard 
clinical management of patients. 
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2. The purposes of the registry are defined before data collection and analysis process, so 
the data collection is purpose driven rather than the purpose being data driven. 
3. Data collected have specific and consistent definitions. 
4. Data are collected in a standard manner for every patient. 
5. Data collected should reflect the clinical status of the patients; it is the type of data used 
by the clinicians for diagnosis and management of patients 
6. At least one element of registry data collection is active or specifically for the purpose of 
the registry (usually collected from the patient and clinician). 
Medical registries are powerful tools for improving the quality of patients’ healthcare. The 
functions of medical registry can be looked at from 2 aspects of healthcare; clinical and funding 
body229, 231-233. 
 
From clinicians and patients’ perspectives, the real-world data from registry are useful: 
1. To understand the natural history of a disease. 
2. To evaluate the existing treatments and outcomes. 
3. To monitor the effectiveness and safety of any intervention delivered. 
4. To audit the clinical practice and manage disease in accordance with regional/national 
guidelines or best available evidence. 
5. For research – descriptive studies, improving research design, hypothesis testing 
 
From the public health or funding body perspectives, registry data can potentially: 
1. Public health surveillance 
2. Plan the provision of health care 
3. Monitor the impact of preventive measure 
4. Evaluate the cost of the treatment 
5. Assess different interventions in different populations. 
6. Monitor the performance of new products or procedures. 
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Registry is often confused with clinical database. Whilst clinical database can be part of the data 
source for the registry, the reverse is not the case. Table 5 summarises the key differences 
between registry and database234. 
 
Table 5 Differences between registry and database 
 Registry Clinical database 
Source of cases Various to ensure 
completeness 
Based on single cases treated 
in a single department. No 
requirement to identify all 
cases in any given population 
Subjects Predetermined inclusion and 
exclusion criteria 
Not defined 
Follow up data Yes Yes 
Principal uses Patient care, aetiological 
studies, needs assessment, 
health outcome assessment, 
surveillance 
Patient care, health 
technology assessment, 
quality improvement 
Advantages Representative distribution of 
cases 
Complete data on cases 
included “clinically-rich” 
Disadvantages Demanding to obtain data on 
all cases 
Cases are selective 
 
In terms of research methodology, there are clear distinctions between a registry and a clinical 
trial. In general, registry data reflect or observe the current standard medical management of 
patients. Whereas in a clinical trial, the data are focusing on the experimental or investigational 
aspects of homogenous groups. Both research methodologies require protocol-based data 
definition to ensure the quality of the data. Table 6 shows the important differences between a 
registry and a clinical trial232: 
 
Table 6 Differences between registry and clinical trial 
Registry Clinical trial 
Observational study design Active/experiment intervention 
Clinical decision is executed by the clinicians. Protocol-based clinical decision 
Broader definition of inclusion and exclusion 
criteria 
Strict definition of inclusion and exclusion 
criteria 
Current standard intervention Protocol-specific interventions 
Current standard follow up Protocol specific follow up 
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The position of registry type studies in the traditional hierarchies of evidence is not entirely clear. 
Due to the data collection methods, a registry is traditionally placed below randomised control 
trials in the conventionally used hierarchies232. The limitations of a registry are often highlighted 
in comparison with a randomised control trial. Some of the limitations are selection bias, non-
standardised follow-up, greater risk of missing data and less strict inclusion or exclusion criteria 
into the registry233. 
Reliability and quality of the data collected is the cornerstone of the robust registry, hence 
minimising the limitations of registry as a health quality improvement and research tool. Using 
the National Intensive Care Evaluation registry (Holland) as case study, Arts et al235 described the 
various data errors that can occur at the various steps in the electronic and manual data 
collection process (Figure 4). Based on the Dutch case study and literature review, Arts et al235 
proposed a framework of procedures for the assurance of data quality which can be implemented 
in order to improve the data quality in medical registry (Table 7). 
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Figure 4 Data errors at the different steps in the data collection process 
 
 
 
 
Ref: Arts et al. J Am Med Inform Assoc. 2002; 9: 600 - 601 
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Table 7 Framework of procedures for the assurance of data quality 
Central coordinating centre Local sites 
Prevention during set up and organisation of registry 
At the onset of the registry At the onset of participating in the registry 
Compose minimum set of necessary data items Assign a contact person 
Define data & data characteristics in data 
dictionary 
Check developed software for data entry and 
for extraction 
Draft a data collection protocol Check reliability and completeness of 
extraction sources 
Define pitfalls in data collection Standardise correction of data items 
Compose data checks Continuously 
Create user friendly case record forms Train (new) data collectors 
Create quality assurance plan Motivate data collectors 
In case of new participating sites Make data definitions available 
Perform site visit Place date & initials on completed forms 
Train new participants Keep completed case record forms 
Continuously Data collection close to the source and as 
soon as possible 
Motivate participants Use the registry data for local purposes 
Communicate with local sites In case of changes (e.g., in data set) 
In case of changes (e.g., in data set) Adjust data dictionary, forms, software, etc. 
Adjust forms, software, data dictionary, protocol, 
training material, etc. 
Communicate with data collectors 
Communicate with local sites  
Detection during data collection 
During import of data into the central database Continuously 
Perform automatic data checks Visually inspect completed forms 
Periodically and in case of new participants Perform automatic data checks 
Perform site visits for data quality audit (registry 
data <> source data) and review local data 
collection procedures 
Check completeness of registration 
Periodically  
Check inter- and intraobserver variability  
Perform analyses on the data  
Actions for quality improvement 
After data import and data checks After receiving quality reports 
Provide local sites with data quality reports Check detected errors 
Control local correction of data errors Correct inaccurate data & fill in incomplete 
data 
After data audit or variability test Resolve causes of data errors 
Give feedback of results and recommendations After receiving feedback 
Resolve causes of data errors Implement recommended changes 
 Communicate with personnel 
Ref: Arts et al. J Am Med Inform Assoc. 2002; 9: 600 – 601 
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1.3.2 The Warwick Carotid Artery Registry 
Warwick Carotid Artery Registry has been designed to study the clinical prediction, radiological 
detection and treatment of cerebral microemboli in acute carotid syndrome. I designed and 
initiated the Registry based on the The Swedish National Registry for Vascular Surgery (Swedvasc) 
model. SwedVasc started in 1987 initially as a local vascular registry in southern Sweden (VRISS)236 
covering a 1.9 million population. Since 1994, all Swedish hospitals have joined the SwedVasc. The 
VRISS was set up with predefined and clear objectives to quantify and evaluate the outcome of 
vascular procedures performed within a well defined area of Southern Sweden236. Below are the 
important learning points based on the Swedish vascular surgeons’ experience in setting up the 
Registry which put the data collection process at the heart of an effective Registry236: 
1. The standardised proforma should be a simple form that can be expanded in the future in 
line with increasing complexity of vascular procedures. The form also should be simple 
and user friendly in order to increase compliance and minimise missing data. A previous 
report has shown that a large amount of data required for registry leads to reduced 
compliance and increased missing data237. 
2. The data collection process must be conducted in systematic manner with designated 
persons. 
3.  A Registry must have a designated steering committee who meet regularly to highlight 
and review any data collection problems. 
The long term aim of this newly established regional Carotid Registry is to evaluate risk factors 
and outcomes of surgical interventions for carotid artery disease. The registry is a collaborative 
project within the acute hospital trusts within the Coventry and Warwickshire region. The registry 
is hosted and managed by the University Hospitals Coventry and Warwickshire NHS Trust which 
serves a population of 950,000. It is the tertiary referral centre for neurovascular disease and 
provides a regional carotid surgery services for the Coventry and Warwickshire region that 
includes the George Eliot Hospital and the South Warwickshire NHS Foundation Trust.  
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The University Hospitals Coventry and Warwickshire NHS Trust has provided transcranial Doppler 
imaging as part of carotid artery disease imaging since 2000218. As part of the local vascular 
surgery department policy209, all patients are required to undergo transcranial Doppler 
examination in 2 clinical circumstances; within 2 weeks of the last symptoms of acute 
symptomatic critical carotid artery stenosis and as part of monitoring tools for carotid 
endarterectomy. 
Currently, the identification of the high risk critical symptomatic carotid artery disease requiring 
urgent carotid endarterectomy relies on carotid duplex. Therefore, it is dependent on the urgency 
of the patient’s referral for the investigation by the clinicians.  NICE guidelines recommend that 
carotid endarterectomy should be performed within 2 weeks of presenting symptoms. A recent 
national survey showed that this is not yet achievable149.  
The most important point in designing this registry was the key research questions related to the 
role of microemboli as the surrogate biomarker to predict and treat the high risk symptomatic 
carotid artery syndrome cohort. 
 In establishing this registry, I hypothesised that the understanding of cardiovascular risk factors, 
combination of the established ABCD2 score100 for predicting very early stroke risk after transient 
ischaemic attack101, and improvement of microemboli detection and treatment, will potentially 
allow improved assessment of hyper-acute symptomatic carotid disease risk and help in decision-
making about the need for more aggressive medical therapy238 and the case for urgent carotid 
revascularisation. The details of the research issues that were considered prior to establishing the 
Carotid Surgery Registry were as follows: 
 
 Our current knowledge is limited with regard both to causes of development and severity 
of microemboli in carotid artery disease and their association with cardiovascular risk 
factors. 
 To assess whether ABCD2 risk score predicts cerebral microemboli. 
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 10-15% of patients have no acoustic temporal bone window for transcranial Doppler 
ultrasound insonation. Therefore, an alternative new method to detect microemboli will 
be required. 
 Despite preoperative antiplatelet treatment, patients still develop microemboli176 , 
therefore monitoring microemboli and their response to treatment enables targeting of 
antiplatelet therapy in patients at high risk of recurrent stroke syndromes36. 
The expected benefits from setting up this Registry are: 
1. The creation of a unique database which reflects the local population and geographical 
area. 
2. The data from the Registry could be used as part of audit or quality improvement and 
research activities. 
3. The Registry could be used as a source for future service planning.  
 
In my thesis, I used the Registry as the source of information with which to test hypotheses about 
predicting risk from the disease, assessing imaging methods and response to treatment for carotid 
artery associated cerebral microemboli. 
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CHAPTER TWO 
 
2 Hypothesis, Aims and Objectives 
 
2.1 Hypothesis 
The study of clinical prediction, radiological detection and treatment of cerebral microemboli will 
improve outcomes in patients with carotid disease and spontaneous embolisation. 
 
2.2 Aims 
1. To establish a Carotid Surgery Registry as a resource with which to test hypotheses about 
predicting risk from the disease, assessing imaging methods, and response to treatment 
for carotid artery associated cerebral microemboli. 
2. From the Registry and prospective observational study, to assess whether information 
from classical cardiovascular risk factor burden predicts the presence of carotid artery 
disease associated cerebral microemboli. 
3. To evaluate transorbital Doppler as an alternative to transcranial Doppler for detecting 
cerebral microemboli in patients with carotid disease without an acoustic temporal bone 
window. 
4. From the registry, to compare effectiveness of agents used to suppress cerebral 
microemboli. 
 
2.3 Objectives 
1. To establish a new Registry of patients who have undergone carotid endarterectomy 
between January 2002 and December 2012 at the Regional vascular surgery centre, 
University Hospital Coventry and Warwickshire NHS trust. To establish a prospective 
cohort of patients who have had hyper-acute symptomatic carotid artery disease 
between February 2011 and May 2013. 
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2. From the Registry and the above prospective observational study, to explore whether the 
Pocock score predicts the likelihood of an increased prevalence of cerebral microemboli, 
and whether the ABCD2 score predicts the likelihood of spontaneous embolisation in 
hyper-acute symptomatic carotid artery disease patients. 
3. From the Registry, to assess the feasibility of using the transorbital Doppler in those 
patients with absence of a suitable temporal acoustic window for transcranial Doppler 
monitoring. 
4. To validate prospectively the use of transorbital Doppler against transcranial Doppler to 
detect cerebral microemboli acutely following carotid endarterectomy. 
5. To compare effects of the glycoprotein IIb/IIIa receptor antagonist tirofiban with the anti-
thrombotic polysaccharide dextran-40 in patients with high microembolic rates acutely 
after carotid endarterectomy. 
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CHAPTER THREE 
3 Methods 
3.1 Establishing the new Carotid Surgery Registry 
3.1.1 Background 
A new Carotid Registry was set up for the purpose of my study. Prior to my work, there was no 
previous database or a collection of clinical information regarding carotid surgery at the 
University Hospital Coventry and Warwickshire NHS Trust. The Registry was set-up based on the 
Solomon et al231 description of setting up an effective Registry. Creating the Registry requires a 
specific range of organisational and technical skills. These are summarised below: 
 
1. An implementation plan 
The committee was set up and met regularly every 4 months in order to discuss the development 
of the Carotid Registry. The committee has agreed that this Registry would be a long-term project 
hosted by the Department of Vascular Surgery in University Hospital Coventry and Warwickshire 
NHS Trust. The long term aims of this Registry, set up at the initial meetings of the committee, 
were: 
 
 To permit review of medical record information contained within the Carotid 
Registry to identify patients who may be eligible for participation in future 
research studies. 
 To create a source of information to initiate future observational research studies 
and audits on the management of carotid artery disease patients and outcomes 
of carotid endarterectomy.  
 
 
 
63 
 
2. Adequate documentation 
The Registry team comprised of the vascular consultants in the Trust and the vascular 
technologists. The research fellow and vascular technologists assumed the responsibility for 
running the registry on a daily basis. They were responsible for identifying patients, collecting 
data, and entering data on the safe electronic database supervised by the research fellow. They 
undertook a short period of training and worked under close supervision to become familiar with 
the Registry data processing and data entry procedure. The Research fellow was responsible for 
implementing the strategies approved by the committee; for monitoring the data collection 
process; and for confirming data accuracy. The principle investigators arranged appropriate office 
space, administrative equipment and IT support.  
 
3. Quality control procedure 
The Registry committee oversaw the quality control procedure, which followed the principle of 
the above framework of procedures for the assurance of data quality231 (Table 7). 
 
4. Completeness of data 
Since 2000, all patients who underwent carotid endarterectomy were required to undergo 
preoperative carotid Duplex and transcranial Doppler examination in the vascular laboratory218. 
Therefore, all the patients’ details were obtained from the vascular laboratory prior to the data 
collection process. The list of the patients included in the registry was also cross-referenced with 
the theatre logbook to avoid missing patients. 
 
5. Validity of the data 
Prospective data were collected using a standardised proforma, which was approved by the 
Registry committee prior to the start of the data collection. Retrospective data were collected 
using the standardised proforma by 2 independent assessors and any discrepancy was re-
examined by a separate assessor. This was to minimise inaccuracy of the retrospective data239. A 
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previous study has shown that by adopting a systematic approach, a high degree of reliability and 
validity of retrospective data could be abstracted from the medical records239.   
Double-entry from 2 independent persons was used to transfer the data from the proforma to the 
registry’s electronic database. They entered both prospective and retrospective data which were 
cleaned in stages to identify invalid entries. Any invalid data were re-examined by a separate 
assessor. A trial of the data collection process was conducted prior to the initiation of the 
Registry176, 240. This initial data collection process trial allowed the evaluation of the accuracy, 
completeness and missing data. 
 
6. Case definition 
The inclusion criteria were all patients with evidence of carotid stenosis ≥ 50% on carotid duplex 
undergoing a carotid endarterectomy. Please see section 3.1.5 for details on data definition, 
coding and collection process. 
 
7. Determination of the data elements 
Only clinically relevant data were collected in this Registry. Validated clinical, laboratory and 
imaging measurements and scales for data collected were used. Data dictionaries were defined in 
accordance with the criteria and reporting standards set by the American Society for Vascular 
Surgery (http://www.vascularweb.org/practiceresources/Documents/Forms) and The Vascular 
Society Great Britain and Ireland (https://www.vsqip.org.uk/resource-documents/). The same 
data dictionaries were used for both the Carotid Registry and prospective observational studies 
conducted following data analysis from the Registry. 
 
8. Data collection procedure 
This Carotid Registry integrated data from various sources. All data were collected using a 
standardised proforma to ensure completeness and uniformity of the data collected. Each patient 
received an individual code to ensure anonymity. Then the data were transferred to the software 
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for further analysis. After completion of the data transfer, the proforma was stored in a secured 
area after the data transferred completed.  
Between January 2002 and December 2012, 670 patients were included in the Registry. Registry 
data from 2002 to 2010 (n=581) were collected retrospectively based on the standardised 
protocol. The clinical information were gathered from the medical records, nursing records, 
preoperative assessment clinic records, laboratory results, diagnostic imaging reports and 
previous anaesthetic charts . 15 patients from the retrospective cohort were excluded in the 
analysis due to lack of data pertinent to the Registry. 
Since January 2011, using a standard protocol, data (n=89) have been collected prospectively. The 
prospective data collection procedure was divided into 3 stages: preoperative, intraoperative and 
postoperative (Table 8) below shows the source of data and the details of data collected during 
each stage. Any data uncertainty was cross-referenced with the patients themselves. 
 
Table 8 Data collection process 
Stages Data source Data collected 
Preoperative Preoperative assessment 
documentation 
Admission clerking 
Nursing Documentation 
IT system 
Demographics 
ABCD2 score 
Cardiovascular risk factors 
Indication for surgery 
Preoperative medications, blood 
pressure, blood results and 
imaging results 
Intraoperative IT system 
Medical notes 
Details of the operation 
Postoperative Discharge letter 
Medical notes 
Follow up clinic 
Postoperative outcomes 
 
 
9. Data access policy 
The principle investigators were responsible for ensuring that the confidentiality of the patients 
included in this Registry was maintained. The proforma contained anonymised or pseudo 
anonymised codes which represented each subject in the database. Once the data were gathered, 
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it was transferred to the spreadsheet. These were entered into coded fields designed for 
statistical analysis. The registry was stored in a secured password protected institutional machine. 
The access of the data has to be approved by the Registry committee. 
 
10. A framework for dissemination of findings 
Any data requested from an outside researcher had to be approved by the committee. 
  
3.1.2 Subjects 
This regional vascular surgery centre provides a carotid surgery service for a geographical area 
that includes a ~ 950 000 catchment population. Overall, 670 patients were included in this 
Registry. 581 patients were entered retrospectively from January 2002 to December 2010. 
Between January 2011 and December 2012, 89 patients were collected prospectively.  
 
3.1.3 Inclusion criteria 
The main inclusion criterium for this registry was to include all patients who had undergone 
carotid endarterectomy at University Hospital Coventry and Warwickshire NHS Trust from January 
2002 and December 2012. 
 
3.1.4 Ethics 
This Registry followed the principles agreed with the Research & Development Department at 
University Hospital Coventry and Warwickshire NHS Trust, confirming that Research Ethics 
Committee review was not required under the harmonised GAfREC for research limited to use of 
previously collected information non-identifiable by researchers outside the usual care team. This 
exception also applies to research undertaken by staff within the care team using information 
previously collected in the course of care for the team’s own patients, with the proviso that data 
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is anonymised or pseudonymised in conducting the research, as such research involves no breach 
of the duty of confidentiality owed by care professionals. 
(http://www.publichealth.hscni.net/sites/default/files/directorates/files/GAfREC_changes_Remit
_REC_2011_08.pdf) 
 
3.1.5 The standard operating procedure (SOP) for data collection 
The standard operating procedure for data collection described in this section was used for the 
carotid registry and subsequent prospective observational studies. In general, the data collection 
process was divided into 3 stages: preoperative, intraoperative and postoperative stages. 
 
Preoperative stage 
Patient demographic data, clinical data, cardiovascular risk factors and details prior to surgery 
were available from the preoperative assessment documentation from the clinic, nursing 
documentation and admission clerking. The cardiovascular blood results were identified from the 
online Hospital IT system. Preoperative drugs including antiplatelet agent details were readily 
available from the drug chart. Carotid Doppler results were obtained from the IT system and 
clarified with our vascular technologists where appropriate. 
 
Data collected 
1. Patient demographics – Age, sex, gender, height and weight. 
2. Validated ABCD2 risk score - The ABCD2 score ranges from 0 – 7101. The score was obtained 
following patients’ assessment in the fast-track TIA/minor stroke clinic by the neurologists 
and stroke physicians.  
 Age ≥ 60 years - 1 point. 
 Blood pressure ≥140/90mmHg - 1 point  
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 Limb weakness - 2 points; speech impairment – 1 point; duration of symptoms - 2 
points for ≥ 60 minutes, and 1 for 10-59 minutes. 
 Diabetes mellitus - 1 point. 
3. Cardiovascular risk factors – Definition was based on the Joint British Societies’ Guidelines 
on Prevention of Cardiovascular Disease in Clinical Practices93. 
 Hypertension was defined as systolic blood pressure (BP) ≥ 140mmHg and 
diastolic BP ≥ 85 mmHg. Hypertension was coded as history of hypertension, 
treatment with antihypertensive drugs, or persistent high blood pressure during 
admission due to undiagnosed or untreated hypertension.  
 Smoking history (self-reported) was divided into non-smokers, current smokers 
(at least one cigarette per day) and ex-smokers. Details of history included 
pack/years history, when stopped and type of tobacco.   
 Family history of cardiovascular disease was based on patients’ history and 
previous documentation in the medical notes.  
 Diabetes mellitus was defined as history of diabetes, including treatment with 
diet, oral medication and insulin, or new finding of diabetic range blood glucose 
(fasting blood glucose≥ 6 mmol/L). 
 Hypercholesterolaemia was defined as history of hyperlipidaemia, treatment with 
antihypercholesterolaemia drugs or new finding of high cholesterol level ≥ 4 
mmol/L.  
 Peripheral vascular disease was defined as documented symptoms of claudication 
with evidence of reduced ankle-brachial pressure index (< 0.9). 
 
4. Cardiovascular risk scores 
Total cardiovascular disease (CVD) risk for an individual is estimated from several risk 
factors and slightly differs between individual cardiovascular risk score. CVD end point is 
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defined as combined end point of coronary heart disease (fatal and non-fatal myocardial 
infarction and new angina) plus stroke (fatal and non-fatal stroke and cerebral 
haemorrhage) and transient cerebral ischaemia93. The total CVD risk score is expressed as 
a probability (percentage chance) of developing CVD or death over a defined period of 
time. Framingham, Joint British Societies’ Guidelines on Prevention of Cardiovascular 
Disease in Clinical Practice (JBS 2), Scottish ASSIGN scores estimate the CVD risk over 10 
years where as Pocock score estimates the risk of CVD death over 5 years93, 99. 
 
Online cardiovascular risk scores calculator developed by University of Edinburgh 
(http://cvrisk.mvm.ed.ac.uk/) was used to calculate Framingham, JBS 2, Scottish ASSIGN 
scores. Pocock cardiovascular risk score was calculated using the online calculator 
(http://www.riskscore.org.uk/). 
 
5. Indications for carotid endarterectomy 
 TIA - Defined as any acute focal ischemic neurological deficit lasting at least 30 
seconds but resolving completely within 24 hours241. Symptoms and signs 
resulting from the right carotid artery include left-sided weakness, paraesthesia, 
neglect, abnormal visual-spatial ability, and right monocular blindness or 
homonymous hemianopia. Symptoms and signs resulting from the left carotid 
artery include right-sided weakness, paraesthesia, aphasia, and left monocular 
blindness or homonymous hemianopia. 
 Stroke - focal neurological deficit of abrupt onset persisting more than 24 hours 
and corresponding to a vascular territory. 
 Amaurosis fugax – Often described as a shade drawn upward or downward over 
the field of view242. The symptom lasting at least 30 seconds but resolving 
completely within 24 hours. 
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 Asymptomatic with carotid artery critical stenosis - Asymptomatic carotid artery 
with stenosis ≥ 70% defined by ultrasound Duplex scan. 
 Pre/post coronary artery bypass carotid endarterectomy. 
 
6. Date of the last symptoms (for symptomatic carotid) – Defined as the date of the last 
symptoms prior to medical assessment. 
7. Preoperative medications – This included antiplatelet agents or anticoagulant, 
antihypertensive medications and antihypercholesterolaemia. 
8. Preoperative blood pressure – blood pressure measured according to British 
Hypertension Society (BHS) guidelines using validated devices. BP measured in both arms 
and the arm with the higher value used to assess BP control. Two measurements (1-2 
minutes apart) were taken on each occasion. If large (>10 mmHg) difference between the 
first and subsequent readings, initial value discarded and further measurements made. 
9. Preoperative blood results, ECG, echocardiogram, carotid Doppler and CT/MRI. 
10. The number of microemboli detected by TCD. 
 
Intraoperative stage 
Operation details were obtained from the electronic copy or medical notes. 
Data collected - Type of anaesthesia, details of arteriotomy closure and details of postoperative 
trancranial Doppler monitoring including microembolic rates. 
 
Postoperative stage 
Thirty days postoperative clinical events were obtained from the medical notes, discharge letter 
to the GP and follow up clinic. Postoperative outcomes coded include TIA/stroke (ischaemic or 
haemorrhagic), myocardial infarction, death, neck haematoma, cranial nerve injuries, 
thrombocytopenia. 
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3.1.6 Preoperative surgical preparation 
Administration of antiplatelet agents 
Aspirin 75mg oral or clopidogrel 75mg oral or, the combination of both antiplatelet agents in 
these doses was given before carotid surgery. The decision on preoperative antiplatelet treatment 
was decided by the individual surgeons. 
 
Carotid duplex 
All the patients who underwent carotid endarterectomy required preoperative carotid artery 
stenosis assessment. The Vascular Society and Society of Vascular Technology of Great Britain and 
Ireland118 recommended criteria based on the NASCET method of grading carotid bulb disease 
were used to assess the stenosis of the carotid artery. See section 2.1.4 for further details of the 
carotid Duplex procedure. 
 
3.1.7 Intraoperative - Imaging and surgical methods 
Transcranial (temporal acoustic window) Doppler 
In order to ensure accurate TCD monitoring, the examiner must have knowledge of the anatomy 
of the extra-cranial arteries and patients must be resting comfortably to avoid movement 
artefacts. The effective transmission of ultrasound through the cranium relies on the bone 
thickness. Ultrasound is transmitted more effectively through thin cranial bone as this reduces the 
power loss in the ultrasound beam. The conventional method relies on the temporal bone 
acoustic window (TAW), one of the thinnest cranial bones through which the ultrasound beam 
can be focused on the intracerebral arteries (Figure 5). 
All patients with haemodynamically significant ≥ 50% carotid stenosis went on to have TCD 
examination which was performed by accredited vascular technologists118. TCD monitoring was 
performed (PC Dop 842, SciMed, Bristol, UK) with a 2 MHz probe focused on the middle cerebral 
artery (MCA) ipsilateral to the endarterectemised carotid artery (Figure 5). The probe was placed 
above the zygomatic arch and just in front of the ear. The identification of the MCA was based on 
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guidelines set out by Alexandrov et al243 including spectral waveform, flow direction, blood flow 
velocity and flow pulsatility. Proof of traceability of the MCA was necessary for identification. The 
traceability referred to the fact that the MCA can be tracked from a shallow insonation depth (~ 
35mm) to deeper depth (~55mm) without changes in the character of the flow profile and flow 
direction.  An insonation depth of at least 45mm was used to identify proximal MCA flow signals 
and depths of 30 – 45mm for distal MCA flow signals. A standard axial sample volume of 5 mm 
and a low gain was used to provide a setting optimal from discriminating microemboli from the 
background arterial wave signals. A head-frame was used to secure a constant angle of insonation 
during TCD monitoring. 
  
Figure 5 Transcranial Doppler apparatus 
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Figure 6 Illustration of MCA insonated by ultrasound probe157 
 
 
MES identification 
Single gating system and a filter set to a low threshold to capture signals was used. Automated 
WinTCD v3.7 software (VIASYS Healthcare Inc., Conshohocken, PA, USA) was used to monitor and 
record the Doppler wave form and audio signals. Our Vascular Technologists have 90% agreement 
with software validated against a panel of international experts244 and have participated in a 
multi-centre prospective study168. The recorded ultrasonographic images were then reassessed to 
exclude artefact and identify true microemboli based on the criteria of the International 
Consensus Group on microembolus detection171. MES were identified as unidirectional, short 
duration signals (range 10–100 ms) with intensity threshold above 6 dB, unidirectional, 
accompanied by characteristic audible clicks and occurring randomly throughout the cardiac 
cycle. In order to improve the accuracy of MES identification, our vascular technologists manually 
Middle cerebral artery 
Ultrasound probe 
insonating middle cerebral 
artery via temporal bone 
window 
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recorded MES in the standard proforma. Any undecided MES signal recorded by the automated 
software can be cross-referenced with the manually recorded MES. 
 
Carotid endarterectomy 
Patients underwent conventional167 CEA under either general (GA) or local anaesthesia (LA). The 
GA CEAs had both intra operative and postoperative TCD monitoring245. An incision was made 
anterior to the sternocleidomastoid muscle between the sternal notch and mastoid process. The 
incision was carried down through the platysma, and the sternocleidomastoid muscle was 
retracted laterally with self-retaining retractors, once the internal jugular vein was visualised, and 
the carotid sheath was opened along the anterior border of the vein. Dissection was continued 
until the common carotid artery and vagus nerve were identified. Careful attention was 
undertaken to avoid injuries to cranial nerves IX (glossopharyngeal nerve), X (vagus nerve), XI 
(accessory nerve), XII (hypoglossal nerve), the marginal mandibular branch of VII (facial nerve). 
The common carotid, internal carotid and external carotid arteries were mobilised and controlled. 
Heparin was administered intravenously, prior to clamping the carotid arteries. Arteriotomy was 
made once the internal carotid artery, the common carotid artery, and the external carotid artery 
were clamped. 
Intraoperative hypotension is the main mechanism of cerebral ischaemia following the clamping 
of the carotid arteries prior to the endarterectomy stage246. In our unit, the intraoperative 
hypotension and neurological monitoring are performed using TCD in GA cases and awake patient 
monitoring in LA cases. Those who underwent surgery under GA will have a shunt to bypass the 
clamped vessel selectively, based on a greater than 50% drop in MCA time averaged mean 
velocity on clamping. Halsey et al identified that a fall in the middle cerebral artery velocity to less 
than 40% of its pre-clamp value caused mild cerebral ischaemia and a fall less than 15% of its pre-
clamp velocity caused severe ischaemia247. A rigid metal head guard was used to protect the TCD 
probe. For those GA patients with no TCD window, shunting was routinely performed, but for 
those under LA selective shunting was used according to whether a neurological deficit occurred 
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on clamping. Both GA and LA CEA had postoperative TCD monitoring. After completion of the 
endarterectomy, selective patching was performed according to surgeon preference245, with 
either a dacron (Fluoropassiv™ Vascutek Ltd, Inchinnan, Scotland) or polyester-urethane 
(Microporus Patch, B.Braun Melsungen Germany) patch. The closure was performed once the 
haemostasis had been achieved. 
 
3.1.8 Post-operative - pharmacological management 
 
Microembolic signal (MES) rate calculation post carotid endarterectomy: 
Post-operative monitoring was started as soon as the patient was in Theatre recovery following 
carotid endarterectomy. Monitoring was continued for at least 30 minutes post-operatively. 
Monitoring was extended if any microembolic signals were detected. In our Unit, the rate of MES 
was calculated based on the number of microemboli detected within 15 minute intervals. Rescue 
antiplatelet therapy was initiated when the MES rate > 50/hr31.  
 
The protocol of postoperative administration of antiplatelet agents for MES rate > 50/hr31 are 
summarised below: 
 
Tirofiban protocol 
Tirofiban protocol recommended for use in acute coronary syndrome248 were used. Tirofiban 
(Aggrastat®; Merck Sharp & Dohme, Hoddeson, UK) was given intravenously as 0.4mcg/kg/min for 
30 minutes then 0.1mcg/kg/min as a continuous infusion for 18 hours. Dosage had to be adapted 
to renal function. Repeat TCD was performed and monitoring was continued until the MES rate 
was < 4/hr. Tirofiban infusion was stopped once the MES ceased. 
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Dextran-40 protocol 
Use of dextran-40 in reducing MES after CEA has been extensively investigated by the Leicester 
Group33, 209. Our dextran-40 practice was based on Leicester Group work33. 
 
Patients were commenced on an intravenous infusion of dextran-40 (10% Gentran-40 [Baxter 
Healthcare, Thetford, UK] in 5% glucose solution). An initial 20-ml bolus was given, and the 
dextran-40 infusion continued at 20 ml/h. 
 
If a patient continued to have TCD evidence of a persistent high rate of MES, the rate of the 
dextran-40 infusion was increased at increments of 20 ml/h until the MES reduced. The dextran-
40 infusion was continued for 18 hours. Repeat TCD was performed and monitoring was 
continued until the MES rate was < 4/hr. Dextran-40 infusion was stopped once the MES ceased. 
 
3.1.9 Statistics 
Statistical analyses were conducted using SPSS® version 21 (Chicago, Illinois, USA).  
Parametric data are expressed as mean and standard error of the mean (SEM). Non-parametric 
data are expressed as median and inter quartile range (IQR). Non-parametric unpaired data were 
analysed using the Mann-Whitney U test for two group comparisons. Categorical variables were 
analysed using the chi-squared test or Fisher’s exact test.  A P-value of less than 0.05 was 
considered significant.  
Framingham, JBS 2, ASSIGN scores considered 20% as the threshold where healthy patients 
should be considered for pharmacology and lifestyle interventions. Pocock score was developed 
based on data of patients who were already established as having cardiovascular disease93, 99. 
Therefore all the patients in my thesis are eligible for Pocock score estimation. The association 
between microemboli and Pocock risk score was analysed using Receiver Operating Characteristic 
Curves (ROC). 
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3.2 Hyper-acute symptomatic carotid artery stenosis study 
Two hundred and six (age 70 ± 1 [SEM] years, male 149, Caucasian 196) patients were included in 
this study. This included 102 patients from our Carotid Registry retrospectively assessed between 
January 2002 and December 2010176. A further 104 consecutive patients were recruited between 
February 2011 and May 2013 within a new prospective study of hyper-acute symptomatic carotid 
artery stenosis. The prospective study was approved by the NHS Ethics Committee (MREC number 
10/H1206/77) and Research & Development Department (R&D C1080610). The details of the 
clinical and imaging methods are discussed in chapter 5. 
 
3.3 Prospective transorbital Doppler validation study  
Two phases are described for studies to evaluate the transorbital Doppler technique in detecting 
cerebral microemboli. The 1st phase was to identify the proportion of patients who required 
transorbital monitoring due to a lack of an accessible temporal window for standard TCD after 
surgery from the Carotid Registry between 2005 and 2008. The 2nd phase was a prospective 
observational study to validate the transorbital technique against the standard transcranial 
Doppler using temporal window technique. One hundred consecutive patients fulfilling the 
inclusion and exclusion criteria who underwent elective CEA between February 2011 and May 
2013 at the University Hospital Coventry and Warwickshire were included in the study. The 
prospective study was approved by the NHS Ethics Committee (MREC Number 10/H1211/51) and 
Research & Development Department (R&D Reference C1081810). The details of the clinical and 
imaging methods are discussed in chapter 6. 
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CHAPTER FOUR 
 
4 Carotid surgery registry and the use of classical cardiovascular risk factors for 
predicting early post-operative microembolisation in patients undergoing carotid 
surgery 
4.1 Introduction 
This newly established regional carotid surgery Registry provides important information on the 
cardiovascular risk factor burden and clinical outcomes of surgery in patients with critical carotid 
artery disease.  The Registry records precisely defined and standardised details on demography, 
cardiovascular risk factors, carotid imaging techniques, surgical technique and postoperative 
outcome at 30 days. The data for this Registry was gathered from unselected haemodynamically 
significant critical carotid artery disease patients who underwent carotid endarterectomy in 
everyday clinical practice. Therefore, it reflects the actual clinical practice and is invaluable for any 
quality improvement programme and research activities. The data available in this Registry has 
been used to evaluate novel carotid imaging techniques240 and a novel antiplatelet agent176 to 
treat transcranial Doppler detected cerebral microemboli to reduce thrombotic stroke risk and 
forms part of my thesis. Data between 2002 and 2012 were analysed for the completion of this 
thesis.  
4.2 Subject and Methods 
Please refer to section 3.1 for the details of methods for the Registry. 
4.3 Results 
4.3.1 Clinical features 
Preoperative 
Between January 2002 – December 2012, 670 patients were included in the Registry (Age 71 ± 0.4 
[SEM] years, 474 [71%] male and 652 [97%] Caucasian) (Table 9). Registry data from 2002 to 2010 
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(n=581) were collected retrospectively based on the protocol. Since January 2011, using a 
standard protocol, data (n=89) have been collected prospectively, including for perioperative 
clinical and laboratory data, and for carotid imaging, including detection of microemboli.  
Table 9 Demographic and clinical profile of the 670 patients who underwent carotid endarterectomy 
between January 2002 and December 2012 
 
 n (%) 
Age, mean ± SEM 71 ± 1 
Male 474 (71) 
Caucasian 
South Asian 
652 (97) 
18 (3) 
Hypertension 496 (74) 
Never smoke 
Current smoker 
Ex-smoker 
196 (29) 
133 (20) 
341 (51) 
Ischaemic heart disease 219 (33) 
Type 2 Diabetes mellitus 123 (18) 
Hypercholesterolemia 
 
327 (49) 
Peripheral arterial disease 98 (15) 
Cerebrovascular disease 144 (22) 
Family history of cardiovascular disease 126 (19) 
 
Carotid endarterectomy was undertaken in 474 (71%) patients for symptomatic carotid stenosis ( 
Table 10). Carotid endarterectomy was undertaken in 196 (24.8%) asymptomatic patients during 
the same period. The proportion of asymptomatic patients who underwent CEA was significantly 
less during the period 2011-2012 than 2002-2010 (10% vs. 33%, P < 0.001, X2 test).  
Of the 670 patients included in this thesis, 74% patients were hypertensive, 71% patients were 
smokers and 49% patients had hypercholesterolaemia (Table 9). Mean systolic BP was 145±1 
(SEM), diastolic BP was 74±1 mmHg, BMI was 27±0.2 kg/m2 and total cholesterol was 4.6±0.1 
mmol/L (Table 11).  
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Table 10 Indications of carotid endarterectomy 
Indications n (%) 
TIA 251 (38) 
Minor stroke 125 (19) 
Amourosis fugax 76 (11) 
Retinal artery occlusion 22 (3) 
Asymptomatic with carotid artery critical stenosis 166 (25) 
Pre/Post CABG 30 (5) 
Table 11 Blood pressure and preoperative laboratory values of 670 patients who underwent carotid 
endarterectomy between January 2002 and December 2012 
 
Laboratory variables Mean ± SEM (n) 
Systolic blood pressure 145±1 (645) 
Diastolic blood pressure 74±1 (645) 
BMI (kg/m2) 27±1 (553) 
Cholesterol (mmol/L) 4.6±0.1 (586) 
Triglyceride (mmol/L) 1.7±0 (433) 
HDL (mmol/L) 1.4±0 (479) 
Creatinine (mol/L) 104±1.3 (670) 
Glucose (mmol/L) 5.8±0.1 (563) 
Haemoglobin (g/L) 135±1 (670) 
Platelet (x 109/L) 253±2.7 (670) 
White cell count (x 109/L) 7.7±0.1 (670) 
CRP (units) 6.3±1.1 (71) 
HbA1C (%) 6.7±1.1 (119) 
 
The proportion of patients with hypercholesterolaemia (44% vs. 50%, P = 0.035), previous history 
of stroke or TIA (13% vs. 23%, P = 0.029) and history of ischaemic heart disease (21% vs. 34%, P = 
0.009) was reduced significantly during the period 2011-2012 than 2002-2010 (Table 12). 
However, the preoperative level of systolic blood pressure (151±2 vs. 145±1mmHg, P = 0.003), 
glucose (6.5±0.4 vs. 5.7± 0.1, P = 0.023) and white cell count (8.2±0.2 vs. 7.6± 0.1, P = 0.024) were 
significantly increased during the period 2011-2012 when compared to 2002-2010 (Table 13). 
Overall, 4 patients were on preoperative anticoagulant, 383 patients were on single antiplatelet 
agent preoperatively, 270 were on dual and 13 were on triple antiplatelet agents preoperatively 
(Figure 7). The proportion of patients who were on dual or triple antiplatelet agents prior to 
carotid endarterectomy were significantly higher during the period 2011-2012 when compared to 
2002-2010 (Table 14) (Figure 7). 
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Table 12 Demographic and clinical profile of 581 patients (retrospective) between January 2002 and 
December 2010 and 89 patients (prospective) who underwent carotid endarterectomy between January 
2011 and December 2012 
 
 Retrospective,  
n =581(%) 
Prospective, n = 
89(%) 
X2 test, P value 
Age, mean ± SEM 70±1 72±1 0.135 
Male 417(72%) 57(64%) 0.087 
Caucasian 565(97%) 87(98%) 0.025 
Hypertension 430(74%) 66(74%) 0.546 
Never smoke 
Current smoker 
Ex-smoker 
165(28%) 
111(19%) 
305(53%) 
31(35%) 
22(25%) 
36(40%) 
0.104 
Ischaemic heart disease 200(34%) 19(21%) 0.009 
Type 2 Diabetes mellitus 101(17%) 22(25%) 0.231 
Hypercholesterolemia 292(50%) 39(44%) 0.035 
Peripheral arterial disease 88(15%) 10(11%) 0.212 
Cerebrovascular disease 132(23%) 12(13%) 0.029 
Family History of 
cardiovascular disease 
115(20%) 11(12%) 0.059 
 
Table 13 Blood pressure and preoperative laboratory values of 581 patients (retrospective) between 
January 2002 and December 2010 and 89 patients (prospective) who underwent carotid endarterectomy 
between January 2011 and December 2012  
 
Laboratory variables Retrospective, 
Mean ± SEM (n) 
Prospective, 
Mean ± SEM (n) 
T-test, P 
value 
Systolic blood pressure 144.5± 1 (556) 151.3±2 (89) 0.008 
Diastolic blood pressure 73.9± 1 (556) 75.6±1 (89) 0.225 
BMI (kg/m2) 26.8± 0.2 (469) 27.6±0.5 (84) 0.182 
Cholesterol (mmol/L) 4.6±0.1 (519) 4.9±0.2 (67) 0.085 
Triglyceride (mmol/L) 1.7±0.1 (398) 1.5±0.1 (35) 0.233 
HDL (mmol/L) 1.4± 0.02 (414) 1.448± 0.1 (65) 0.942 
Creatinine (mol/L) 105.1± 1. (581) 95.2± 4.4 (89) 0.01 
Glucose (mmol/L) 5.7± 0.1 (510) 6.5±0.4 (53) 0.023 
Haemoglobin (g/L) 135±1 (581) 134± 2 (89) 0.578 
Platelet (x 109/L) 252.1±2.9 (581) 262.7±7.5 (89) 0.187 
White cell count (x 109/L) 7.6± 0.1 (581) 8.2±0.2 (89) 0.024 
CRP (units) 7.0± 1.4 (53) 4.2±0.4 (18) 0.064 
HbA1C (%) 6.6±0.1 (98) 6.8± 0.3 (21) 0.510 
 
Table 14 Different antiplatelet therapy regime prior to carotid endarterectomy (n = 670) 
 Retrospective, n (%) Prospective, n (%) 
X2 test, P value 
Anticoagulant 4 (1) 0 
< 0.001 Single antiplatelet 352 (60) 31 (35) 
Dual antiplatelet 221 (38) 49 (55) 
Triple antiplatelet 4 (1) 9 (10) 
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Figure 7 Different antiplatelet regime therapy prior to carotid endarterectomy (n = 670) 
 
 
Intraoperative 
465 patients underwent carotid endarterectomy under general anaesthesia and 205 patients 
were under sedation and local anaesthesia. Following endarterectomy of the carotid artery, 351 
patients underwent prosthetic patch, 11 patients underwent vein patch and 302 patients 
underwent primary arteriotomy closures. A shunt was required in 168 patients while 493 patients 
did not require a shunt during endarterectomy. 
 
Post-operative 
Following carotid endarterectomy, 335 (53%) patients developed acute postoperative cerebral 
microemboli (≥ 1 emboli). The proportion of patients who developed acute postoperative cerebral 
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microemboli was significantly higher in the retrospective group (n = 327, 56%) than prospective 
group (n = 28, 32%), (Odds ratio 0.357 95%CI 0.221 – 0.574, P < 0.001). 
Eighty six (13%) patients developed sustained high microembolic rate (MES > 50hr-1) requiring 
additional antiplatelet therapy to reduce risk of postoperative stroke. The proportion of patients 
who developed sustained high microembolic rate (MES > 50hr-1) were higher in the retrospective 
group (n = 80, 14%) than prospective group (n = 6, 7%), (Odds ratio 0.453 95%CI 0.191 – 1.07, P = 
0.065). 
 
The overall 30 day mortality was 13 out of 670 patients (1.9%). The 30 day morbidity was CVA or 
TIA in 16 (2.4%), myocardial infarction in 9 (1.3%), neck haematoma in 24 (3.6%) and transient 
cranial nerve injury in 34 (5.1%) patients (Table 15). Cumulative major event included 
perioperative stroke or TIA, myocardial infarction and death and cumulative minor event included 
neck haematoma and cranial nerve injuries. The cumulative 30 day major event rate was 4.3% 
(29) and minor event rate 8.4% (56) (Table 15).  
 
Table 15 30 day complications of 670 patients who underwent carotid endarterectomy between January 
2002 and December 2012 
 
Complications n (%±95%CI) 
Cerebrovascular accident 16 (2.4 ± 1.24 – 3.56) 
Myocardial infarction 9 (1.3 ± 0.44 – 2.16) 
Death 13 (1.9 ± 0.87 – 2.93) 
Neck haematoma 24 (3.6 ± 2.19 – 5.01) 
Cranial nerve injury 34 (5.1 ± 3.43 – 6.77) 
Cumulative major event (CVA,MI, Death) 29 (4.3 ± 2.76 – 5.84) 
Cumulative minor event (neck haematoma, cranial nerve 
injuries) 
56 (8.4 ± 6.3 - 10.5) 
 
There was a trend of increasing cardiovascular risk score with 30-day mortality, but this was not 
statistically significant (Table 16). There was no difference in terms of cardiovascular risk score 
between patients who had a postoperative major event and those who did not have any 
postoperative major events (Table 17). Overall, there was a trend of increasing number of major 
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cumulative events with increasing cardiovascular risk scores, but this was not statistically 
significant (Table 18). 
 
Table 16 Cardiovascular risk score for 30-day mortality of 670 patients who underwent carotid 
endarterectomy between January 2002 and December 2012 
Cardiovascular risk score P – value (MW test) 
Pocock 0.139 
CVD (Cardiovascular Disease) Framingham 0.730 
CVD-Death Framingham 0.145 
JBS2 0.701 
ASSIGN 0.552 
 
Table 17 Cardiovascular risk score for 670 patients for any 30-day postoperative major event (n = 30) vs. 
non-major event (n = 640) between January 2002 and December 2012 
Cardiovascular risk score P – value (MW test) 
Pocock 0.315 
CVD Framingham 0.942 
CVD-Death Framingham 0.386 
JBS2 0.981 
ASSIGN 0.656 
 
Table 18 Cardiovascular risk score for 30-day major cumulative events of 670 patients who underwent 
carotid endarterectomy between January 2002 and December 2012 (1 event vs. 2 events vs. 3 events) 
Cardiovascular risk score P – value (Kruskal Wallis 
test) 
Pocock 0.451 
CVD Framingham 0.241 
CVD-Death Framingham 0.425 
JBS2 0.245 
ASSIGN 0.736 
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4.3.2 Classical cardiovascular risk factor to predict for microemboli in patients acutely 
following carotid surgery 
Overall 
The proportion of patients who had Pocock risk score ≥ 0.8% was higher than patients who had 
Framingham, ASSIGN and JBS2 scores ≥ 20% (Table 19). The proportion of patients who had 
Framingham, ASSIGN scores ≥ 20% and Pocock risk score ≥ 2.3% were similar. The proportion of 
patients who developed microemboli (≥ 1 microemboli) among this cohort were similar between 
these 4 scores (Framingham≥ 20%: microemboli 53%, JBS 2: 55%, ASSIGN: 55%, Pocock ≥ 2.3%: 
microemboli 55%). 
 
Table 19 Distribution of microembolic patients based on risk score: 355 with postoperative microemboli vs. 
315 without postoperative microemboli 
Cardiovascular risk score, n Non-embolising, n Embolising, n X2 test 
P value 
Pocock ≥ 0% (18) 10 8 0.370 
Pocock ≥ 0.3% (37) 23 14 
Pocock ≥ 0.8% (135) 67 68 
Pocock ≥ 2.3% (218) 98 120 
Pocock ≥ 6.1% (191) 84 107 
Pocock ≥ 15.6% (71) 33 38 
CVD Framingham ≥20% (481) 223 258 0.607 
CVD-Death Framingham ≥20% 
(134) 
60 74 0.629 
JBS2 ≥20% (357) 162 195 0.394 
ASSIGN ≥20% (473) 212 261 0.089 
 
Microembolic cohort vs. non-microembolic cohort 
Patients with evidence of cerebral microemboli acutely following CEA had a significantly higher 
Pocock score at baseline (microemboli 4.6% [2.2 – 9.5] vs. non-microemboli 4.2% [1.7 – 7.9], P = 
0.039, MW test) (Table 20). 
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Table 20 Cardiovascular risk score for 670 patients who underwent carotid endarterectomy between 
January 2002 and December 2012: 355 with postoperative microemboli vs. 315 without postoperative 
microemboli 
Cardiovascular risk score P – value (MW test) 
Pocock 0.039 
CVD Framingham 0.178 
CVD-Death Framingham 0.291 
JBS2 0.216 
ASSIGN 0.067 
 
Figure 8 Shows the difference of Pocock score between 355 with postoperative microemboli and 315 
without postoperative microemboli who underwent carotid endarterectomy between January 2002 and 
December 2012
 
Cardiovascular risk score showed an increasing trend, but this was not statistically significant, to 
predict patients who developed sustained high MES rate > 50hr1  acutely following carotid 
endarterectomy requiring additional antiplatelet therapy (Table 21). 
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Table 21 Cardiovascular risk score for 670 patients who underwent carotid endarterectomy between 
January 2002 and December 2012: 86 patients had a sustained high microembolic rate requiring additional 
antiplatelet therapy vs. 584 did not require additional antiplatelet therapy 
Cardiovascular risk score P – value (MW test) 
Pocock 0.164 
CVD Framingham 0.638 
CVD-Death Framingham 0.503 
JBS2 0.695 
ASSIGN 0.196 
 
Receiver Operating Characteristic 
For further analyses, whether Pocock score was able to predict the presence of cerebral 
microemboli acutely post carotid endarterectomy was analysed in 4 stages; general, Pocock score 
≥ 0.8%, Pocock score ≥ 2.3% and Pocock score ≥ 6.1% as a cut-off point. Patients who had a 
Pocock score ≥ 0.8%, 2.3% and 6.1% are 0.8%, 2.3% and 6.1% at risk of cardiovascular mortality in 
5 years. 
 
The Receiver Operating Characteristic score (ROC) for the Pocock score was statistically significant 
for predicting acute post-operative microemboli (AUC 0.546 95% CI 0.502 – 0.590, P = 0.039: 
Figure 9). The ROC for Pocock score showed no significant prediction of acute postoperative high 
microemboli rate (MES > 50hr-1) requiring additional antiplatelet therapy. (AUC 0.546 95% CI 
0.482 – 0.610, P = 0.164: Figure 10). 
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Figure 9. ROC for Pocock score against presence of microemboli acutely following carotid endarterectomy 
(n = 670) (AUC 0.546 95% CI 0.502 – 0.590, P = 0.039) 
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Figure 10. ROC for Pocock score against presence of high microemboli rate (MES > 50hr-1) acutely following 
carotid endarterectomy (n = 670) (AUC 0.546 95% CI 0.482 – 0.610, P = 0.164) 
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The ROC for Pocock’s score ≥ 0.8% showed significant prediction of acute postoperative 
microemboli (AUC 0.582 95% CI 0.507 – 0.658, P = 0.038) (Figure 11). The ROC for Pocock’s score 
≥ 0.8% showed no significant prediction of acute postoperative high microemboli rate (MES > 
50hr-1) requiring additional antiplatelet therapy. (AUC O.514 95% CI 0.437 – 0.590, P = 0.371) 
(Figure 12). 
 
Figure 11 ROC for Pocock score ≥ 0.8% against presence of microemboli acutely following carotid 
endarterectomy (n = 670) (AUC 0.582 95% CI 0.507 – 0.658, P = 0.038) 
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Figure 12 ROC for Pocock score ≥ 0.8% against presence of microemboli >50-1 acutely following carotid 
endarterectomy (n = 670) (AUC O.514 95% CI 0.437 – 0.590, P = 0.371) 
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The ROC for Pocock score ≥ 2.3% showed no significant prediction of acute postoperative 
microemboli (AUC 0.531 95% CI 0.487 – 0.574, P = 0.172: Figure 13). The ROC for Pocock score ≥ 
2.3% showed no significant prediction of acute postoperative high microemboli rate (MES > 50hr-
1) requiring additional antiplatelet therapy. (AUC 0.530 95% CI 0.466 – 0.594, P = 0.367: Figure 
14). 
 
Figure 13 ROC for Pocock score ≥ 2.3% against presence of microemboli acutely following carotid 
endarterectomy (n = 670) (AUC 0.531 95% CI 0.487 – 0.574, P = 0.172) 
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Figure 14. ROC for Pocock score ≥ 2.3% against presence of high microemboli rate (MES > 50hr-1) acutely 
following carotid endarterectomy (n = 670) (AUC 0.530 95% CI 0.466 – 0.594, P = 0.367)  
 
The ROC for Pocock score ≥ 6.1% showed no significant prediction of acute postoperative 
microemboli (AUC 0.519 95% CI 0.475 – 0.562, P = 0.408). The ROC for Pocock score ≥ 6.1% 
showed no significant prediction of acute postoperative high microemboli rate (MES > 50hr-1) 
requiring additional antiplatelet therapy. (AUC 0.529 95% CI 0.463 – 0.595, P = 0.382). 
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Diagnostic accuracy 
 
Pocock score ≥ 0.8% showed a high sensitivity for the presence of acute postoperative cerebral 
microemboli. It also showed high sensitivity and negative predictive value for patients who 
developed sustained high microembolic rate (MES > 50hr-1) requiring additional antiplatelet 
therapy to reduce risk of postoperative stroke (Table 22, Table 23). Pocock score ≥ 2.3% showed 
similar diagnostic accuracy as Pocock score ≥ 0.8% (Table 24, Table 25). Pocock score ≥ 6.1% 
showed high specificity and negative predictive value for the presence of microemboli (Table 26, 
Table 27). 
 
Table 22. Diagnostic accuracy Pocock’s score ≥ 0.8% vs MES 
Sensitivity 93.80% 95% CI:  90.77 to 96.07 
Specificity 11.42% 95% CI:  15.47 to 8.13  
Positive Predictive Value 54.41% 95% CI:  50.37 to 58.41 
Negative Predictive Value 62.07% 95% CI:  48.37 to 74.48  
 
Table 23. Diagnostic accuracy Pocock’s score ≥ 0.8% vs MES rate > 50hr1 
Sensitivity 93.02% 95% CI:  85.42 to 97.38 
Specificity 8.90% 95% CI:  6.72 to 11.51 
Positive Predictive Value 13.07% 95% CI:  10.50 to 16.00 
Negative Predictive Value 89.66% 95% CI:  78.82 to 96.08 
 
Table 24. Diagnostic accuracy Pocock score ≥ 2.3% vs MES 
Sensitivity 74.37% 95% CI: 69.49 to 78.83 
Specificity 31.75% 95% CI: 26.64 to 37.20   
Positive Predictive Value 55.11% 95% CI: 50.54 to 59.63   
Negative Predictive Value 52.36% 95% CI: 45.02 to 59.61 
 
Table 25. Diagnostic accuracy Pocock score ≥ 2.3% vs Postoperative MES rate > 50hr1 
Sensitivity 76.74% 95% CI: 66.39 to 85.17 
Specificity 29.28% 95% CI: 25.62 to 33.16 
Positive Predictive Value 13.78% 95% CI: 10.82 to 17.19 
Negative Predictive Value 89.53% 95% CI: 84.29 to 93.49  
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Table 26. Diagnostic accuracy Pocock score ≥ 6.1% vs MES 
Sensitivity 40.85% 95% CI: 35.69 to 46.16 
Specificity 62.86% 95% CI: 57.26 to 68.21 
Positive Predictive Value 55.34% 95% CI: 49.10 to 61.46 
Negative Predictive Value 48.53% 95% CI: 43.58 to 53.50 
 
Table 27. Diagnostic accuracy Pocock score ≥ 6.1% vs MES rate > 50hr1 
Sensitivity 44.19% 95% CI: 33.48 to 55.30 
Specificity 61.64% 95% CI: 57.56 to 65.61 
Positive Predictive Value 14.50% 95% CI: 10.47 to 19.36 
Negative Predictive Value 88.24% 95% CI: 84.71 to 91.20 
 
4.4 Discussion 
Our Registry data on carotid surgery demonstrated patients’ baseline characteristics and 
perioperative outcomes are comparable with recent major randomised carotid intervention 
studies155, 156. Persistent high rates of transcranial Doppler detected – microemboli acutely 
following carotid endarterectomy have been associated with thrombotic stroke31. These high risk 
patients require additional anti-thrombotic agents to reduce stroke risk176, 215, 217. Based on the 
Registry data, the Pocock score has been shown to be associated with the presence of transcranial 
Doppler detected – microemboli acutely following carotid endarterectomy. Here I show that 
Pocock score ≥ 0.8% significantly predicted the presence of microemboli following surgery. I have 
shown that a Pocock score ≥ 0.8% has a high sensitivity and negative predictive value in detecting 
those cohort who required additional antiplatelet agent to treat persistent acute postoperative 
microemboli. These findings suggest that the Pocock score could potentially be used as a clinical 
tool to identify patients who are at increased risk of developing acute postoperative microemboli. 
The Registry demographic profiles such as age and sex were similar to the expected carotid 
disease characteristics and consistent with other recent major carotid intervention studies155, 156. 
The proportion of asymptomatic patients who underwent CEA was significantly less during the 
period of 2010 and 2012. This is expected as a previous randomised controlled trial has shown 
that carotid endarterectomy is beneficial in only a selective cohort of asymptomatic critical 
carotid artery stenosis patients249. The proportion of TIA, amaurosis fugax and retinal artery 
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occlusion patients who underwent carotid endarterectomy in the Registry were similar to the 
participants in a multi-centre European study on carotid intervention155. The proportion of 
ischaemic stroke patients who underwent carotid endarterectomy was half of those participating 
in the European carotid intervention study155. 
The baseline cardiovascular risk factors in our cohort were similar to the 2 most recent multi-
centre randomised controlled trials on carotid intervention155, 156. There is a trend of decreasing 
incidence of hypercholesterolaemia, TIA or stroke and ischaemic heart disease in the Registry 
cohort. There is also an increasing trend of using multiple antiplatelet agents prior to carotid 
endarterectomy in order to reduce the risk of perioperative stroke. This can be explained with the 
general improvement of medical treatment for cardiovascular disease such as better antiplatelet 
therapy, widespread use of statins and decline of smoking habit140, 250, 251. Those who were on 
triple preoperative antiplatelet agents had the additional antiplatelet agent started in hospital. In 
the preoperative dual antiplatelet group, the number of patients who had the additional 
antiplatelet agent started cannot be determined reliably due to individual surgeon preference and 
the various sources of referral either from the community, TIA clinics in other hospitals or the 
Emergency Department in Coventry or the surrounding regions.  
In terms of the operative technique, the proportion of patients who underwent carotid 
endarterectomy under general anaesthesia and requiring a shunt during the carotid clamp stage 
was significantly less than a recent multi-centre randomised controlled trial on carotid 
intervention156. This could be explained by the utilisation of TCD during carotid endarterectomy. A 
shunt was used selectively depending upon TCD evaluation of cerebral blood flow before and 
after carotid clamping. 
The overall 30 day mortality and morbidity rate such as CVA/TIA, myocardial infarction and 
postoperative bleeding were similar to the most recent nationwide UK carotid endarterectomy 
audit192. Our postoperative cranial nerve injury (5.1%) was higher than the national audit. 
The proportion of patients who developed microemboli acutely following surgery were similar to 
a previous published report252. There is a decreasing trend in the proportion of patients who 
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developed microemboli acutely following surgery over the years. The number of patients who 
developed a persistent high rate of microemboli requiring additional anti platelet therapy was 
also fewer in more recent years. These findings correlate with the increasing use of multiple anti 
platelet agents prior to carotid endarterectomy during the same period. The use of multiple 
antiplatelet agents has been shown to be more effective in reducing the rate of carotid associated 
microemboli37, 217.   
None of the cardiovascular composite risk scores were able to predict the presence of 
microemboli in these high risk patients. Only the Pocock score showed an association with the 
presence of transcranial Doppler detected – microemboli acutely following carotid 
endarterectomy. Further analysis confirmed that the Pocock score predicted the presence of 
transcranial Doppler detected – microemboli acutely following carotid endarterectomy. The 
association of the Pocock score with acute postoperative MES rate > 50hr1 was unclear. These 
were the patients at high risk of developing postoperative thrombotic stroke and requiring 
additional antiplatelet therapy176.  
In this study, I found that a Pocock score ≥ 0.8% was able to predict microemboli. It also has a high 
sensitivity and negative predictive value for those with a rate of > 50hr1. A Pocock score ≥ 2.3% 
has been shown to have high sensitivity for the presence of microemboli and negative predictive 
value for the presence of microembolic rate of > 50hr1. When the level of Pocock score was ≥ 
6.1%, a high negative predictive value for the presence of microemboli was noted. This suggests 
that the Pocock score could potentially be used as a clinical tool for identifying patients at very 
high risk of developing significant post-operative microembolisation. 
There are several limitations to this Registry. Fifteen patients from the retrospective cohort were 
excluded for the final analysis due to lack of relevant data pertinent to the Registry. Therefore 
only 670 patient data were analysed in this chapter. This small number of missing patients is 
unlikely to influence the overall results. Furthermore, the baseline patient characteristics between 
the retrospective and prospective cohorts were similar and any relevant differences were 
consistent with the improvement of medical therapy and changes in clinical practice. Another 
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possible limitation of this Registry is the external data validation. The Registry demographic 
profiles and cardiovascular risk factor burden were similar to the expected carotid disease 
characteristics and consistent with other recent major European carotid intervention studies155, 
156. It is possible to cross-match the Registry data against the UK National Vascular Registry192. 
However, the National Registry was only formed in 2013 by the amalgamation of the National 
Vascular Database and UK Carotid Interventions Audit projects192. The data also relies on 
individual surgeons self-reporting, so is subject to selection and information bias. In 2012, a new 
validated cardiovascular disease risk score (QRISK2) was published based on the routinely 
collected data from general practice in the UK253. It has incorporated similar data as Framingham, 
JBS2 and ASSIGN with additional information such as rheumatoid arthritis, atrial fibrillation and 
chronic kidney disease. It has a clear advantage of reflecting the cardiovascular disease state of 
the UK population and has been shown to be more accurate than the established Framingham 
score254. However, there are a few limitations that are worth noting. First, the data were based on 
the self-reporting by the general practitioners with potentially significant selection and 
information biases, so it unlikely to be as robust as data collected in the Framingham or Pocock 
risk score. Unlike the Framingham and Pocock risk scores, the cohort included in this risk score 
was not standardised and cardiovascular disease treatment naive with unclear natural history. 
Due to its limitation and the publication timing of the validated study, the QRISK2 risk score was 
not considered in my thesis. 
In conclusion, a Registry is useful in demonstrating clinical population based data which can be 
used to review and improve clinical practice. In this chapter, I used the data to evaluate the 
association between composite cardiovascular score and the presence of microemboli acutely 
following carotid endarterectomy. The analysis of the data has shown that the Pocock score has 
the potential to identify patients who are at risk of developing microemboli following carotid 
endarterectomy. 
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CHAPTER FIVE 
 
5 Classical cardiovascular risk factor burden and ABCD2 stroke risk score to predict the 
presence of cerebral microemboli in patients with hyper-acute symptomatic critical 
carotid artery stenosis 
 
5.1 Introduction 
The risk of recurrent stroke following a first TIA or minor stroke is highest during the first 7 – 14 
days1. About 15% of ischaemic strokes are associated with carotid artery stenosis, which confers a 
higher risk of early stroke recurrence compared with other stroke syndromes such as cardio-
embolic or small vessel stroke15. Previous studies have shown that the benefit of surgery is 
greatest if it was performed within 2 weeks after the last ischaemic event51. United Kingdom 
National Institute for Health and Clinical Excellence (NICE) guidelines recommend that patients 
with symptomatic carotid artery stenosis undergo urgent endarterectomy within 2 weeks103. 
Transcranial Doppler (TCD) – detected cerebral microembolic signals (MES) predict short term 
stroke risk in patients with symptomatic carotid stenosis34. Cerebral microemboli have in 
particular been reported to be a reliable biomarker of short term ischaemic stroke risk35, 36,32, 60. 
The ABCD2 risk prognostic scoring system101 predicts who is likely to be at increased risk of 
suffering a recurrent early stroke following onset of the initial stroke/ TIA101, irrespective of the 
mechanism for acute stroke/TIA. The ABCD2 stroke risk score 101 can be used to triage the urgency 
for seeing recently symptomatic patients with a TIA or minor stroke in cerebrovascular clinics. 
National Institute for Health and Care Excellence (NICE) guidelines103 recommend that patients 
with an ABCD2 risk score ≥4 should be assessed within 24 hours and those with an ABCD2 risk 
score <4  should be evaluated within a week of symptoms onset. 
The ABCD2 risk score is based on standard classical cardiovascular risk factors and clinical features 
for symptomatic carotid disease. One would expect symptomatic carotid artery disease patients 
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to have a high cardiovascular risk factor burden and high ABCD2 risk score. TCD-detected 
microemboli have been associated with recent symptoms and vulnerable carotid plaque 
characteristics188. Both the ABCD2 score and the presence of cerebral microemboli predict the risk 
of early recurrent stroke.  
The association between ABCD2 risk score and cerebral microemboli has not been studied. The 
aim of this study was to explore whether the ABCD2 risk score predicts the presence of cerebral 
microemboli in patients with hyper-acute symptomatic critical carotid artery stenosis. 
 
5.2 Subjects and Methods 
University Hospitals Coventry and Warwickshire NHS Trust serves a population of 950,000. Our 
Neurovascular Fast-Track Clinic assesses approximately ~80 patients per month who are 
suspected of having suffered a TIA/minor stroke and who have been referred from the 
Community or by the Emergency Department. In the same visit, patients also undergo carotid 
duplex examination. Since 2002, it has been the policy in our Centre that patients who present 
within 2 weeks of index symptoms have an additional TCD examination to detect cerebral 
microemboli as this cohort of patients merits more aggressive treatment to prevent recurrent 
stroke218. In this thesis, I defined the hyper-acute period as within 2 weeks of stroke or TIA255. 
 
Two hundred and six (age 70 ± 1 [SEM] years, male 149, Caucasian 196) patients were included in 
this study. This included 102 patients from our Carotid Registry retrospectively assessed between 
January 2002 and December 2010176. In this chapter, the retrospectively cohort patient will be 
discussed in the Registry section. A further 104 consecutive patients were recruited between 
February 2011 and May 2013 within a new prospective study of hyper-acute symptomatic carotid 
artery stenosis. 
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Inclusion and exclusion criteria 
Only patients who presented within 2 weeks of symptoms of acute non-disabling stroke (The 
Modified Rankin Scale [mRS] ≤ 2) or TIA were included. All had at least haemodynamically 
significant 50% carotid artery stenosis121 measured by carotid duplex scan based on NASCET 
criteria as recommended by the Vascular Society and Society of Vascular Technology of Great 
Britain and Ireland118. All patients with haemodynamically significant ≥ 50% carotid stenosis went 
on to have TCD examination which was supervised by accredited vascular technologists118. 
 
Patients with atrial fibrillation, because this confers risk of an additional non-carotid source of 
emboli were excluded. In addition, patients with a prosthetic heart valve, because of the 
recognised effect of these valves to generate gaseous and other embolic signals256 were also 
excluded. Patients who had a major stroke were excluded because the ABCD2 risk score only 
applied to TIA or minor stroke100. Patients who presented more than 2 weeks of last symptoms of 
stroke or TIA were also excluded because this is not considered to be within the defined 
hyperacute period255. 
 
Assessment of the ABCD2 risk score 
It ranged from 0 - 7101.  [Scale9: age ≥60 years - 1 point; blood pressure ≥140/90mmHg - 1 point; 
limb weakness - 2 points; speech impairment – 1 point; duration of symptoms - 2 points for ≥ 60 
minutes, and 1 for 10-59 minutes; diabetes mellitus - 1 point]. The ABCD2 score9 was available in 
all patients recruited for the prospective observational study from 2011 to 2013.  Seven patients 
from the Carotid Surgery Registry from the period of 2002 and 2005 were excluded from the 
analysis due to lack of data pertinent to the ABCD2 risk score calculation. 
 
Assessment of cardiovascular risk factors 
Classical cardiovascular risk factors were assessed based on validated scoring systems93. Total 
cardiovascular disease (CVD) risk for an individual is estimated from several risk factors and 
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slightly differs between individual cardiovascular risk score. CVD end point is defined as combined 
end point of coronary heart disease (fatal and non-fatal myocardial infarction and new angina) 
plus stroke (fatal and non-fatal stroke and cerebral haemorrhage) and transient cerebral 
ischaemia93. The total CVD risk score is expressed as a probability (percentage chance) of 
developing CVD or death over a defined period of time. Framingham, Joint British Societies’ 
Guidelines on Prevention of Cardiovascular Disease in Clinical Practice (JBS 2), Scottish ASSIGN 
scores estimate the CVD risk over 10 years where as Pocock score estimates the risk of CVD death 
over 5 years93, 99. 
 
Transcranial Doppler recording 
TCD monitoring171 was performed (PC Dop 842, SciMed, Bristol, UK) with a 2 MHz probe focused 
on the middle cerebral artery ipsilateral to the stenotic carotid artery. The TCD signal was 
assessed by an experienced vascular scientist. The MCA was identified by placing the probe above 
the zygomatic arch and just in in front of the ear. A head-frame was used to secure a constant 
angle of insonation during the TCD monitoring. Doppler signals were obtained within the depth 
range of 55 – 64 mm and time–averaged mean velocity in the region of 55 ± 12 cm/sec. Single 
channel was chosen and a filter set to a low threshold to capture all possible signals. The recorded 
ultrasonographic images were then assessed to differentiate artefact from microemboli based on 
criteria of the International Consensus Group on microembolus detection171. MES were identified 
as unidirectional, short duration signals (range 10–100 ms) with intensity threshold above 6 dB, 
accompanied by characteristic audible clicks and occurring randomly throughout the cardiac cycle 
170, 171 Monitoring was performed for 60 minutes after carotid duplex assessment. TCD 
examination was performed by accredited vascular technologists118. 
 
Microembolic signals 
In patients who had acute symptoms suggestive of TIA/non-disabling stroke with evidence of a 
haemodynamically significant 50% carotid stenosis, TCD monitoring was commenced for up to 60 
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minutes following the completion of the carotid duplex examination. Based on Markus et al36, 
dichotomous outcome was used to classify patients with microembolic TIA or stroke, according to 
MES presence rather than rate or number of MES. This study showed that the presence of MES, 
but not the rate of MES, was associated with a high risk of recurrent stroke.36 This policy has also 
been adopted in a recent prospective multi-centre study looking at the association between MES 
and stroke.32 
 
Ethics 
Registry 
Data collection for the Registry was agreed with the Research & Development Department at 
University Hospital Coventry Warwickshire NHS Trust, which confirmed that Research Ethics 
Committee (REC) review was not required under the harmonised Governance Arrangement for 
REC (GAfREC) for research257. 
 
Prospective cohort study 
The study was approved by the NHS Ethics Committee (MREC number 10/H1206/77) and 
Research & Development Department (R&D C1080610). 
 
Statistical analyses 
In view of differences among patients in antiplatelet treatment prior to their acute neurological 
events, the data were analysed in 2 stages.  Initially, both microembolic and non-microembolic 
cohorts were studied together. Then, taking into account the influence of antiplatelet treatment 
on cerebral microemboli37, the data were analysed separately for patients with or without pre–
neurological event antiplatelet and statin treatment. Framingham, JBS 2, ASSIGN scores 
considered 20% as the threshold where patients should be considered for pharmacology and 
lifestyle interventions. The Pocock score was developed based on patients who were already 
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established as having cardiovascular disease93, 99. Therefore all the patients in this thesis were 
eligible for Pocock score estimation. 
Statistical analyses were conducted using SPSS® version 21 (Chicago, Illinois, USA).  
Parametric data are expressed as mean and standard error of the mean (SEM). Non-parametric 
data are expressed as median and inter quartile range (IQR). Non-parametric unpaired data were 
analysed using the Mann-Whitney U test for two group comparisons. Categorical variables were 
analysed using the chi-squared test or Fisher’s exact test.  The association between microemboli 
and ABCD2 risk score was also analysed using Receiver Operating Characteristic Curves (ROC). A P-
value of less than 0.05 was considered significant.  
 
Sample size calculation: 
We set an area under the curve (AUC) of 0.5 or below as the cut-off point for ABCD2 score not 
predicting the presence of microemboli. For the whole group, the study had 80% power at the 5% 
level in a 2-tailed test to detect at least 0.69 as AUC for ROC (71 subjects per group).  
 
5.3 Results 
5.3.1 Clinical features 
Two hundred and six patients (age 70 ± 1 year, 149 male, 196 Caucasians) were included in this 
study. Eighty six patients (age 70 ± 1, 58 male, 83 Caucasians) had evidence of one or more 
microemboli; 72 (84%) of these underwent carotid endarterectomy (CEA). A single patient had a 
TIA, one patient developed myocardial infarction and one embolising patient died due to renal 
failure 30 days after CEA. One hundred and twenty patients (age 72 ± 1 years, 91 male, 113 
Caucasians) did not have microemboli detected; 102 (85%) of these underwent CEA. Thirty days 
complications after CEA were TIA in 2 patients, stroke in 3 patients, and death in 3 non-embolising 
patients (sepsis and haemorrhagic strokes). Antiplatelet treatment had been prescribed to 67 of 
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86 (78%) patients with microemboli, and to 82 of 120 (68%) patients without microemboli (P = 
0.130, X2). 
 
Cardiovascular risk factor burden 
A family history of vascular disease was more common in the non-embolising group (42 (35%)) 
than in those who had microemboli following a non-disabling stroke/TIA (19(22%); odds ratio 1.5 
(95%CI 0.98-2.2) P = 0.045, Table 28). Peripheral arterial disease was also more common in the 
non-embolising group (21(18%)) compared with those who had microemboli associated with 
stroke or TIA (7(8%); odds ratio 1.8 (95%CI 0.95-3.6) P = 0.038, Table 28). 
Detection of microemboli was not associated with significant differences in prevalence or severity 
of hypertension, diagnosed hyperlipidaemia, diabetes mellitus or ischaemic heart disease (Table 
28, Table 29).   
 
Laboratory and imaging investigations 
The microembolic stroke/TIA cohort had a slightly higher level of total cholesterol (4.9 ± 0.2 
mmol/L) than controls (4.5 ± 0.1 mmol/L; P = 0.01, MW; Table 2). There were no significant 
differences between these cohorts in renal function, blood glucose, HbA1c, or in inflammatory 
markers (white blood count or C-reactive protein: Table 29). Carotid ultrasound imaging revealed 
no difference in degree of carotid artery stenosis between those with vs. those without 
microemboli (microemboli: 80 ± 1% vs. controls: 79 ± 1%; P = 0.845, MW test). 
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Table 28.  Demographic and clinical profile in patients with hyper-acute symptomatic carotid stenosis: 120 
without microemboli and 86 with microemboli 
 Non-embolising group 
n (%) 
Embolising group 
n (%) 
X2  test 
P value 
Age, mean ± SEM 72 ± 1 70 ± 1 0.339 
Male 91(76) 58(67) 0.184 
Caucasian 
South Asian 
113(94) 
3(2.5) 
83(97) 
(0) 
0.290 
Hypertension 93(78) 65(76) 0.748 
Never smoke 
Current smoker 
Ex-smoker 
42(35) 
46(38) 
32(27) 
28(33) 
30(34) 
28(33) 
0.655 
Ischaemic heart disease 28(23) 17(20) 0.157 
Type 2 Diabetes mellitus 20(17) 16(19) 0.907 
Hypercholesterolaemia 65(54) 51(59) 0.464 
Peripheral arterial disease 22(18) 7(8) 0.038 
Cerebrovascular disease 24(20) 20(23) 0.574 
Family History 42(35) 19(22) 0.045 
 
Table 29. Blood pressure and preoperative laboratory values in patients with hyper-acute symptomatic 
carotid stenosis: 120 without microemboli and 86 with microemboli 
Laboratory variables Non-embolising group 
Mean ± SEM (n) 
Embolising group 
 
Mean ± SEM (n) 
Mann-Whitney 
U test 
P value 
Systolic blood pressure 151 ± 2 (120) 152 ± 3 (86) 0.88 
Diastolic blood pressure 77 ± 1 (120) 82 ± 3 (86) 0.986 
Cholesterol (mmol/L) 4.5 ± 0.1 (102) 4.9 ± 0.2 (66) 0.041 
Triglyceride (mmol/L) 1.6 ± 0.1 (56) 1.95 ± 0.2 (41) 0.869 
HDL (mmol/L) 1.37 ± 0.1 (95) 1.46 ± 0.1 (64) 0.697 
Creatinine (mol/L) 99 ± 3 (120) 104 ± 6 (51) 0.692 
Glucose (mmol/L) 5.8 ± 0.2 (97) 5.8 ± 0.2 (56) 0.548 
Haemoglobin (g/L) 137 ± 12 (119) 134 ± 02 (86) 0.133 
Platelet (x 109/L) 254 ± 6 (119) 259 ± 8 (86) 0.762 
White cell count (x 109/L) 8.2 ± 0.2 (119) 8.1 ± 0.3 (86) 0.418 
CRP (units) 7.4 ± 2.0 (34) 7.8 ± 1.3 (57) 0.954 
HbA1C (%) 6.3 ± 0.2 (19) 6.1 ± 0.1 (12) 0.764 
Carotid stenosis (%) 79 ± 1 (86) 80 ± 1 (86) 0.845 
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5.3.2 Prediction of cardiovascular risk score for microemboli in 206 patients with hyper-acute 
symptomatic carotid artery stenosis 
 
Table 30 shows the proportion of patients who developed microemboli among this high risk 
cohort were similar between these 4 scores. 
 
Table 30. Distribution of microembolic patients based on risk score: 120 without microemboli and 86 with 
microemboli 
Cardiovascular risk 
score, n 
Non-embolising, n Embolising, n X2 test 
P value 
Pocock ≥ 0% (5) 2 3 0.875 
Pocock ≥ 0.3% (7) 4 3 
Pocock ≥ 0.8% (29) 16 13 
Pocock ≥ 2.3% (53) 29 24 
Pocock ≥ 6.1% (86) 54 32 
Pocock ≥ 15.6% (26) 15 11 
CVD Framingham ≥20% 
(169) 
102 67 0.203 
CVD-Death Framingham 
≥20% (61) 
40 21 0.467 
JBS2 ≥20% (148) 90 58 0.234 
ASSIGN ≥20% (159) 98 61 0.07 
 
Microembolic cohort vs. non-microembolic cohort 
There was no significant difference in cardiovascular risk score between patients who had 
evidence of microemboli and no microemboli in patients with hyper-acute symptomatic carotid 
artery stenosis. Based on the Framingham score, there was a trend towards a higher risk of death 
from cardiovascular disease in patients with microemboli (P=0.055, MW test) (Table 31). 
Table 31. Cardiovascular risk score in patients with hyper-acute symptomatic carotid stenosis: 120 without 
microemboli vs. 86 with microemboli 
Cardiovascular risk score P – value (MW test) 
Pocock 0.11 
CVD Framingham 0.172 
CVD-Death Framingham 0.55 
JBS2 0.121 
ASSIGN 0.084 
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There was no significant difference in cardiovascular risk score between patients included from 
Registry and prospective study cohorts (Table 32).  
Table 32. Cardiovascular risk score in patients with hyper-acute symptomatic carotid stenosis: Prospective 
cohort (n = 104) vs. Registry cohort (n = 102) 
Cardiovascular risk score P – value (MW test) 
Pocock 0.229 
CVD Framingham 0.161 
CVD-Death Framingham 0.222 
JBS2 0.19 
ASSIGN 0.259 
 
Prospective cohort 
There was no significant difference in cardiovascular burden score between patients who had 
evidence of microemboli and no microemboli in patients with a hyper-acute symptomatic carotid 
artery stenosis (Table 33). 
 
Table 33. Cardiovascular risk score in prospective hyper-acute symptomatic carotid stenosis cohort: 53 
without microemboli vs. 51 with microemboli 
Cardiovascular risk score P – value (MW test) 
Pocock 0.375 
CVD Framingham 0.793 
CVD-Death Framingham 0.208 
JBS2 0.485 
ASSIGN 0.642 
 
Registry cohort 
There was no significant difference in calculated cardiovascular risk score between patients who 
had evidence of microemboli and no microemboli in patients with hyper-acute symptomatic 
carotid artery stenosis ( 
Table 34). 
 
Table 34. Cardiovascular risk score in Registry hyper-acute symptomatic carotid stenosis cohort: 67 without 
microemboli vs. 35 with microemboli 
Cardiovascular risk score P – value (MW test) 
Pocock 0.104 
CVD Framingham 0.063 
CVD-Death Framingham 0.074 
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JBS2 0.064 
ASSIGN 0.019 
In the hyper-acute symptomatic carotid artery stenosis cohort, 57 patients were not on any 
antiplatelet agent or anticoagulant prior to the TIA or minor stroke events. Prior to the TIA or 
minor stroke events, 126 were already on single antiplatelet agent and 23 were on dual 
antiplatelet agents. Taking into account the influence of antiplatelet agents on microemboli, those 
who were not on antiplatelet agents and those on antiplatelet agents prior to the TIA or minor 
stroke events were analysed separately.  
There was no significant difference in calculated cardiovascular risk score between patients who 
had evidence of microemboli and no microemboli in patients without antiplatelet treatment pre-
neurological event (Table 35). 
Table 35. Cardiovascular risk score in hyper-acute symptomatic carotid stenosis cohort without antiplatelet 
treatment pre-neurological event (n = 57): 38 without microemboli vs. 19 with microemboli 
Cardiovascular risk score P – value (MW test) 
Pocock 0.660 
CVD Framingham 0.919 
CVD-Death Framingham 0.66 
JBS2 0.986 
ASSIGN 0.498 
 
In patients already on antiplatelet treatment, the non-embolising symptomatic carotid artery 
disease cohort showed trend towards a higher cardiovascular risk factor burden (Pocock risk 
score, P = 0.055, MW test) and were at significantly higher long term risk of cardiovascular death 
(CVD-Death Framingham, P = 0.037, MW test) than the embolising cohort. 
 
Table 36. Cardiovascular risk score in hyper-acute symptomatic carotid stenosis cohort with antiplatelet 
treatment pre-neurological event (n = 149): 82 without microemboli vs. 67 with microemboli 
Cardiovascular risk score P – value (MW test) 
Pocock 0.055 
CVD Framingham 0.142 
CVD-Death Framingham 0.037 
JBS2 0.077 
ASSIGN 0.088 
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Taking into account the influence of statins on microemboli and atherosclerotic carotid disease, 
those who were not on statins and those on statins prior to the TIA or minor stroke events were 
analysed separately.  
There was no significant difference in the cardiovascular burden score between patients who had 
evidence of microemboli and no microemboli in patients with hyper-acute symptomatic carotid 
artery irrespective of statins treatment (Table 37,  
Table 38). 
 
Table 37. Cardiovascular risk score in hyper-acute symptomatic carotid stenosis cohort without statins pre-
neurological event (n = 72): 41 without microemboli and 31 with microemboli 
Cardiovascular risk score P – value (MW test) 
Pocock 0.293 
CVD Framingham 0.193 
CVD-Death Framingham 0.144 
JBS2 0.185 
ASSIGN 0.248 
 
Table 38. Cardiovascular risk score in hyper-acute symptomatic carotid stenosis cohort with statins pre-
neurological event (n = 134): 79 without microemboli and 55 with microemboli 
Cardiovascular risk score P – value (MW test) 
Pocock 0.252 
CVD Framingham 0.476 
CVD-Death Framingham 0.203 
JBS2 0.364 
ASSIGN 0.200 
 
Receiver Operating Characteristics 
For further analyses, I examined whether the Pocock score was able to predict the presence of 
cerebral microemboli in hyper-acute symptomatic carotid artery disease cohort in 4 stages; 
general and using Pocock score ≥ 0.8%, 2.3% and 6.1% as a cut-off point.  
The ROC for Pocock score showed no significant prediction for microemboli in patients with 
hyper-acute symptomatic carotid artery stenosis (AUC 0.435 95% CI 0.355 – 0.514, P = 0.11: 
Figure 15). 
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Figure 15. ROC for Pocock score against presence of microemboli in patients with hyper-acute symptomatic 
carotid artery stenosis (n = 206) (AUC 0.435 95% CI 0.355 – 0.514, P = 0.11)
 
The ROC for a Pocock score ≥ 0.8% showed no significant prediction of microemboli following 
hyper-acute symptomatic carotid artery disease (AUC 0.509 95% CI 0.326 – 0.692, P = 0.922: 
Figure 16). The ROC for a  Pocock score ≥ 2.3% showed no significant prediction of microemboli 
following hyper-acute symptomatic carotid artery disease (AUC 0.481 95% CI 0.401 – 0.562, P = 
0.646). The ROC for a Pocock score ≥ 6.1% showed no significant prediction of acute 
postoperative microemboli (AUC 0.463 95% CI 0.383 – 0.542, P = 0.359). 
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Figure 16 ROC for Pocock score ≥ 0.8% against presence of microemboli following hyper-acute symptomatic 
carotid disease (n = 206) (AUC 0.509 95% CI 0.326 – 0.692, P = 0.922) 
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Diagnostic accuracy 
A Pocock score ≥ 0.8% and 2.3% showed high sensitivity for the presence of microemboli 
following acute symptomatic carotid disease (Table 39, Table 40). A Pocock score ≥ 6.1% showed 
general poor diagnostic accuracy for the presence of microemboli (Table 41). 
 
Table 39 Diagnostic accuracy Pocock’s score ≥ 0.8% vs MES 
Sensitivity 95.35% 95% CI: 88.51 to 98.69 
Specificity 5.00% 95% CI:  1.87 to 10.57 
Positive Predictive Value 41.84% 95% CI:  34.85 to 49.08 
Negative Predictive Value 60.00% 95% CI:  26.37 to 87.60 
 
Table 40. Diagnostic accuracy Pocock score ≥ 2.3% vs MES 
Sensitivity 77.91% 95% CI: 67.67 to 86.14 
Specificity 18.33% 95% CI: 11.86 to 26.43    
Positive Predictive Value 40.61% 95% CI: 33.04 to 48.52    
Negative Predictive Value 53.66% 95% CI: 37.45 to 69.34 
 
Table 41. Diagnostic accuracy Pocock score ≥ 6.1%% vs MES 
Sensitivity 38.39% 95% CI: 29.36 to 48.06 
Specificity 54.26% 95% CI: 43.66 to 64.58    
Positive Predictive Value 50.00% 95% CI: 39.02 to 60.98     
Negative Predictive Value 42.50% 95% CI: 33.53 to 51.85  
 
 
5.3.3 ABCD2 risk score to predict presence of cerebral microemboli in hyper-acute 
symptomatic critical carotid artery stenosis patients 
 
Table 42, figure 17 and figure 18 show the overall distribution of cerebral microemboli and their 
associated ABCD2 score in hyper-acute symptomatic critical carotid artery stenosis patients.  
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Table 42. Distribution of ABCD2 score and microemboli based on degree of carotid stenosis 
Carotid stenosis 
(%), n 
No MES MES 
 ABCD2 score <4 ABCD2 score ≥4 ABCD2 score <4 ABCD2 score ≥4 
50 – 59 (15) 2 9 1 3 
60 – 69 (25) 3 11 3 8 
70 – 79 (47) 10 17 4 16 
80 – 89 (48) 8 17 11 12 
90 – 99 (71) 16 27 8 20 
 
 
Figure 17. Distribution of microembolic patients based on carotid stenosis: 120 without microemboli and 86 
with microemboli 
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Figure 18. Distribution of ABCD2 score based on carotid stenosis: 120 without microemboli and 86 with 
microemboli. 
 
 
One hundred and forty of 206 (68%: 95%CI 62 – 74%) patients with hyper-acute symptomatic 
critical carotid stenosis had an ABCD2 risk score ≥4. The ABCD2 risk score was ≥4 in 59 of 86 (69%: 
95%CI 59 – 79) embolising patients and in 81 of 120 (68%: 95%CI 60 – 76) without cerebral 
microemboli. There was no significant difference in the NICE criterion for early assessment (ABCD2 
risk score ≥4) for patients with cerebral microemboli vs. those without microemboli (59/86 vs 
81/120 patients: odds ratio 1.05 (95% CI 0.58 - 1.90, P = 0.867). 
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Sixty six of 206 (32%: 95%CI 26 – 38) patients with hyper-acute symptomatic critical carotid 
stenosis had an ABCD2 risk score <4. The ABCD2 risk score was <4 in 27 of 86 (31%: 95%CI 21 – 41) 
embolising patients and in 39 of 120 (31%: 95%CI 23 – 39) without cerebral microemboli. 
 
There was no significant ABCD2 score difference between these 2 cohorts (non-embolising group, 
n = 120: ABCD2 score 4(IQR 3 – 5) vs. embolising group, n = 86: 4(IQR 3 – 5), P = 0.855 MW test). 
There was no significant ABCD2 score difference between Registry patients and prospective cohort 
study patients (Registry, n = 102 (ABCD2 score 4(IQR 3 – 5) vs. prospective cohort study, n = 104: 
4(IQR 3 – 5) P = 0.661 MW test). 
 
Registry (n = 102) 
Seventy-one of the 102 patients (70%: 95%CI 61.11 – 78.89) with acutely symptomatic critical 
carotid stenosis had an ABCD2 risk score ≥4. The ABCD2 risk score was ≥4 in 25 of 35 (71%: 95%CI 
56 – 86%) embolising patients and in 46 of 67 (69%: 95%CI 58 – 80%) without cerebral 
microemboli. There was no significant difference in the NICE criterion for early assessment (ABCD2 
risk score ≥4) for patients with cerebral microemboli vs. those without microemboli (25/35 vs 
46/67 patients: odds ratio 1.14 (95% CI 0.47 – 2.80, P = 0.773). 
Twenty-one of the 67 patients (31%: 95%CI 20– 42%) with symptomatic critical carotid stenosis 
had an ABCD2 risk score <4. The ABCD2 risk score was <4 in 10 of 35 (29%: 95%CI 14 – 44%) 
embolising patients and in 21 of 67 (31%: 95%CI 20 – 42) without cerebral microemboli. 
 
Prospective hyper-acute symptomatic carotid artery stenosis study (n = 104) 
Sixty-nine of the 104 patients (66%: 95%CI 57 – 75) with symptomatic critical carotid stenosis had 
an ABCD2 risk score ≥4. The ABCD2 risk score was ≥4 in 34 of 51 (67%: 95%CI 54 – 80) embolising 
patients and in 35 of 53 (66%: 95%CI 53 – 79) without cerebral microemboli. There was no 
significant difference in the NICE criterion for early assessment (ABCD2 risk score ≥4) for patients 
117 
 
with cerebral microemboli vs. those without microemboli (34/51 vs 35/53 patients: odds ratio 
1.03 (95% CI 0.46 – 2.23, P = 0.946). 
Thirty-five of the 104 patients (34%: 95%CI 25 – 43%) with symptomatic critical carotid stenosis 
had an ABCD2 risk score <4. The ABCD2 risk score was <4 in 17 of 51 (33%: 95%CI 20 – 46) 
embolising patients and in 18 of 53 (34%: 95%CI 21 – 47) without cerebral microemboli. 
 
Receiver Operating Curve (ROC) for ABCD2 score to predict the presence of microemboli 
 
Two hundred and six patients were included into this analysis. One hundred and twenty patients 
without and eighty six patients with microemboli. The ROC for ABCD2 risk score showed no 
significant prediction of microemboli (AUC 0.49 95% CI 0.41 – 0.57, P = 0.860: Figure 19). 
Figure 19. ROC for ABCD2 risk score against presence of microemboli in patients (n = 206) with hyper-acute 
symptomatic carotid stenosis (AUC 0.49 95% CI 0.41 – 0.57, P = 0.860) 
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Patients without antiplatelet treatment before the neurological event: 
Fifty seven patients were included in this analysis, where 19 of those patients had an evidence of 
microemboli and 38 patients had no evidence of microemboli. The ROC for ABCD2 risk score 
showed no prediction of microemboli (AUC 0.45 (95% CI 0.30 – 0.60), P = 0.531: Figure 20). 
 
Figure 20. ROC for ABCD2 risk score against presence of microemboli in patients (n = 57) without 
antiplatelet treatment pre-neurological event (AUC 0.45 (95% CI 0.30 – 0.60), P = 0.531) 
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Patient with antiplatelet treatment before the neurological event: 
One hundred and forty nine patients were included in this analysis. Sixty seven of these patients 
had an evidence of microemboli and eighty two patients had no evidence of microemboli. The 
ROC for ABCD2 risk score showed no prediction of microemboli (AUC 0.51 (95% CI 0.42 – 0.60), P = 
0.804: Figure 21) 
 
Figure 21. ROC for ABCD2 risk score against presence of microemboli in patients (n = 149) with antiplatelet 
treatment pre-neurological event (AUC 0.51 (95% CI 0.43 – 0.60), P = 0.531) 
 
 
 
120 
 
Patients without statin treatment before the neurological event: 
Seventy two patients were included in this analysis, where 31 of those patients had an evidence 
of microemboli and 41 patients had no evidence of microemboli. The ROC for ABCD2 risk score 
showed no prediction of microemboli (AUC 0.48 (95% CI 0.34 – 0.61), P = 0.716: Figure 22). 
 
Figure 22. ROC for ABCD2 risk score against presence of microemboli in patients (n = 72) without statin 
treatment pre-neurological event (AUC 0.48 (95% CI 0.34 – 0.61), P = 0.716) 
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Patient with statin treatment before the neurological event: 
One hundred and thirty four patients were included in this analysis, where 55 of those patients 
had an evidence of microemboli and 79 patients had no evidence of microemboli. The ROC for 
ABCD2 risk score showed no prediction of microemboli (AUC 0.50 (95% CI 0.40 – 0.60), P = 0.980: 
Figure 23). 
 
Figure 23. ROC for ABCD2 risk score against presence of microemboli in patients (n = 134) with statin 
treatment pre-neurological event (AUC 0.50 (95% CI 0.40 – 0.60), P = 0.980) 
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5.4 Discussion 
In this study, the ABCD2 risk score was found to be unable to identify patients with cerebral 
microemboli associated with symptomatic critical carotid artery stenosis. The study also suggests 
that 66 (32%) patients with hyper-acute symptomatic carotid disease with or without 
microemboli are unlikely to be triaged effectively for urgent management using the ABCD2 risk 
score alone. Furthermore, 27 (31%) out of 86 patients with microemboli with an ABCD2 risk score 
<4 would also not have been assessed within 24 hours if NICE guidelines had been followed. Both 
ABCD2 risk score and cerebral microemboli predict short term risk of recurrent stroke. Therefore, 
the ABCD2 risk score is expected to be associated with occurrence of cerebral microemboli. These 
patients are known to benefit from targeted medical treatment37 to suppress microemboli prior 
to urgent carotid endarterectomy218. To my knowledge, this is the first study to explore the 
possible links between ABCD2 risk score and cerebral microemboli in patients with hyper-acute 
symptomatic critical carotid artery stenosis. Taken together with previous reports32, 34-36, 60, the 
study provides important evidence that the occurrence of cerebral microemboli, predictors of 
stroke risk, is dissociated from the results for the ABCD2 risk score.  
Of note, in this study, vascular complications were lower in patients with microemboli. This is 
likely to be due to reverse causality as in our centre patients with microemboli were assigned to 
receive more aggressive antiplatelet treatment compared to those in whom microemboli were 
not detected214, 218. 
Currently, the association between the ABCD2 risk score and the severity of structural carotid 
artery disease is unclear. This is an important issue to clarify as Ois et al58 reported that patients 
presenting with symptomatic critical carotid artery stenosis incur a 17% risk of recurrent stroke at 
72 hours, increasing to 22% at 7 days58. These patients are reported to benefit from carotid 
endarterectomy within 2 weeks53.  
Whilst Amarenco et al106 and Walker et al112 did not find an association between ABCD2 risk score 
and carotid artery disease, Schrock et al113, Sheehan et al111 and Koton et al110 suggested that high 
ABCD2 risk score may identify patients with significant carotid artery disease. However, Amarenco 
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et al106 reported that an ABCD2 risk score < 4 would miss 9% (62/679) of patients with 
symptomatic critical carotid artery stenosis.  
 Patients with symptomatic carotid artery disease are at high risk of developing stroke. I would 
expect to find a significantly higher cardiovascular risk factor burden in patients with cerebral 
microemboli. It appeared in this study that prevalence and severity of individual classical 
cardiovascular risk factors were similar or lower in the microembolic stroke cohort. Peripheral 
arterial disease and family history of vascular disease were more common in the non-
microembolic stroke cohort. Of note, a moderate ~10% increase in total cholesterol might 
contribute to excess risk of microembioli.  
The cardiovascular composite score including the Pocock score showed no significant difference 
between microembolic and non-microembolic cohorts. However, a high risk Pocock score (≥ 0.8% 
and 2.3%) showed high sensitivity for the presence of microemboli. None of the cardiovascular 
composite risk scores were able to predict the presence of microemboli in this high risk 
symptomatic carotid disease patients.  
The proportion of patients on antiplatelet therapy prior to the stroke syndrome event was similar 
in patients with or without microemboli. Thus differences in prescribed antiplatelet treatment 
were not sufficient on their own to explain whether a patient would have a higher or lower 
prevalence of embolisation. Of note, in patients already on antiplatelet treatment, the non-
embolising symptomatic carotid artery disease cohort showed a trend towards a higher 
cardiovascular risk factor burden and were at significantly higher long term risk of cardiovascular 
death than the embolising cohort. This may reflect the fact that the embolising cohort received 
more aggressive antiplatelet treatment37.  
Seven patients from the Registry were excluded in the analysis due to lack of relevant data 
pertinent to the ABCD2 risk score calculation, therefore only 206 patients were included for the 
final analysis. This was the retrospective cohort between the period of 2002 and 2005. The clinical 
features and duration which comprise 4 of the 7 possible points were not able to abstract reliably 
from the medical notes. This small number of missing data is unlikely to influence the overall 
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results. Furthermore, the baseline patient characteristics and results analysis between the 
retrospective and prospective cohorts were similar (high convergent validity)258 and any relevant 
differences were consistent with the improvement of medical therapy and changed of clinical 
practice. Overall, one quarter of patients in this study were not on antiplatelet agents prior to 
hospital admission with TIA or minor stroke despite well-established best medical treatment for 
cardiovascular disease. The reasons for this are unknown and beyond the scope of this study. It 
would be worthwhile to study the effectiveness and compliance of the best medical treatment in 
carotid disease patients. 
This study also emphasises the need for further work to elucidate cardiovascular risk factors and 
causative mechanisms for microemboli associated with acute stroke syndromes, and to identify 
optimal treatment to reduce microemboli-attributable stroke risk. 
In conclusion, the ABCD2 risk score offers a low cost and rapid assessment to identify patients at 
high risk of recurrent stroke syndrome. However, the study showed that the ABCD2 risk score 
does not appear to predict the presence of cerebral microemboli in hyper-acute symptomatic 
carotid stenosis cohort. Thus, based on ABCD2 risk score alone, a significant minority of patients 
with hyper-acute symptomatic carotid stenosis with or without cerebral microemboli would be 
likely to be overlooked in triage for more urgent assessment and these exposed to delayed 
treatment for preventable recurrent stroke. 
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CHAPTER SIX 
 
6 Transorbital Doppler as an alternative to transcranial Doppler for detecting cerebral 
microemboli in patients with carotid disease without an acoustic temporal bone 
window. 
 
Two phases for studies to evaluate the transorbital Doppler technique in detecting cerebral 
microemboli in patients who lacked acoustic temporal window were conducted. The 1st phase was 
to identify the proportion of patients who underwent transorbital examination and its feasibility 
to monitor microembolic signal after surgery from the Carotid Registry. The 2nd phase was a 
prospective observational study to validate the transorbital technique against the standard 
transcranial Doppler using temporal window technique for detecting microemboli. 
 
6.1 The feasibility of transorbital Doppler to detect carotid associated cerebral microemboli 
in patients without a temporal bone acoustic window 
 
6.1.1 Introduction 
Microemboli associated thrombotic stroke and cerebral hyperperfusion syndrome most 
commonly occurred acutely post carotid endarterectomy167. Transcranial Doppler (TCD) 
monitoring in the postoperative phase can be used to detect both cerebral hyperperfusion and 
transient cerebral microemboli. Persistent high levels of postoperative cerebral 
microembolisation are associated with early carotid thrombosis and based on the historical data, 
it was accounted for 2-3% of postoperative strokes 167. 
Transcranial Doppler ultrasound is a non-invasive technique that can be used to detect changes in 
middle cerebral artery (MCA) velocity and circulating cerebral microemboli. It has been shown to 
reliably detect carotid circulation-associated microemboli259. The use of this ‘through-the-skull’ 
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ultrasonography relies on an ‘acoustic window’ through which the ultrasound beam focuses on 
the intracranial arterial tree. The temporal bone acoustic window (TAW) is said to be absent or 
unsatisfactory in 10-15% of subjects although a figure as high as 29.1% is reported in the 
literature260, 261. This technical limitation has reduced the general routine clinical applicability of 
TCD.  
The transorbital Doppler approach has been described as an alternative to the standard TCD in 
monitoring blood flow velocity during carotid surgery262, 263. In the setting of post carotid surgery, 
those patients who lacked an acoustic temporal window, transorbital approach could be used to 
monitor the blood flow velocity for hyperperfusion syndrome. Its role in detecting cerebral 
microemboli has not been investigated before. In transorbital Doppler (TOD) monitoring the 
ultrasound beam is focused on the distal internal carotid, rather than the middle cerebral artery. 
It utilizes the thin orbital plate of the frontal bone, optic canal and superior orbital fissure for the 
penetration of ultrasonic waves. In transorbital Doppler (TOD) monitoring the ultrasound beam is 
focused on the distal internal carotid, rather than the middle cerebral artery (Figure 24). 
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Figure 24 Angiographic image of the carotid siphon. C5 (pre-cavernous/ganglionic segment), C4 (inferior 
carotid siphon), C3 (carotid knee), C2 (upper carotid siphon), and C1 (terminal ICA segment). Ref: Valaikiene 
et al. Am J Neuroradiol. 2008; 29:347-53. 
 
 
 
The aim of this study was to assess the feasibility of using the transorbital acoustic window in 
those patients with absence of a suitable temporal bone acoustic window to detect acute cerebral 
microemboli post carotid endarterectomy.   
 
6.1.2 Subjects and Methods 
A Registry review was undertaken of all CEA performed between 2002 and 2008 at the University 
Hospital Coventry and Warwickshire. All patients who underwent CEA between 2005- 2008 were 
assessed for a temporal acoustic window (TAW) for TCD examination prior to carotid surgery. 
Within this period, patients who were found to be unsuitable for standard TCD examination, were 
assessed for suitability via the transorbital approach. 
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The standard TCD examination has been described in chapter 3. All patients who underwent 
postoperative TCD or TOD examination during this period had manually recorded data on the 
presence of microemboli by the vascular technologists using a standardised proforma. The TCD 
spectral wave was also recorded using the automated detection software for further reviewed. 
 
Transorbital Doppler imaging 
The equipment used for TOD was the same as for TCD – a PC Dop 842 (SCI Med, Bristol, UK) 2 
MHz transducer probe. The probe was placed on the closed eye ipsilateral to the CEA, after 
acoustic coupling gel had been applied to that eye (Figure 25). Care was taken to avoid exerting 
undue pressure on the eye. An anterior-posterior orientiation was used to insonate the cavernous 
sinus and supraclinoid portions of the internal carotid artery. Once the carotid siphon wave 
spectrum had been identified (depth typically 65–70 mm), the acoustic amplitude was reduced to 
10% (Thermal Index (TI) < 0.1) of its initial transmitting power264. This allowed, adequate 
visualisation, while minimising the theoretical risk of orbital tissue heating265. 
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Figure 25 Ultrasound probe is placed on the closed eyelid by a vascular scientist for the TOD technique. The 
candidate (MH Mahmud Saedon) placing a second Doppler probe on the temporal bone window 
 
 
 
 
Ethics 
University Hospitals Coventry Warwickshire (UHCW) research ethics department has advised that 
this study did not fall under the remit of the National Health Service Research Ethics Committee 
as it was audit/service evaluation. Therefore informed consent process has been waived by UHCW 
research ethics department. 
 
6.1.3 Results 
318 CEAs were performed between 2005 and 2008. Of this subgroup, 29 (9.1%) had no TAW. TOD 
windows were used in 25 (86%) of these 29 patients. 4 (1.2%) patients could not be monitored.  
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Twenty-five patients (19 women) were detected with TOD windows; their ages ranged between 
59-86 years. Nineteen patients had symptomatic carotid disease with an average stenosis of 82% 
(range 70% to 99 %), and 21 were performed electively. The postoperative duration of monitoring 
was between 30 minutes to 70 minutes, while the number of emboli detected by TOD 
ultrasonography ranged from 1 to 28.  None of the TOD monitored patients had postoperative 
detectable neurological deficits. A single patient required glycoprotein IIb/IIIa receptor antagonist 
(Tirofiban) infusion for 1 day postoperatively due to excessive carotid microembolisation214. 
 
6.1.4 Discussion 
The key finding in this study is the feasibility of using transorbital approach in the majority of 
patients without a temporal acoustic window to detect microemboli were demonstrated. In one 
patient, intravenous glycoprotein IIb/IIIa receptor antagonist infusion to reduce the microembolic 
rate were monitored by the TOD technique. In that particular case, the transorbital approach was 
used on the basis of clinical judgement with intention to reduce postoperative stroke risk. 
The rate of encountering an absence TAW rate in the vascular unit was comparable to the rate 
quoted in the literature260. Failure to identify TAW has been attributed to age, female gender and 
skull thickness266. Transcranial Doppler is also an operator dependant technique. All these factors 
explained the significant variation of absent TAW rate reported in literature260, 266. 
The potential hazard of thermal injury to the eye is a concern with the transorbital approach. 
During the study period, there were no complications associated with this approach. A sufficient 
amount of gel was applied on the closed eyelid to minimise any mechanical pressure. Spencer and 
Whisler267 showed that transorbital Doppler examination is safe for the eye and reported no 
complaints or adverse effects. Subsequently, the safety of transorbital ultrasound examination 
has been discussed in the literature and believed to be safe for the eyes268. 
Recent evidence highlighted the importance of transcranial Doppler as a monitoring tool in 
carotid disease and antiplatelet infusion in reducing cerebral microemboli176. Wolf et al28 found 
significant correlation between microembolic signals and ischaemic lesions as well as brain 
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infarction during dissection. Abbott et al207 concluded that, postoperative detected TCD 
microembolic signal are associated with 15 times higher risk of stroke. Sharpe et al has 
demonstrated the high risk patients could be identified within 30 minutes of TCD examination 
following skin closure208. Therefore, early postoperative TCD monitoring provides important 
information relevant to perioperative carotid endarterectomy stroke prevention.  
In this study, the transorbital approach has been shown to enable us to monitor the majority of 
patients with an absent TAW post-carotid endarterectomy and to commence antiplatelet agent 
infusion in patients with high microembolic loads. The technique is fairly challenging for any 
untrained scientist and the patient undergoing the procedure. However, the evidence is 
overwhelmingly supportive of the use of TCD as part of stroke prevention in carotid surgery. This 
should offset the perceived challenging practicality of the transorbital approach. 
In conclusion, using the carotid Registry data, I was able to demonstrate the technical feasibility of 
transorbital approach in detecting microemboli in those patients with an absent temporal 
acoustic window for standard TCD examination. 
 
6.2 A prospective validation study of transorbital Doppler for the detection of cerebral 
microemboli using transtemporal Doppler imaging as the reference standard 
 
6.2.1 Introduction 
Transcranial Doppler (TCD) detected microemboli has provided direct evidence of 
thromboembolism as the main mechanism of symptomatic carotid artery disease269. Transcranial 
Doppler ultrasound studies show that the presence of microemboli in symptomatic carotid artery 
disease are associated with an increased risk of stroke31-33. Microemboli have also been used as an 
indirect biomarker to evaluate the efficacy and safety of using dual anti platelet or novel 
antiplatelet therapies in symptomatic carotid artery disease37, 168, 176, 217. More recently, TCD has 
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been used to monitor and guide the antiplatelet treatment for cerebral microemboli during 
carotid stenting procedure to prevent stroke270. 
Transcranial Doppler is the only real-time clinical imaging modality for detecting microembolic 
signals associated with carotid artery disease.  TCD relies on there being an acoustic temporal 
bone window through which the ultrasound beam can focus on the middle cerebral artery. The 
temporal bone acoustic window (TAW) is reported to be absent or unsatisfactory in around 15% 
of subjects, with an absent TAW in up to 29% of patients in some populations240. 
The transorbital Doppler (TOD) method has been suggested as an alternative option for patients 
who do not have a temporal bone window240. In TOD monitoring, the ultrasound beam is focused 
on the distal internal carotid artery, rather than the middle cerebral artery. In my earlier work, I 
have demonstrated the feasibility of using the transorbital approach to detect microemboli240. 
The next stage was to assess the validity and reliability of this technique to detect microemboli. 
The aim of this study was to validate the transorbital Doppler method for detecting carotid 
disease-associated transient cerebral microemboli, using the transcranial Doppler method as the 
reference standard. 
 
6.2.2 Subjects and Methods 
Subjects 
For the validation of TOD, patients undergoing elective carotid endarterectomy (CEA) were 
studied prospectively. A previous study has shown that up to 60% of patients may develop MES 
acutely following carotid surgery33. So, carotid endarterectomy was used as the research setting 
for this validation study due to the higher frequency of encountering microemboli following 
surgery. Patients who had both temporal and orbital acoustic windows were identified before 
surgery. Patients who did not have temporal bone or orbital acoustic windows were excluded 
from the study. Patients with atrial fibrillation were excluded, because this confers a risk of an 
additional non-carotid source of emboli. Patients with a prosthetic heart valve were also 
excluded, because of the recognised effect of these valves to generate gaseous and other embolic 
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signals256. 105 patients were initially recruited for the study based on the presence of a temporal 
acoustic window. However 5 of those patients did not have a satisfactory TOD window for 
monitoring. Therefore, 100 consecutive patients fulfilling the above inclusion and exclusion 
criteria who underwent elective CEA between February 2011 and May 2013 at the University 
Hospital Coventry and Warwickshire were included in the study. All patients gave written 
informed consent to the validation study, which was approved by the Local Research Ethics 
Committee. 
Prior to carotid endarterectomy, 35 patients were on single antiplatelet agent; 55 patients were 
on dual antiplatelet agents and 10 patients were on triple antiplatelet agents. Immediately after 
recovery from anaesthesia (typically less than 30 minutes after skin closure) patients underwent 
simultaneous TCD and TOD monitoring for 30 minutes by 2 vascular technologists accredited by 
the Society for Vascular Technology of Great Britain and Ireland118. The recorded signals were 
then re-examined by a 3rd accredited vascular technologist to confirm or refute the presence of 
microembolic signals.  
 
Transcranial Doppler method 
TCD monitoring was performed (PC Dop 842, SciMed, Bristol, UK) with a 2 MHz probe focused on 
the middle cerebral artery (MCA) ipsilateral to the endarterectemised carotid artery. The MCA 
was identified by placing the probe above the zygomatic arch and just in front of the ear. The 
identification of the MCA was based on guidelines set out by Alexandrov et al243 including spectral 
waveform, flow direction, blood flow velocity and flow pulsatility. A head-frame was used to 
secure a constant angle of insonation during TCD monitoring. An insonation depth of at least 
45mm was used to identify proximal MCA flow signals and depths of 30 – 45mm for distal MCA 
flow signals. 
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Transorbital Doppler Method 
The equipment used for TOD was the same as for TCD – a PC Dop 842 (SCI Med, Bristol, UK) 2 
MHz transducer probe. The probe was placed on the closed eye ipsilateral to the CEA, after 
acoustic coupling gel had been applied to that eye. Care was taken to avoid exerting undue 
pressure on the eye. An anterior-posterior orientation was used to insonate the cavernous sinus 
and supraclinoid portions of the internal carotid artery. Once the carotid siphon wave spectrum 
had been identified (depth typically 65–70 mm), the acoustic amplitude was reduced to 10% 
(Thermal Index (TI) < 0.1) of its initial transmitting power264. This allowed, adequate visualisation, 
while minimising thermal index to reduce theoretical risk of tissue heating265. 
 
MES identification and treatment 
For both methods, a single gating system and a filter set to a low threshold to capture signals 
were used. Automated WinTCD v3.7 software (VIASYS Healthcare Inc., Conshohocken, PA, USA) 
were used to monitor and record the Doppler wave form and audio signals. The recorded 
ultrasonographic images were then reassessed to exclude artefact and identify true microemboli 
based on the criteria of the International Consensus Group on microembolus detection171. MES 
were identified as unidirectional, short duration signals (range 10–100 ms) with intensity 
threshold above 6 dB, unidirectional, accompanied by characteristic audible clicks and occurring 
randomly throughout the cardiac cycle. We added treatment with tirofiban (Aggrastat®; MSD, 
Hoddeson, UK) in patients with an MES rate >50/hr176. Tirofiban248 was given intravenously at 
0.4mcg/kg/min for 30 minutes then at 0.1mcg/kg/min for 18 hours. 
 
Carotid endarterectomy 
CEA was performed as described in chapter 3. Shunting was performed if the patient developed 
focal neurological signs when CEA was performed under local anaesthetic; or in those cases 
performed under general anaesthetic when mean velocity of the middle cerebral artery dropped 
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by more than 50%. All patients received intravenous heparin (40 units kg-1) prior to the cross 
clamp phase of the carotid endarterectomy.  
 
Ethics 
This prospective observational study was approved by the Regional Coventry and Warwickshire 
Research Ethics Committee. 
 
Statistical analyses 
The diagnostic accuracy parameters of TOD in comparison to TCD were reported based on the 
STAndards for the Reporting of Diagnostic accuracy studies (STARD) statement 
recommendations271. TCD detected the clinically important circulating microemboli in the MCA 
(Reference standard), therefore the microemboli which ended up in the anterior circulating artery 
were unaccounted for. TOD detected microemboli at the distal end of the internal carotid artery. 
The same ultrasonography technique was used at different anatomical sites, so direct comparison 
between these two methods was not possible. We aimed to demonstrate that TOD is not clinically 
inferior to the TCD method. Therefore, for this experimental study, a false positive was defined as 
cerebral microemboli detected by means of TOD only as TCD remains the ‘gold standard’ imaging 
modality to identify microemboli 272, 273. During this study, the decision to treat cerebral 
microemboli acutely post carotid surgery was based on the findings of TCD only as TOD is not a 
validated method. It was therefore not considered ethical to use TOD findings as the basis to 
initiate antiplatelet treatment to reduce the risk of stroke 273 for those who have had a sustained 
high microembolic signal rate on TOD alone during this experimental study. 
  
Data are show as mean ± SEM. Categorical data were analysed by Chi – Squared test (X2) and non-
parametric data by Mann – Whitney U test (MW). Spearman’s rank correlation coefficient was 
used to assess the strength of relationship between numbers of microemboli detected by TCD vs. 
TOD. A P-value of less than 0.05 was considered significant. Bland – Altman analysis, including was 
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used to compare absolute numbers of microemboli detected by TCD vs. TOD. Statistical analyses 
were conducted using SPSS® version 21 (Chicago, Illinois, USA).  
 
Sample size 
The sample size for the study was estimated by considering the confidence interval (CI) width for 
the ratio of microemboli detected by TCD vs. TOD, based on the ratio of blood flow and the 
distribution of microemboli from the internal carotid artery into the MCA184.  For an estimated 
agreement rate of TCD vs. TOD of 83% based on pilot data, and a minimum acceptable agreement 
rate set at 70%184, a sample size of 100 patients provided a power of 80% at the 5% significance 
level (2-tailed) for a confidence interval width of 18% (95% CI 74 – 92%) for microemboli detected 
by TCD vs. TOD.  
 
6.2.3 Results 
Background profiles 
100 patients (age 72 ± 1 [SEM], male 65, Caucasian 97) were included in the study. Indications for 
CEA were: TIA 55, non-disabling stroke 19, asymptomatic critical artery stenosis 10, and amaurosis 
fugax 16. Carotid ultrasound imaging revealed the degree of carotid artery stenosis as 76 ± 1% 
(mean ± SEM). 
 
MES detection 
The depth for optimum ultrasound insonation for TCD was 53 ± 0.3 mm (mean ± SEM) and for 
TOD 69 ± 0.3 mm. The time - averaged mean velocity from TCD was higher than for TOD (40 ± 2 
vs. 33 ± 1 cm s-1, P = 0.002 MW). 
TCD detected 426 microemboli in 30 minutes whereas TOD detected 415 microemboli in 30 
minutes (P = 0.157, X2 test) in total. There was no significant difference in MES detected in 
patients symptomatic before surgery vs. those asymptomatic before surgery (TCD: median 3, 1QR 
(1-12), X2, P = 0.126; TOD: median 3, 1QR (1-10), X2, P = 0.621). 
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Microemboli were detected by one or both methods in 40 patients: by TOD and TCD in 24 
patients, by TOD alone in 10 patients; by TCD alone in 6 patients. The overall level of agreement 
between these 2 diagnostic methods was 86% (86/100). The diagnostic odds ratio for TOD vs. TCD 
was 24.0 [95% CI 1.8 – 314.3]. There was a strong positive association for MES detection between 
the two methods (rs = 0.74 (2-tailed), P < 0.001 – Spearman’s test; Figure 26).  
 
Figure 26. Correlation plot for microembolus signal (MES) detection by the two techniques TCD and TOD 
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To assess further the level of agreement of MES detection between both techniques, a Bland and 
Altman analysis was performed. This revealed no significant bias [bias 0.11 microemboli (95% CI: -
0.52 to 0.74), P = 0.81], with upper and lower limits of agreement of + 6 microemboli and – 6 
microemboli. However, there was a systematic variation for the mean differences of the two 
measurements: at low MES rate (~ 2 – 4 MES/hour), both methods yielded false negative findings; 
at high MES rates (≥ 50 MES/hour), TOD has a higher sensitivity than TCD (Figure 27). 
 
Figure 27.  The Bland and Altman plot shows limits of agreement of -6 to +6 MES/30 mins with no significant 
bias [0.11 microemboli (95% CI: -0.52 to 0.74), P = 0.81] between the two diagnostic methods TCD and TOD 
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Table 43 shows the overall diagnostic accuracy parameters of TOD in comparison to TCD, 
reflecting the variation that may occur in clinical practice. TOD had better specificity and negative 
predictive value than sensitivity or positive predictive value for detecting cerebral microemboli. 
 
Table 43. TOD diagnostic accuracy vs TCD 
Sensitivity 80 % 95% CI: 61 % to 92 % 
Specificity 86 % 95% CI: 76 % to 93 % 
Positive Predictive Value 71 % 95% CI: 53 % to 85 % 
Negative Predictive Value 91 % 95% CI: 82 % to 97 % 
 
MES intervention 
In this study, both methods simultaneously detected a sustained high MES rate (MES > 50hr1) in 7 
patients following carotid endarterectomy. Five out of 7 of those patients were treated with 
additional tirofiban176 post-surgery to suppress the high microembolic rate.  None of those 
patients developed post-operative thrombotic stroke. 
 
6.2.4 Discussion 
In this study, the same ultrasonography technique was used in different anatomical sites. The 
objective of this study was to compare TOD with an established TCD method with a view to 
demonstrating that it is not clinically inferior for detecting transient cerebral microemboli. This is 
the first prospective study comparing TOD with TCD for the detection of cerebral microemboli. On 
the basis of our results, TOD can be considered as an alternative to TCD in patients with an absent 
temporal acoustic window. Based on our study, TOD identified a high proportion, 8 out of 10 
patients in whom microemboli were detected by the current reference standard, trans-temporal 
TCD, following carotid endarterectomy. 
There are two clinical settings in which ability to detect cerebral microemboli is important for 
identifying patients at risk of thrombotic stroke, and in monitoring their suppression by rescue 
anti-platelet treatment. In acute symptomatic carotid disease, the presence of microemboli rather 
than the rate or number of microemboli36 has been associated with recurrent stroke following TIA 
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or non-disabling stroke.  In contrast, acutely following carotid endarterectomy, a sustained high 
MES rate has been associated with an increased risk of thrombotic stroke 33 and antiplatelet 
treatment can then be initiated to suppress these high rates of MES 272.  
In this study, the sensitivity of detecting MES at low rates was similar between TOD and TCD 
methods. Thus either method appears clinically appropriate for detecting subsequent stroke risk 
in patients presenting with acute symptomatic carotid disease. However, TOD was more sensitive 
than TCD at high MES rates. Therefore, TOD appears an at least as good alternative method to 
TCD for identifying microemboli and directing antiplatelet treatment in these high risk carotid 
disease patients.  
In this study, the source of microemboli was the denuded endothelial - intima area of the 
operated carotid artery following endarterectomy. One would expect any microemboli from the 
denuded carotid artery to travel past the carotid siphon before reaching the middle cerebral 
artery, the site insonated by the TCD method. As TOD insonates the carotid siphon which is closer 
to the endarterectomised area than the middle cerebral artery, TOD was expected to be more 
sensitive than TCD in detecting embolic signals. This may help to explain the increased 
microembolus detection frequency in our study for TOD vs. TCD at high microembolus rates. 
There are several challenges to monitoring by TOD compared with TCD. Doppler images may be of 
lower quality with TOD for two major reasons. Unlike the TCD method, where the probe is held in 
place on the temporal bone using a head frame, for TOD the vascular technologist has to hold the 
ultrasound probe constantly throughout the monitoring in order to avoid exerting too much 
pressure on the eye. Despite having a probe on the orbital area for 30 minutes, none of our 
patients expressed concerns about the TOD examination nor did any express a preference for one 
imaging technique over the other. 
Secondly, Doppler images are obtained using a small sample volume in the centre of an area of 
blood flow. Since the carotid siphon has a larger diameter than the middle cerebral artery, there is 
a risk of missing MES with the TOD method. It is unlikely that the lower sensitivity of TOD at low 
MES rates results from lack of expertise, or that emboli detected in TOD alone are likely to be 
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artefactual, as the vascular technologists in this study had at least 5 years of experience of TOD274 
and our observers have 90% agreement with software validated against a panel of international 
experts244.  
Thermal Indices (TI) of <0.1 through the orbit were maintained during the TOD insonation. A 
theoretical paper265 has suggested that the real temperature increase in the orbit may be more 
than estimated by the TI, mainly due to poorer cooling than assumed during the calculation of the 
TI. Even so, at a TI of 0.1 transorbitally the real temperature increase would be unlikely to exceed 
1oC, at which level no significant adverse effects of ultrasound have been demonstrated. 
 
Limitation 
Further studies are required in additional cohorts of patients to validate our findings and to assess 
the diagnostic benefit from combining TCD with TOD following carotid surgery to identify patients 
who could benefit from additional antiplatelet treatment to suppress cerebral microemboli. In 
this study, a single-gated method was used for microembolus detection. Dual gated 
microembolus detection may have increased potential compared to single-gated methods to 
differentiate microemboli from artefacts. Future comparative studies between TCD and TOD 
should be performed to investigate the effect on sensitivity of microemboli detection if a dual 
gated method is used. However, the technical challenge will be to decide two different depths of 
TOD insonation of the carotid siphon. Previous study has shown that the sensitivity of 
microemboli detection with dual gated methods may be reduced due to the fact that microemboli 
may not be appear in both windows275. 
In conclusion, our study indicates that TOD appears a valid alternative to TCD for detecting 
transient cerebral microemboli. Further studies should address whether there is a difference in 
clinical end-points between microemboli detected by these two methods.  
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CHAPTER SEVEN 
 
7 Kinetics of rescue antiplatelet treatment to abolish cerebral microemboli after 
carotid endarterectomy 
 
7.1 Introduction 
Antiplatelet treatment is well established as effective in reducing clinical vascular disease210. In 
patients with symptomatic carotid stenosis, developing a stroke is believed to result primarily 
from platelet-derived microemboli 32, 38. Both a recent prospective, international study (ACES)32 
and a systematic meta-analysis35  have established transcranial Doppler-detected cerebral 
microemboli as a biomarker of high risk of stroke syndromes both in patients with symptomatic 
carotid stenosis and after carotid endarterectomy (CEA). 
Transcranial Doppler (TCD) is a simple non-invasive technique that both allows identification of 
high risk patients of stroke and evaluation of the efficacy of antiplatelet therapy as it provides real 
time monitoring of cerebral microemboli35.  
Randomised controlled trials have shown efficacy of antiplatelet agents in reducing the frequency 
of TCD-detected microemboli 37, 213, 215-217, 276. Treatments assessed include  dextran-40 218, S-
nitroso-glutathione 221, tirofiban214, von Willebrand inhibitor 168, high dose aspirin175 and a 
combination of aspirin and clopidogrel 37, 217. There is no consensus on which antiplatelet therapy 
or combination is most effective in abolishing TCD-detected microemboli, with the aim of 
preventing postoperative thrombotic stroke. 
Disease processes within the coronary artery and the internal carotid artery share much in 
common60. Antiplatelet treatment with the intravenous glycoprotein IIb/IIIa inhibitor tirofiban is 
effective in acute coronary syndromes 248. Pharmacological agents effective in acute coronary 
syndromes could theoretically be beneficial in thromboembolic carotid diseases associated with 
transient ischaemic attacks (TIA) and strokes60. 
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The aim of this study was to compare our experience of using the glycoprotein IIb/IIIa inhibitor 
tirofiban with response to dextran-40 in patients with high microembolic rates after carotid 
endarterectomy. 
 
7.2 Subjects and methods 
From the Carotid Registry, 128 out of 576 patients who had microembolic signals (MES) detected 
by TCD after elective CEA between August 2000 and December 2010 were identified. The Vascular 
Unit at The University Hospitals of Coventry and Warwickshire NHS Trust vascular performs 
approximately 60 CEA per annum. 
Dextran-40 was our preferred choice33, 222 as the rescue anti-thrombotic agents in patients with 
high microembolic rates after carotid endarterectomy until 2003. We noticed that a number of 
patients developed early stroke despite being on a dextran-40 infusion. We have since changed 
our department policy to tirofiban 214, 277. Using the Registry data, a case controlled-study was 
used to explore the benefits of tirofiban over dextran-40 treatment. Patients who had tirofiban 
were compared with those who received dextran-40 and those who had MES rate < 50/hr which 
spontaneously resolved. The cardiovascular burdens between groups were similar. 
Seventy four patients who had an MES rate ≥ 50/hr and were either given intravenous tirofiban 
(n=40) or intravenous dextran-40 (n=34) were reported. I also reported on 54 patients who had 
MES rate < 50/hr which spontaneously resolved on standard antiplatelet treatment. 
All patients had oral antiplatelet treatment (aspirin, or aspirin and clopidogrel, or aspirin and 
dipyridamole) prior to carotid endarterectomy.  
In the tirofiban group, 32 patients received single antiplatelet agent prior to the carotid surgery 
(aspirin, clopidogrel and dipyridamole) and 8 patients received dual antiplatelet agents. Two 
patients from the dextran-40 group and 18 from the spontaneous MES resolved group received 
dual antiplatelet agents. 
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Cardiovascular risk factors 
Prevalence of hypertension, smoking (self-reported), ischaemic heart disease, 
hypercholesterolaemia, diabetes mellitus and previous medical history or family history of 
vascular diseases was recorded. Peripheral vascular disease was based on symptoms of 
claudication with evidence of reduced ankle-brachial pressure index. 
  
Carotid endarterectomy 
Carotid endarterectomy was performed as described in chapter 3. Shunting was performed if the 
patient developed focal neurological signs when CEA was performed under local anaesthetic; or in 
those cases performed under general anaesthetic when mean velocity of the middle cerebral 
artery dropped by > 50%. All patients received intravenous heparin (40 units kg-1) prior to the 
cross clamp phase of the carotid endarterectomy.  
 
TCD monitoring 
TCD monitoring was used to assess half-life of MES decay, MES to resolution and cumulative 
number of microemboli detected. 
TCD monitoring 274 was performed by an experienced vascular scientist (PC Dop 842, SciMed, 
Bristol, UK) with a 2 MHz probe focused on the middle cerebral artery ipsilateral to the operated 
carotid artery following recovery from anaesthesia. Monitoring was performed for at least 30 
minutes if no MES was detected. In patients lacking an acoustic temporal bone window, TCD 
monitoring was performed via the transorbital window which focuses on the carotid siphon274 . 
Microemboli were identified as recommended by the International Consensus Group on 
Microembolus Detection 171. Doppler wave forms and audio signals were examined by a trained 
vascular scientist. MES were identified as unidirectional, short duration signals (range 10–100 ms) 
with intensity threshold above 6 dB, accompanied by characteristic audible clicks and occurring 
randomly throughout the cardiac cycle 170, 171 The rate of MES was calculated based on the 
number of microemboli detected within 15 minute intervals. Additional post-operative rescue 
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anti-thrombotic agents was initiated in patients with a MES rate > 50/hr based on the study by 
Levi et al 31 
 
Tirofiban protocol 
The tirofiban protocol recommended for use in acute coronary syndrome248 was used. Tirofiban 
(Aggrastat®; Merck Sharp & Dohme, Hoddeson, UK) was given intravenously as 0.4mcg/kg/min for 
30 minutes then 0.1mcg/kg/min as a continuous infusion for 18 hours. TCD monitoring was 
continued until the MES rate was < 4/hr. 
 
Dextran-40 protocol 
Patients were commenced on an intravenous infusion of dextran-40 (10% Gentran-40 (Baxter 
Healthcare, Thetford, UK), in 5% glucose solution). An initial 20-ml bolus was given, and the 
dextran-40 infusion continued at 20 ml/h. 
Based on Hayes's study220, if a patient continued to have TCD evidence of a persistent high rate of 
MES, the rate of the dextran-40 infusion was increased at increments of 20 ml/h until the MES 
reduced. The dextran-40 infusion was continued for 18 hours.  
 
Ethics 
University Hospitals Coventry Warwickshire (UHCW) Research Ethics Department advised that this 
registry report did not fall under the remit of the National Health Service Research Ethics 
Committee. 
 
Data and statistical analysis 
Statistical analyses were conducted using SPSS® version 21 (Chicago, Illinois, USA).  
Demographic variables are expressed as mean and standard error means (SEM). Data on MES rate 
are expressed as median and quartile range (IQR). Non-parametric unpaired data were analysed 
using the Kruskal-Wallace analysis of variance for multiple groups or Mann-Whitney U test for two 
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groups comparison. Categorical variables were analysed using the chi-squared test or Fisher’s 
exact test.  Parametric data were assessed with one-way ANOVA.  Survival data were evaluated by 
Kaplan-Meier curves. A P-value of less than 0.05 was considered significant. 
7.3 Results 
The age, gender and ethnicity profiles of the 3 groups were comparable (Table 44). The 
preoperative laboratory blood profiles were also similar between groups (Table 45).Eight (20%) 
patients who went on to receive tirofiban were on dual antiplatelet agents preoperatively 
compared with 2 (6%) patients who received dextran-40 after surgery, and 18 (33%) patients in 
whom  MES resolved (P = 0.199, X2 test). 
 
Table 44 Demographic and clinical profile of patients who had MES monitored after carotid endarterectomy 
 
n (%) 
Spontaneous 
resolution 
n = 54 
Tirofiban 
n = 40 
Dextran-40 
n = 34 
X2  test 
P value 
Age (mean ± SEM) 71 ± 1 74 ± 1 69 ± 2 0.199 
Male 36 (67) 27 (66) 22 (65) 0.199 
Caucasian 
Asian 
52 (96) 
2 (4) 
38 (95) 
2 (5) 
30 (88) 
4 (12) 
0.199 
0.223 
Hypertension 47 (87) 31 (78) 27 (79) 0.442 
Never smoke 
Current smoker 
Ex-smoker 
15 (28) 
12 (22) 
27 (50) 
19 (47) 
13 (33) 
8 (20) 
 
12 (38) 
9 (24) 
13 (38) 
 
0.143 
Ischaemic heart disease 24 (44) 14 (35) 14 (41) 0.611 
Type 2 Diabetes mellitus 16 (30) 10 (25) 6 (18) 0.45 
Hypercholesterolaemia 30 (56) 26 (65) 15 (44) 0.197 
Peripheral vascular 
disease 
8 (15) 8 (20) 10 (29) 0.253 
Cerebrovascular disease 13 (24) 12 (30) 5 (15) 0.299 
Family History 25 (46) 13 (33) 4 (12) 0.04 
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Table 45 Preoperative laboratory values of patients who had MES monitored after carotid endarterectomy 
Laboratory 
variables 
Spontaneous 
resolution 
Tirofiban Dextran-40 One-way 
ANOVA,  
P value  Mean ± SEM (n) Mean ± SEM (n) Mean ± SEM (n) 
Cholesterol 
(mmol/L) 
4.6 ± 0.1 (n=43) 4.6 ± 0.2 (n=32) 4.6 ± 0.5 (n=12) 0.97 
Triglyceride 
(mmol/L) 
1.6 ± 0.1 (n=27) 1.7 ± 0.2 (n=12) 1.8 ± 0.3 (n=12) 0.85 
HDL (mmol/L) 1.6 ± 0.1 (n=20) 1.4 ± 0.1 (n=26) 1.2 ± 0.2 (n=5) 0.21 
Creatinine 
(mmol/L) 
106 ± 4 (n=53) 114 ± 10 (n=40) 96 ± 3 (n=40) 0.17 
Glucose 
(mmol/L) 
5.3 ± 0.2 (n=41) 5.3 ± 0.3 (n=30) 5.9 ± 0.5 (n=9) 0.571 
Haemoglobin 
(g/dL) 
13.5 ± 0.2 (n=53) 13.4 ± 0.2 (n=40) 12.8 ± 0.3 (n=34) 0.1 
Platelet       (x 
109/L) 
256 ± 8 (n=53) 282 ± 12 (n=40) 257 ± 16 (n=34) 0.21 
White cell 
count          (x 
109/L) 
7.8 ± 0.2 (n=53) 7.9 ± 0.3 (n=40) 7.8 ± 0.4 (n=34) 0.97 
 
 
Microembolic signal kinetics after carotid endarterectomy 
In view of differences in preoperative antiplatelet treatment between groups, data were analysed   
in 2 ways: An analysis of all subjects and separate analysis for those who were only on single 
antiplatelet treatment before surgery. There was no early postoperative stroke in the tirofiban 
treated group but 5 early strokes despite dextran-40 treatment. I also included an additional 
analysis excluding patients who had an early stroke despite dextran-40 treatment. 
 
a) Comparison of the MES rate between tirofiban and dextran-40 treated groups 
The initial MES rate was similar in dextran treated and tirofiban treated patients (P = 0.234) (Table 
46).  
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Table 46 MES decay rate after carotid endarterectomy in patients who received rescue antiplatelet therapy 
(tirofiban or dextran-40 for MES ≥ 50/hr; for MES < 50/hr). After Mann – Whitney U test: ** Spontaneous 
resolution vs tirofiban, P < 0.001. * Spontaneous resolution vs tirofiban, P = 0.007. † Spontaneous 
resolution vs dextran-40 P < 0.001. ^ tirofiban vs dextran-40 P < 0.001 
 Spontaneous 
resolution 
Median (IQR) 
Tirofiban 
Median (IQR) 
Dextran-40 
Median (IQR) 
Kruskal-
Wallis test 
P value 
Initial MES rate 
(MES/hr) 
24 (16 – 36)**, † 88 (68 – 134) 102 (79 – 150) < 0.001 
Half-life of MES 
decay (minutes) 
30 (22 – 38) )**, † 23 (15 - 28)^ 56 (43 – 83) < 0.001 
Time to MES 
resolution (minutes) 
53 (49 - 68) )*, † 68 (53 - 94)^ 113 (79 – 146) < 0.001 
 
Table 47 Comparison of MES decay rate between tirofiban and dextran-40 in patients who received 
different antiplatelet therapy prior to carotid surgery 
 Single antiplatelet therapy Dual antiplatelet therapy 
 Tirofiban 
(n = 32) 
Median 
(IQR) 
Dextran-40 
(n=32) 
Median 
(IQR) 
Mann – 
Whitney 
U test 
P value 
Tirofiban 
(n = 8) 
Median 
(IQR) 
Dextran-40 
(n=2) 
Median (1st 
QR) 
MW-U 
test 
P value 
Initial MES 
rate (MES/hr) 
96 (69 – 
136) 
104 (81 – 
150) 
0.268 81 (65 – 
123) 
77 (76) 0.6 
Half-life of 
MES decay 
(minutes) 
23 (15 – 30) 60 (40 – 83) < 0.001 19 (15 – 
23) 
49 (45) 0.29 
Time to MES 
resolution 
(minutes) 
68 (53 – 98) 113 (71 – 
154) 
< 0.001 53 (53 – 
79) 
105 (83) 0.48 
 
Figure 28 demonstrates the rapid initial reduction of MES rate in patients who received the 
tirofiban infusion in comparison to patients with no rescue antiplatelet treatment. This is despite 
almost 4 times higher initial MES rate after surgery (Tirofiban 88 minutes (IQR 68 – 134), 
spontaneous resolution 24 (16 – 36), p <0.001) (Table 46). 
 
The time for 50% reduction in MES rate was shorter in patients who received tirofiban compared 
to dextran-40 (Tirofiban 23 (15 – 28), dextran-40 56 (43 – 83), P < 0.001;Table 46). Patients who 
received tirofiban had a significantly lower cumulative MES burden than dextran-40 treated 
patients (44 (28 – 65) vs. 91 (48 – 304), P < 0.001, MW test). 
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b) Results for subjects who had single antiplatelet treatment before surgery 
Results for analysis of data on patients who received only single antiplatelet therapy prior to 
carotid endarterectomy were similar to those for the overall analysis; For tirofiban vs. dextran-40 
treatment, the half-life for MES was shorter (23 minutes (15 – 28) vs. 60 (43 – 83), P < 0.001); the 
time to resolution was shorter (68 (53 – 98) vs. 113 (71 - 154), P < 0.001) (Table 47). Cumulative 
MES in tirofiban treated patients were lower at less than half that in dextran-40 treated patients: 
tirofiban 45 (32 – 75) vs. dextran-40 103 (51 – 308), P = 0.001, MW test (Figure 31, Figure 32). 
 
Figure 28 Results of MES rate after carotid endarterectomy in all patients.     dextran-40 infusion (n = 34) 
for MES ≥ 50/hr.      Tirofiban infusion (n = 40) for MES ≥ 50/hr.      No additional antiplatelet treatment 
(n = 54) - MES < 50/hr. Initial MES rate for all groups: P < 0.001, KW test. Initial MES for tirofiban vs. 
dextran-40: P = 0.243, MW test. For half-life of MES decay rate: P < 0.001, KW test. Half-life of MES decay 
rate for tirofiban vs. dextran-40: P < 0.001, MW test. Time to MES resolution: P < 0.001, KW test. Time to 
resolution for tirofiban vs. dextran-40: P < 0.001, MW test 
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Figure 29 MES rate monitored following carotid endarterectomy.       Dextran-40 infusion (n = 29) for MES 
≥ 50/hr.       MES ≥ 50/hr patients (n = 5) who developed early stroke despite dextran-40 infusion 
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Figure 30 Results of MES rate after carotid endarterectomy in single antiplatelet therapy patients prior to 
surgery.     dextran-40 infusion (n = 28) for MES ≥ 50/hr.       MES ≥ 50/hr patients (n = 4) who 
developed early stroke despite dextran-40 infusion.     Tirofiban infusion (n = 32) for MES ≥ 50/hr.      
No additional antiplatelet treatment (n = 36) - MES < 50/hr. Initial MES for tirofiban vs. dextran-40: P = 
0.268, MW test. Half-life of MES decay rate for tirofiban vs. dextran-40: P < 0.001, MW test. Time to 
resolution for tirofiban vs. dextran-40: P < 0.001, MW test 
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Figure 31 Cumulative MES following carotid endarterectomy in patients with single antiplatelet therapy 
prior to surgery.    dextran-40 infusion (n = 28) for MES ≥ 50/hr.    MES ≥ 50/hr patients (n = 4) who 
developed early stroke despite dextran-40 infusion.       Tirofiban infusion (n = 32) for MES ≥ 50/hr.    
No additional antiplatelet treatment (n=36) - MES < 50/hr. Cumulative MES for all groups; spontaneous 
resolution 12 (7 – 20), tirofiban 45 (32 – 20), dextran 40 103 (51 – 308): P < 0.001, KW test. For tirofiban vs. 
dextran-40: P < 0.001, MW test 
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Figure 32 Cumulative MES following carotid endarterectomy in patients with dual antiplatelet therapy prior 
to surgery.   dextran-40 infusion (n = 1) for MES ≥ 50/hr.    MES ≥ 50/hr patients (n = 1) who developed 
early stroke despite dextran-40 infusion.      Tirofiban infusion (n = 8) for MES ≥ 50/hr.    No additional 
antiplatelet treatment (n = 18) - MES < 50/hr. For Spontaneous resolution 11 (7 – 19) vs tirofiban 35 (25 – 
54), P = 0.001, MW test 
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Time to resolution 
The Kaplan – Meier plot shows that patients who received rescue tirofiban infusion achieved 
earlier complete MES resolution in comparison to dextran-40 treatment (Figure 33). This finding 
was similar when patients who were only on single preoperative antiplatelet therapy was 
analysed (Figure 34). 
 
Figure 33 Kaplan – Meier plot comparing frequency of continued occurrence of MES acutely after carotid 
endarterectomy. Dotted & Dashed line: Patients (n = 5) who developed early stroke despite dextran-40 
infusion. Dotted line: Dextran-40 infusion (n=34) for MES ≥ 50/hr. Bold line: Tirofiban infusion (n = 40) for 
MES ≥ 50/hr. Dashed line: No additional antiplatelet treatment (n = 54) as MES < 50/hr resolved 
spontaneously. Log Rank (Mantel-Cox), 4-way P < 0.001. Tirofiban vs dextran-40, Log Rank (Mantel-Cox), 2-
way P < 0.001. Tirofiban vs early stroke dextran-40, Log Rank (Mantel-Cox), 2-way P = 0.001 
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Figure 34 Kaplan – Meier plot comparing frequency of continued occurrence of MES acutely after carotid 
endarterectomy in patients with single antiplatelet therapy prior to surgery. Dotted & Dashed line: Patients 
(n = 4) who developed early stroke despite on dextran-40 infusion. Dotted line: Dextran-40 infusion (n = 28) 
for MES ≥ 50/hr. Bold line: Tirofiban infusion (n = 32) for MES ≥ 50/hr. Dashed line: No additional 
antiplatelet treatment (n = 36) as MES < 50/hr resolved spontaneously. Log Rank (Mantel-Cox), 4-way P < 
0.001. Tirofiban vs dextran-40, Log Rank (Mantel-Cox), 2-way P = 0.001. Tirofiban vs early stroke dextran-40, 
Log Rank (Mantel-Cox), 2-way P = 0.002 
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Complications 
a) Early events – 24 hours post-surgery 
5 patients developed stroke despite being on dextran-40 infusion for MES ≥ 50/hr following 
surgery. In the 5 patients, the MES rate was persistently higher than in patients (n=29) whom the 
MES rate resolved following dextran-40 infusion (Table 48).  
 
b) Further events between 24 hours to 30 days post-surgery 
One ischaemic stroke occurred in a tirofiban treated patients one week after the surgery. 2 fatal 
myocardial infarctions (MI) occurred in the dextran-40 treated patients and 1 fatal MI in both 
tirofiban treated patients and patients who did not receive rescue antiplatelet treatment. One 
patient who received postoperative tirofiban was readmitted from home and died from an 
intracerebral haemorrhage 4 days after surgery and 2 days post discharge. In the immediate 
postoperative phase, this patient had received an intravenous nitrate infusion for hypertension 
and a hyperperfusion syndrome but systolic blood pressure appeared to be controlled on 
discharge. The platelet count on discharge was normal.  
 
c) Late events between 30 days and 1 year after surgery 
One fatal myocardial infarction and one fatal intracerebral haemorrhage occurred in patients who 
did not receive rescue antiplatelet treatment (Table 48). 
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Table 48 Complications up to 30 days and between 30 days and 1 year after carotid endarterectomy in 
patients who received rescue antiplatelet therapy (tirofiban or dextran 40 for MES ≥ 50/hr) and no 
additional antiplatelet therapy (MES < 50/hr) 
 
 
7.4 Discussion 
Antiplatelet therapy prior to carotid endarterectomy is now standard practice to prevent post – 
surgical microemboli and early ischaemic stroke. However, despite this practice, patients may still 
have a high microembolic load acutely after carotid endarterectomy. This is of clinical concern 
because MES are known to lead to increased risk of postoperative thrombotic stroke31, 33. 
TCD-directed tirofiban therapy appears to be significantly more effective than dextran-40 in 
suppression of cerebral microembolisation in patients who were refractory to basal antiplatelet 
treatment. Despite having a similar initial MES rate to dextran-40 treated patients, tirofiban 
treatment resulted in a large ~ 60% reduction of the half-life of MES decay. Furthermore, earlier 
complete MES resolution was demonstrated in all patients treated with tirofiban than dextran-40. 
Similar effects were demonstrated in patients with single antiplatelet therapy prior to surgery. 
 
None of the tirofiban patients had TIA or acute stroke while on tirofiban infusion. Some of the 
patients appeared to be resistant to dextran-40, both in terms of failure to suppress high MES 
rates and in that 5 out of 34 patients had adverse neurological outcomes.  
 30 days post carotid surgery 12 months post carotid surgery 
Spontaneous 
resolution 
n = 54 (%) 
Tirofiban 
n = 40 (%) 
Dextran-
40 
n = 34 
(%) 
Spontaneous 
resolution 
n = 54 (%) 
Tirofiban 
n = 40 
(%) 
Dextran-
40 
n = 34 
(%) 
Stroke 
(Ischaemic or 
haemorrhagic) 
 1(3) 5 (15)    
Myocardial 
Infarction 
 
1(2) 1(3) 2 (6) 1(2)   
Death, cause: e.g. 
bleeding, 
thrombocytopenia 
etc. 
1(2) 
MI 
2(6) 
MI 
Intracerebral 
bleeding 
3 (9) 
MIs, 
one case 
unknow
n 
2(4) 
MI 
Intracerebral 
bleeding 
1(3) 
Renal 
failure 
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Dextran-40 was one of the first and most common antithrombotic agent used to treat acute 
microemboli following surgery167, 222, 278 to prevent stroke. Naylor et al showed that this strategy 
has worked well in abolishing postoperative stroke in Leicester, UK from 1995 to 2006279. It has 
been suggested that dextran-40 exerts a combined therapeutic effect, enhancing endogenous 
fibrinolysis, whilst also reducing platelet adhesion to von Willebrand factor and platelet activation 
by thrombin226. A study from Boston, US227 found that dextran-40 used was not associated with 
lower peri-operative stroke but was associated with higher rates of myocardial infarction and 
congestive heart failure. In the study from Boston227, the intraoperative dextran infusion was 
given based on the preference of the individual surgeon rather than based on the TCD monitoring. 
However, the documented dextran related complications were similar to our experience214. 
An experimental study by Junghans et al277 has shown for the first time the effectiveness of 
tirofiban in reducing the frequency of cerebral microembolisation. The previous case-series from 
this unit anecdotally suggested that tirofiban could be used as an alternative to those patients 
who were resistant to dextran-40214.  However, until this present report, it had not been clear 
whether tirofiban would have benefits over dextran-40 treatment. Using the kinetics of the 
microemboli, I was able to demonstrate the effectiveness of tirofiban in abolishing the 
microemboli and compared tirofiban and dextran-40 effectiveness in reducing the frequency of 
microemboli in more detail. A number of anti-thrombotic agents have been used to treat carotid 
surgery patients with microemboli, who are otherwise at a high risk of suffering stroke. These 
treatments include using dextran-40 218, S-nitroso-glutathione 221, von Willebrand inhibitor 168 and 
a combination of aspirin and clopidogrel 37, 217. Two randomised controlled trials which 
investigated TIA/minor stroke and post CEA TCD-detected MES cohorts have shown that a 
combination of aspirin and clopidogrel reduced the frequency of TCD-detected MES, but did not 
completely abolish the microembolisation37, 217. However, my study has shown that the use of 
selective platelet GPIIb/IIIa receptor inhibitor tirofiban results in complete suppression of MES in 
all patients including 8 of our patients who were on dual antiplatelet agents prior to CEA. In these 
cases, the medications were either not sufficient or not effective. The short acting selective 
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GPIIb/IIIa receptor antagonist provides an effective treatment option in patients resistance to 
aspirin and clopidogrel 280. 
The commonly used antiplatelet agents such as aspirin and clopidogrel do not fully inhibit platelet 
aggregation activated through pathways different from thromboxane and adenosine 
phosphate277. Irrespective of the particular platelet activating pathway, final platelet aggregation 
is mediated by the GPIIb/IIIa receptor277. These fibrinogen receptors are exclusively expressed on 
platelets. Binding of GPIIb/IIIa receptor antagonist such as tirofiban results in highly selective 
inhibition of platelet aggregates independent from the respective platelet activating mechanism. 
Activated GPIIb/IIIa receptors bind fibrinogen molecules, which form bridges between adjacent 
platelets forming the platelet aggregates248. Tirofiban has a short half-life (2 hours) and platelet 
function fully recovers within hours after cessation of infusion 248. Due to this unique 
pharmacodynamics, tirofiban could be used as the bridge treatment in acute symptomatic carotid 
artery disease who required urgent carotid endarterectomy. 
Within the study, the high MES rate despite dextran-40 treatment was associated with an 
increased risk of stroke than with tirofiban. Bleeding complications were the most commonly 
reported events associated with tirofiban in previous clinical trials248. In the study, including 
rescue antiplatelet treatment, most of patients were on multiple antiplatelet agents 
perioperatively, yet the incidence of major bleeding was surprisingly low. The tirofiban bleeding 
complication rate was comparable to a recently published larger randomised controlled trial 
looking at the safety on tirofiban in the different setting of acute stroke281.  The single episode of 
major bleeding was a cerebral haemorrhage occurring after discharge from hospital, 3 days after 
the end of the tirofiban infusion. Since the half-life of tirofiban is two hours, I believe this adverse 
outcome was unlikely to be directly related to the tirofiban therapy.  
TCD-directed tirofiban therapy appears more effective than dextran-40 in rapid suppression of 
cerebral microembolisation in patients despite preoperative antiplatelet treatment. The report 
provides support for randomised controlled trials for the clinical and cost-effectiveness of 
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tirofiban and other antiplatelet agents in suppressing microemboli and reducing the incidence of 
stroke in patients undergoing carotid endarterectomy.  
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CHAPTER EIGHT 
 
8 Discussion and future development 
8.1 Carotid Surgery Registry 
The effectiveness of carotid endarterectomy in reducing the risk of stroke in symptomatic critical 
carotid artery stenosis has been well investigated in randomised trials38, 47, 155. In general, concern 
regarding randomised control trial (RCT) has been expressed that the results from the highly 
internally and externally validated patient characteristics in RCT may not be transferable to the 
real and routine clinical setting282. The population based Registry would make it possible to assess 
the efficacy and effectiveness of the intervention based on these randomised trials in the real 
population. The Registry data also allows an immediate feedback of data which could be used as 
part of an ongoing clinical quality improvement programme or an assessment of new techniques 
or treatment tools. The main drawbacks of the Registry are similar to any observational study. It 
relies on robust data collection and there is a lack of internally validated characteristics of the 
patients. 
There are 2 key findings in establishing this carotid Registry. Firstly, I was able to evaluate the 
current clinical practice, radiological technique and a pharmacological approach in evaluating and 
treating microemboli. The baseline patient characteristics and perioperative outcomes of patients 
who underwent carotid endarterectomy in Coventry and Warwickshire were reviewed against the 
major randomised trials and national audits. The similarities of the data indirectly validated the 
accuracy of the Registry data. The smaller number of carotid endarterectomies performed on 
asymptomatic carotid disease reflected the changing practice following the completion of the 
randomised controlled trial on long term outcome of carotid endarterectomy on asymptomatic 
carotid stenosis patients249. Our knowledge of perioperative antiplatelet therapy in carotid 
endarterectomy has improved over the last few years. This is reflected in the increasing use of 
dual antiplatelet agents prior to carotid endarterectomy based on the Registry data. This, in turn, 
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is associated with a lower number of patients developing microemboli acutely following carotid 
surgery.  
The second key finding in establishing the registry was being able to: conduct cohort studies 
evaluating the association between composite Pocock cardiovascular risk score and microemboli; 
determine the feasibility of using transorbital Doppler technique to detect microemboli; and 
perform a case-control study to evaluate the effectiveness of tirofiban in abolishing microemboli 
acutely following carotid surgery. 
The Swedish National Registry for Vascular Surgery has provided an excellent template on 
developing an effective Registry. The key to the development of the Swedish Registry is the robust 
data collection which I replicated in this thesis. The Swedish National Registry for Vascular Surgery 
has undergone a long process of internal and external validation of its data to eliminate any 
potential bias283. This can be seen in the increasing number of publications over the last 20 
years284. The UK National Registry in Vascular Surgery was only formed in 2013 by the 
amalgamation of the National Vascular Database and UK Carotid Interventions Audit projects192. 
However, the data collection and registration still relies on self-reporting by individual surgeons. 
This data collection process will subject the Registry to selection and information biases. 
The future development of the carotid Registry will be to standardise and link the data collected 
with the National Registry. This will minimise the selection and information biases of the regional 
data submitted to the National Registry. It also will act as an external validation for the carotid 
Registry. The Registry can also be expanded beyond carotid endarterectomy and the current 
geographical area. 
 
8.2 Clinical prediction of MES 
 
Pocock risk score 
A recent observational study in the Leicester and Northampton region,2 which shares a similar 
demographic area as ourselves, demonstrated a 23% recurrence rate of stroke/TIA in acute 
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symptomatic carotid artery disease in patients who had an evidence of microemboli. In the hyper-
acute symptoms cohort (i.e. index symptoms within 14 days of assessment), the overall 
recurrence rate of stroke/TIA in patients who had an evidence of microemboli was 17%. These 
findings were in the context of the modern era of best medical therapy and rapid access to the 
TIA clinic255. Spence et al238 reported a significant 3-fold reduction of the proportion of 
microemboli and cardiovascular event with intensive medical therapy in carotid artery disease 
patients. This demonstrated that those patients with microemboli are at higher risk of recurrent 
stroke/TIA within the already high risk group of acute symptomatic patients. It also confirmed the 
role of microemboli as an independent biomarker for short-term risk of stroke.  
One would expect these high risk patients to have a high cardiovascular risk factor burden. This 
cohort has been shown to face a greater risk of death from myocardial infarction than stroke11. To 
date, the association between classical cardiovascular risk factors and microemboli has not been 
studied. In my thesis, I attempted to evaluate the association between the Pocock risk score and 
presence of microemboli following acute symptomatic carotid artery disease. The Pocock score is 
the only risk score derived from the established cardiovascular disease cohort. Unsurprisingly, 
98% of our hyper-acute symptomatic carotid artery disease cohort had a quantifiable score which 
corresponded to a 5-year risk of death. In general, the Pocock score was unable to predict the 
presence of microemboli in hyper-acute symptomatic patients. However, a Pocock score ≥ 0.8% 
showed a high sensitivity (95%) for the presence of microemboli in this cohort.  
Stroke, especially in the immediate post-operative period, remains one of the most important 
complications following successful carotid endarterectomy. The main mechanisms leading to 
stroke include post-operative hypertension causing hyperperfusion syndrome and 
thromboembolism from the endarterectomised area or elsewhere. Hyperperfusion syndrome is 
uncommon and strict post-operative blood pressure control with the provision of written 
guidance has been shown to minimise this285. Multi-centre studies have confirmed that acutely 
persistent microembolisation are associated with short-term stroke risk31, 167, 198-200, 205. TCD 
remains the only proven method of predicting post carotid endarterectomy carotid thrombosis, 
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hence identifying those at risk of stroke/TIA286. Therefore, a clinical scoring system that might be 
able to the risk of post-operative micro-emboli would be useful if the outcome were either 
stroke/TIA prevention by increasing peri-operative treatment and/or by longer-term strategy to 
reduce the severity of factors within the Pocock score contributing to the increased stroke/TIA 
risk.  
Clinically, it is unclear which patients will develop acutely persistent microembolisation post 
carotid surgery. Surgical technical error has been excluded as the cause of microembolisation287. 
Patients who underwent staged bilateral carotid endarterectomy have been shown to have 
similar rates of postoperative microembolisation288. A randomised clinical trial has shown that the 
incidence of high rate postoperative embolisation was unrelated to carotid patch type289. 
Observational studies290, 291 have suggested that postoperative microembolisation is more 
common in women. To date, the most promising theory came from Hayes et al’s228 work which 
showed that with increasing concentrations of ADP, the magnitude of platelet aggregation is 
higher in patients with a high rate of microembolisation. This may reflect the physiological 
increased platelet reactivity to the ADP pathway. Therefore the cause of the postoperative 
microembolisation may be related to the inherent characteristics of the patient or the 
atherosclerotic disease process itself. To date, the association between classical cardiovascular 
risk factors and microemboli acutely following carotid surgery has not been studied. One of the 
key findings of my study is that Pocock score shows an association with the presence of 
postoperative microemboli. A Pocock score of ≥ 0.8% was able to predict the presence of acute 
microemboli following carotid endarterectomy. A Pocock score of ≥ 0.8% and 2.3% was shown to 
have a high sensitivity regarding the presence of microemboli and a high negative predictive value 
regarding a microembolic rate of > 50hr1. This cut off point could possibly be employed to guide 
post-operative transcranial Doppler monitoring where it is not routinely available and could help 
identify patients where a more aggressive strategy of cardiovascular risk factor reduction could be 
employed. However, the association of Pocock score with a high rate of post-operative 
microemboli requiring additional antiplatelet agents was unclear in our cohort, as the score was 
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not significantly associated with an MES rate of > 50hr1 when ROC analysis was used. This could be 
cofounded by the fact that the majority of patients in our cohort were already on dual antiplatelet 
therapy (Aspirin and Clopidogrel). Naylor et al217 group demonstrated that dual-antiplatelet 
agents are effective in minimising the occurrence of post-operative microemboli. A more recent 
audit279 from the same group reported that with routine use of preoperative dual-antiplatelets an 
evening before surgery, the prevalence of high rate MES was reduced to the extent that post-
operative TCD monitoring was abandoned in 2010. This finding needs to be validated in a multi-
centre study setting because in my study, a small proportion of patients with high rate 
microembolisation were on dual-antiplatelet treatment more than 24 hours prior to surgery. 
Taking account into our findings and the aforementioned data on dual-antiplatelet therapy, we 
could argue that post-operative TCD can selectively be used in those with a Pocock score ≥ 0.8%, 
given that they already receive dual-antiplatelet agents. A multi-centre prospective observational 
study is obviously needed to prove and validate this hypothesis.  
 
ABCD2 risk score 
Even though the use of the ABCD2 risk score was not intended to replace clinical assessment of 
individual patients, it has been well established in triaging patients with suspected stroke/TIA for 
urgent investigation and treatment102, 112 from the community to emergency departments and 
rapid access TIA clinics255. The key elements of the score such as age, hypertension and diabetes 
are standard classical cardiovascular risk factors for carotid stenosis16, 66, 74. Weakness and speech 
disturbance are signs of middle cerebral artery ischaemic stroke. The association between ABCD2 
risk score and carotid associated microemboli has not been studied before. Since both ABCD2 risk 
score and microemboli predict short term stroke risk, I attempted to investigate whether ABCD2 
risk score predicts the presence of microemboli. The study’s findings have major policy 
implications as ABCD2 risk score has been recommended by NICE as the key clinical tool in triaging 
suspected stroke/TIA103. Our study has shown that the ABCD2 risk score, a widely used and relied 
on score to guide stroke management is seriously flawed in failing to detect many high risk carotid 
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disease patients with or without microemboli.  The presence of microemboli is already a well–
established predictor of stroke35 and treatment to suppress microemboli has been shown to 
reduce the rate of recurrent stroke37, 238. The attractiveness of using the ABCD2 risk score lies in its 
simplicity. Unfortunately, our findings demonstrated that using ABCD2 risk score alone is not 
sufficient to identify the high risk embolising carotid artery disease patients. It would not have 
been ethical to deprive patients identified as having microemboli from early active treatment. 
TCD should form part of carotid imaging and this service should be urgently available to any 
suspected stroke/TIA patients.  
The inadequacy of the ABCD2 risk score alone for stratification of high risk of a recurrent event 
after a stroke or TIA has been recognised by Merwick et al292 in an international multicentre 
observational study based on pooled data from Europe and North America. Merwick et al292 
expanded the standard ABCD2 risk score to the ABCD3-I risk score by including presence of ≥2 TIA 
within 7 days, critical carotid artery stenosis and acute diffusion-weighted imaging hyperintensity 
lesion. The ABCD3-I risk score was found to be better at stratifying stroke risk than the ABCD2 risk 
score in stroke/TIA patients. A recent Japanese validation study confirmed that the ABCD3-I risk 
score was found to be better at stratifying stroke risk than ABCD2 risk score in stroke/TIA 
patients293. This finding should be expected as patients with recent symptomatic carotid stenosis 
and diffusion-weighted imaging were at least 3-fold higher risk of stroke292. However, diffusion-
weighted imaging and carotid imaging are only available at the secondary care level, so this 
defeats the initial purpose of applying the ABCD2 risk score for triage in the community. Additional 
carotid stenosis in the risk score means that carotid imaging should generally be performed in all 
TIA/minor ischemic stroke patients as soon as possible before the score could be completed. This 
is potentially problematic in clinical settings with limited access to carotid imaging (whether the 
patient is admitted or not). Another limitation of studies by Merwick et al292 and Kiyohara et al293 
was that only 12% and 20% of patients respectively had carotid disease in their studies. 
Overall, the relationship between the Pocock risk score, ABCD2 risk score and carotid-associated 
microemboli remains unclear. The hypotheses tested in this thesis were investigated in already 
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high risk established cardiovascular risk factor patients. Using microemboli as the biomarker of 
higher risk patients among patients with an already established cardiovascular risk factor burden 
was probably looking at a small number of patients, of which precluded reliable analysis of Pocock 
risk score and ABCD2 risk score in predicting the presence of microemboli.  It may be that for a 
significant result to become clear, a greater number of patients is needed (i.e. there may be a 
type 2 error). 
My work has highlighted the risk of overlooking embolising symptomatic carotid artery disease 
patients based on the ABCD2 risk score alone. A multi-centre prospective observational study with 
a greater number of patients is needed to further evaluate the relationship between Pocock risk 
score, ABCD2 risk score and carotid-associated microemboli. 
 
8.3 Transorbital Imaging 
 
Evidence has consistently demonstrated the importance of TCD as a clinical tool for short term 
stroke risk stratification. The use of TCD in a general clinical setting is restricted by the lack of 
acoustic temporal window in a small proportion of patients and reliable automated microembolic 
signal identification software. Currently, the gold standard of microembolic signal identification 
relies on the combination of trained human observer and automated detection software to 
identify its audio and visual characteristics171. Previous inter-observer reproducibility study has 
reported a high reproducibility among trained observers in the detection of microembolic 
signals294. However, the review process of the recorded data for the presence of microembolic 
signal is time consuming and may limit its applicability in daily routine clinical environment. 
Therefore, an improved automated detection software which is sensitive and specific to 
microembolic signals is needed to reduce the dependency on trained human observer.  
A lack of temporal acoustic window remains the main technical limitation in undertaking TCD 
examination, even in the presence of a trained observer. The exclusion of patients due to a lack of 
temporal acoustic window can be found consistently in any TCD-based study including major 
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clinical trials32, 37, 217. The temporal bone acoustic window (TAW) is said to be absent or 
unsatisfactory in 10-15% of subjects although a figure as high as 29.1% is reported in the 
literature260, 261. The combination of the technical challenge of conducting the standard TCD 
examination and its limitations precluded its use as a routine part of carotid imaging in any 
vascular laboratory.  
Prior to my research, the transorbital Doppler approach has only been used as an alternative to 
the standard TCD in monitoring blood flow velocity 37, 262, 263 and it has been used to identify 
carotid arterial siphon stenosis. In our unit, the main purposes of postoperative monitoring was to 
identify microemboli and hyperperfusion syndrome. In those patients who lacked an acoustic 
temporal window, the transorbital approach was being used to monitor for hyperperfusion 
syndrome postoperatively only. Our vascular technologists have extensive experience with the 
transorbital Doppler approach as they also provide the regional service for the sickle cell anaemia 
screening programme in which this approach is also being used295. 
I used the Registry data as a proof of concept to demonstrate the feasibility of using the 
transorbital approach in detecting circulating microemboli. I demonstrated that using the 
combination of standard TCD examination and the transorbital technique, approximately 99% of 
patients were able to be monitored for microemboli240. I further expanded my work by setting up 
a prospective observational study to validate TOD against the standard TCD examination for 
microemboli detection. In the validation study, I demonstrated that TOD has good diagnostic 
agreement to detect microemboli with the standard TCD approach296. It also has a high sensitivity 
and specificity in detecting microemboli. These findings have reduced the technical limitations of 
using TCD as a clinical tool for risk stratification especially in those who lack of suitable acoustic 
temporal window. 
All previous studies of microemboli detection were based on the ipsilateral middle cerebral 
artery160. This is because the middle cerebral artery is the main branch of the carotid artery and 
corresponds to the most commonly affected area in ischaemic stroke22, 181, 182. In the TOD 
approach, the same ultrasonographic technique was used in a different anatomical site (i.e the 
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carotid siphon). TOD is not a direct replacement for standard TCD examination, but a valid 
alternative technique in those patients who do not have an acoustic temporal window. 
A future study should be another TOD validation study in a different centre to assess the inter-
observer agreement. The next stage would be to evaluate the difference in the clinical end point 
between microembolic detection by these 2 methods. 
 
8.4 Antiplatelet treatment 
There are two general key findings resulting from the analysis of the Registry data. Despite a 
general consensus that antiplatelet therapy is important in reducing perioperative cardiovascular 
complications for carotid endarterectomy, little is known about the type and optimal dose of 
antiplatelet agents required. The kinetics analysis of the microemboli detected in response to 
antiplatelet agents are invaluable in assessing the efficacy and effectiveness of antiplatelet agents 
in the non-randomised controlled trial setting.  
A single dose of aspirin administered an evening before carotid surgery has been reported to 
reduce postoperative stroke events297. Based on the NASCET data47, the risk of perioperative 
stroke and death was 1.8% for patients taking 650mg – 1300mg aspirin daily, compared with 6.9% 
for patients taking 0 – 325mg daily. Following this observation, a randomised controlled trial was 
set up to investigate the optimal dose of preoperative aspirin in patients undergoing carotid 
endarterectomy298. Patients were divided into a ‘low dose’ cohort receiving 81mg or 325mg 
aspirin daily, while those who received 650mg or 1300mg aspirin daily were considered the ‘high 
dose’ cohort. Surprisingly, the perioperative stroke, myocardial infarction and death rates were 
significantly lower in the ‘low dose’ cohort than the ‘high dose’ cohort. The data suggested that 
low dose aspirin is required for optimum cardiovascular protection in patients undergoing carotid 
endarterectomy. It has been suggested that the exposed non-endothelialised endarterectomy 
zone would act as a strong stimulus for platelet aggregation299. With additional effect of individual 
cardiovascular risk factor burden and insult to the arterial vessel and its surrounding tissue, one 
would expect patients who undergo carotid endarterectomy to require a larger dose of 
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antiplatelet agents. This finding may suggest an unknown mechanism related to the patient 
selection and its correlation with aspirin. The CAPRIE study300 demonstrated that the use of 
clopidogrel in patients with atherosclerotic vascular disease is more effective than aspirin in 
reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death. 
Subsequently, further randomised control trials have shown that the combination of clopidogrel 
and aspirin is superior to aspirin alone for reducing the risk of early recurrent stroke in high-risk 
patients with recent ischaemic stroke or transient ischaemic attack140, 141, 301. 
The emergence of TCD detected microemboli as a surrogate marker of short term stroke risk 
allows us to evaluate the efficacy of antiplatelet agents in randomised controlled trials. Tytgat et 
al216 have shown that a single preoperative dose of 120mg aspirin did not significantly reduce the 
microembolic rate during and after CEA. Markus et al37, 212 have demonstrated that the 
combination of clopidogrel and aspirin is superior to aspirin alone in reducing the frequency of 
microemboli and early recurrent stroke in symptomatic carotid artery disease. Payne et al217 also 
demonstrated the superior effect of the combination of clopidogrel and aspirin to aspirin alone in 
reducing the frequency of microemboli after carotid endarterectomy. However, the additional 
clopidogrel significantly prolonged wound closure, which was considered an indirect marker of 
haemostasis. Both aspirin and clopidogrel have irreversible platelet-inhibitory effects, therefore 
the risk of bleeding needs to be considered in choosing antiplatelet regimes. Li et al302 have shown 
that clopidogrel must be stopped for 10 days to achieve a normal platelet aggregatory response in 
comparison to 4 days for aspirin. The dose of platelets required to reverse the anti-aggregatory 
effect of aspirin is significantly lower than the dose required for clopidogrel. 
In my study, tirofiban (a reversible GPIIb/IIIa receptor inhibitor) was shown to be superior to 
dextran-40 and dual antiplatelet regime in treating microemboli176. This is unsurprising because it 
is a highly selective GPIIb/IIIa receptor inhibitor which is the final pathway of platelet aggregates. 
Despite using additional tirofiban, the risk of complications including bleeding was similar to the 
non-tirofiban cohort. This could be explained by the unique pharmacodynamic properties of 
tirofiban having a short half-life of only 2 hours. The SaTIS trial281 addressed the safety of tirofiban 
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especially bleeding risk in an open-label randomised controlled trial in acute ischaemic stroke 
patients.  Tirofiban was found to be safe in the acute ischaemic stroke setting and the risk of 
bleeding was comparable to the placebo cohort. 
Microembolic signals are much more common than clinical events. Previous studies have also 
confirmed that microemboli independently predict stroke in symptomatic carotid artery disease36 
and acutely following carotid surgery31. Therefore, the use of microemboli as a surrogate marker 
will reliably allow us to design a study with a smaller number of patients. This is reflected in 
previous TCD based studies which were designed to evaluate the efficacy of novel antiplatelet 
agents168, 174. Dawson et al303 investigated the relationship between aspirin resistance defined by 
platelet function tests and the presence of microemboli in symptomatic carotid artery disease 
patients. It showed that aspirin resistance appeared more common in patients with carotid 
disease who had microemboli compared to those without. This potential relationship between 
the presence of microemboli and antiplatelet resistance could be utilised as a powerful research 
or clinical tool.  
By using the Registry data on the kinetics of microemboli, I was able to demonstrate the efficacy 
of tirofiban compared to dextran-40 in a non-randomised trial setting. I was also able to assess 
the cessation duration of the microemboli in response to tirofiban and dextran-40. These data are 
very useful in designing future randomised controlled trials (appendix 1). The Registry data also 
demonstrated a small number of patients who despite already being on dual antiplatelet agents, 
developed a persistently high rate of microembolic signals requiring additional tirofiban. This 
information suggests the possibility of aspirin or clopidogrel resistance or different platelet 
aggregation activating pathways. Further studies are needed to evaluate the prevalence of 
aspirin/clopidogrel resistance in this cohort (appendix 2). It also emphasised the value of highly 
selective GPIIb/IIIa receptor inhibitors in symptomatic carotid artery disease patients who do not 
respond to conventional antiplatelet agents.   
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8.5 Conclusions 
The Pococks risk score has shown an association and high sensitivity for predicting the presence of 
microemboli following carotid surgery. However, the relationship between the Pocock score, 
ABCD2 score and cerebral microemboli in hyper-acute symptomatic carotid artery disease patients 
needs further evaluation. Transcranial Doppler should be part of the routine vascular laboratory 
examination to complement ABCD2 risk score in order to identify the high risk acute symptomatic 
carotid artery disease. With the discovery of the transorbital approach as an alternative to the 
standard transcranial Doppler in detecting microemboli, most patients would be eligible for 
microemboli screening. My report provides support for randomised controlled trials into the 
clinical and cost-effectiveness of tirofiban (a GPIIb/IIIa receptor inhibitor) and other antiplatelet 
agents in suppressing microemboli and reducing the incidence of stroke in patients with acute 
carotid syndrome.  
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Appendix 3 Antiplatelet therapy after carotid endarterectomy – The ANTIPACE Trial 
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Abstract 
Sustained transcranial Doppler detected cerebral microembolisation post carotid surgery has 
been shown to cause thrombotic stroke. Antiplatelet treatment has been shown to suppress 
cerebral microembolisation after carotid surgery. However, it is unclear the best strategy to 
suppress cerebral microemboli. Aspirin and clopidogrel are widely use, however there are 
concerns about the resistance of these agents in a significant minority of patients. Registry 
experience in our centre suggests that glycoprotein IIb/IIIa antagonist tirofiban is an effective 
option.  We therefore propose a randomised controlled trial to compare the efficacy of rescue 
tirofiban against rescue clopidogrel in patients who have cerebral microembolisation after 
endarterectomy despite background aspirin treatment 
 
Background 
The risk of recurrent stroke following first transient ischaemic attack (TIA) or stroke is highest in 
the first few weeks [1]. About 15 – 20% of strokes are caused by carotid artery stenosis and this 
has a high early risk of recurrent stroke compared with other subgroups such as cardioembolic 
and small vessel stroke [1]. The degree of carotid stenosis is strongly associated with stroke risk in 
symptomatic patients, and the mechanism of stroke is believed to be primarily embolic 
[2].Randomised controlled trials[2, 3] have shown carotid endarterectomy (CEA) is highly effective 
in reducing the risk of further strokes in moderate to severe carotid artery stenosis. However, 
carotid endarterectomy is associated with up to 7.5% risk of stroke and death at 30 days [4] . 
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Thromboembolism from the endarterectomised zone has been shown as the principal of 
mechanism of ischaemic stroke following carotid endarterectomy [5-10]. Human and animal 
studies have shown that platelet deposition is increased at the site of carotid endarterectomy [11, 
12]. The platelet nature and origin of embolism in this group was further confirmed when the 
endarterectomised site was re-explored [13-15] and by its response to antiplatelet agents. 
Despite quality control strategies to eliminate intraoperative stroke and minimise technical error, 
thromboembolism still causes 2-3 % of post carotid endarterectomy stroke [16].Strategies capable 
of reducing perioperative stroke will potentially improve the risk/benefit ratio and cost-
effectiveness of the operation.  
 
Transcranial Doppler (TCD) ultrasound is a non-invasive technique that can be used to detect 
platelet-based and thrombus microemboli [17-19]. Current aims of carotid imaging are 
assessment of luminal stenosis and classification of atherosclerotic plaque characteristics. Carotid 
duplex ultrasound has been the mainstay imaging in diagnosing carotid artery stenosis and the 
decision to proceed for carotid endarterectomy [20, 21]. Currently, Magnetic resonance imaging 
of the carotid plaque imaging is emerging as the treatment of choice in identification of unstable 
plaque features in patients with recent carotid thromboembolic symptoms [22]. 
The effectiveness of various antiplatelet agents in abolishing TCD detected cerebral microemboli 
following carotid endarterectomy have been evaluated in randomised controlled trials [23-26]. 
Unfortunately, there is no consensus on which antiplatelet agent is the most effective in reducing 
TCD detected cerebral microembolisation. With increasing prevalence of aspirin and clopidogrel 
resistance [27, 28], the search for the best antiplatelet agent or its combination to abolish 
microemboli is challenging. A combination of oral antiplatelet agents (aspirin and clopidogrel) 
appear to have reduced rather than abolished TCD detected cerebral microembolisation [25, 29]. 
Our pilot study [30] concurs with Junghans’s [19] finding that intravenous GPIIb/IIIa receptor 
antagonist (Tirofiban) resulted in complete suppression of TCD detected cerebral 
microembolisation. 
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Preliminary work 
We compared the effects on high rates of cerebral microemboli after carotid endarterectomy of 
the glycoprotein IIb/IIIa receptor antagonist tirofiban with the anti-thrombotic polysaccharide 
dextran-40. 
Based on our carotid surgery registry, we identified 100 subjects refractory to basal single anti-
platelet treatment given prior to surgery between August 2002 and December 2012. 
Anti-thrombotic treatment was given for MES ≥ 50/hr (Tirofiban in 32 patients (age 74±2 (SEM), 
males 23, Caucasian 31); dextran-40 in 32 patients (age 67 ± 2, males 21, Caucasian 28)). In 36 
patients with MES < 50/hr (age 71±1, male 23, Caucasian 34), MES were monitored during their 
spontaneous resolution (controls). Cardiovascular risk factor burden was similar between groups 
receiving tirofiban vs. dextran treatment. We assessed half-life of MES decay, time to resolution 
and cumulative MES. Data are median (IQR). Groups were compared by Mann-Whitney or 
Kruskal-Wallis tests as appropriate. 
The initial MES rate was similar in dextran (median 104/hr (IQR: 81-150) compared to tirofiban 
treated patients (96(69-136), P = 0.268, MW).  Times were shorter for tirofiban vs. dextran for 
50% reduction in MES (tirofiban: 23 minutes (15-30); dextran:  60 (40 – 83), P<0.001, MW) and for 
complete MES resolution (Tirofiban: 68 minutes (53-98); dextran: 113 minutes (71 – 154), 
P<0.001, MW). Cumulative MES shows similar differences (Tirofiban 45 MES (32 – 75); dextran 
103 MES (51 – 308); controls 12 MES (7 – 20), P = 0.001, KW). There were more early 
cardiovascular complications in patients who received dextran. Early event rates were low and 
similar for tirofiban treatment compared to no additional anti-platelet treatment. 
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 Results of MES rate after carotid endarterectomy in single antiplatelet therapy patients prior to 
surgery.    dextran-40 infusion (n = 28) for MES ≥ 50/hr.    MES ≥ 50/hr patients (n = 4) who 
developed early stroke despite dextran-40 infusion.    Tirofiban infusion (n = 32) for MES ≥ 
50/hr.     No additional antiplatelet treatment (n = 36) - MES < 50/hr. 
Analysis of our registry data suggests that TCD-directed tirofiban therapy is more effective than 
dextran-40 in rapid early suppression of cerebral microemboli after carotid surgery in patients 
refractory to basal antiplatelet treatment. 
 
Hypothesis 
Glycoprotein IIb/IIIa receptor is the final common step in platelet aggregation. There are several 
key genetic polymorphism influences which may make patients prone to the resistant pro drug 
clopidogrel.   Our hypothesis is that tirofiban would lead to more rapid and lower suppression of 
cerebral microemboli after carotid surgery compared with clopidogrel. 
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Aim 
In a double-blind, double placebo randomised controlled trial we aim to assess the relative 
efficacy of rescue tirofiban compare to clopidogrel in reducing cerebral microemboli after carotid 
endarterectomy in patients not responding to basal antiplatelet therapy. 
 
Primary end points 
1. Total number of microemboli to resolution within 3 hours monitoring period 
2. Time for microemboli to cease 
 
Secondary end points 
1. Proportion of patients that require rescue anti platelet treatment 
2. MRI scan evidence if cerebral ischaemic lesion 
3. All vascular events prior to discharge from hospital, 30 days and 12 months after the 
procedure. 
 
Objectives 
1. Monitor HITS by TCD or TOD for 3 hours after CEA  
2. Use MRI brain to monitor for evidence of cerebral emboli 
3. Pre-operative MRI imaging of surgical CEA site 
4. Assess genetic and functional markers of resistance to anti-platelet treatment 
 
Study design 
Double blind, double placebo randomised control trial 
 
Subjects 
Patients who undergo elective carotid endarterectomy. All recruited patients will be commenced 
on 75mg oral aspirin and other antiplatelet agents will be stopped 5 days prior to surgery. 
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Randomise process will be started when 2 or more microemboli identify in any 15 minutes period 
in the initial 3 hours after CEA. 
 
Transcranial Doppler ultrasound 
TCD monitoring [31] will be performed by an experienced vascular scientist (PC Dop 842, SciMed, 
Bristol, UK) with a 2 MHz probe focused on the middle cerebral artery ipsilateral to the operated 
carotid artery following recovery from anaesthesia. Microemboli will be identified as 
recommended by the International Consensus Group on Microembolus Detection [32]. Doppler 
wave forms and audio signals will be assessed by a trained vascular scientist. MES were identified 
as unidirectional, short duration signals (range 10–100 ms) with intensity threshold above 6 dB, 
accompanied by characteristic audible clicks and occurring randomly throughout the cardiac cycle 
[32, 33] 
 
Magnetic Resonance Imaging (MRI) of neck and brain  
The MRI of the neck will be using a standard neck coil. This will allow us to obtain sufficient 
resolution to image the plaque, to separate the fat from the surrounding tissues and to identify 
ulceration of the endothelial surface on these images. The brain will be imaged using both 
standard imaging and diffusion weighted imaging to best demonstrate the small areas of damage 
cause by the micro embolic events. Post-surgical imaging of the brain will be obtained to see if 
there is a significant difference in lesion characteristic following surgery [34].    
 
Assessment of resistance to anti-platelet treatment 
Assessment of platelet function is imperative in patients undergoing carotid endarterectomy as 
most of them are already on at least single antiplatelet agent. Those who on high on-treatment 
platelet reactivity will be at risk developing thrombotic stroke and low platelet reactivity will be at 
risk to develop bleeding intra or post carotid endarterectomy. Options available to assess platelet 
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functions are platelet aggregometry, Flow cytometry, Point of care platelet function assays 
(VerifyNow, Thrombelastogram)[35] 
 
Statistics 
a) Sample size estimation 
A sample size of 22 subjects per group is expected to give at least 80% power to detect a 
difference to one standard deviation in the total number of cerebral microemboli after carotid 
surgery at the 5% level (2 tailed test) with expected 90% participation rate. 
 
b) Statistical methods for data analysis 
Significance between the groups are determine using t-tests or Mann-Whitney U test for 
continuous variables and chi squared tests for categorical data with a p-value of <  
in 0.05 (2 – tailed) considered to represent significance. 
 
Expected value of results 
This randomised control trial will be an important step of establishing the efficacy of tirofiban in 
acute stroke syndrome. It allows us to compare the effectiveness of widely used antiplatelet 
agents such as aspirin and clopidogrel against tirofiban. This will enable us to form a more 
effective and focused strategy to abolish the cerebral microembolisation especially on those who 
have resistance to aspirin and clopiogrel. Whilst the point-of-care platelet function tests are not 
yet establish in clinical practice, the knowledge of effectiveness and safety of commonly used 
antiplatelet agents will be valuable. All of this will ultimately benefit patients with acute stroke 
syndrome in the UK, who will be given access to an effective antiplatelet treatment. 
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Appendix 4 Indices of aspirin response in patients with acute stroke syndromes 
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Professor Donald Singer, Clinical Pharmacology and Therapeutics 
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Wm Harvey Research Institute, QMUL: 
Professor Tim Warner, Platelet Biology & Vascular Inflammation 
 
Background: Cerebral microemboli are established biomarkers of risk of recurrent stroke in 
patients with carotid disease who present with an acute stroke syndrome and following carotid 
artery surgery (1).  
It is not clear what mechanisms determine which patients with carotid disease will develop 
microemboli. Patients with carotid disease may develop microemboli despite aspirin treatment. 
One explanation is poor adherence to treatment with aspirin previously prescribed to prevent the 
occurrence of clinical vascular events. Another reason may be failure to suppress platelet 
aggregation and activation despite aspirin treatment. 
 Aim: To assess biochemical indices of responsiveness to aspirin following an acute stroke 
syndrome 
Subjects: Patients within 2 weeks of an acute stroke syndrome attending the vascular lab for 
studies of carotid structure, flow and presence or not of cerebral microemboli. Patients will have 
given written informed consent. Exclusions are causes of cardiac sources of emboli including: 
heart valve disease, recent acute coronary syndrome (may result in formation of cardiac mural 
thrombus) and/or presence of atrial fibrillation. 
Design: Cohort study: sample size tbc 
228 
 
a) Patients with acute stroke syndrome with carotid disease and i) cerebral microemboli or ii) no 
cerebral microemboli;  
b) Patients with acute stroke syndrome with no carotid disease;  
c) Patients seen immediately before and after surgery for carotid endarterectomy 
d) Controls: patients with asymptomatic carotid disease identified as the incidental finding of 
carotid bruit(s). 
Methods:  
1. Clinical assessment according to standard clinical guidelines 
a) Phenotyping for clinical and laboratory cardiovascular risk factors, including full blood 
count with platelet indices (with MPV…), lipid profile, glucose, renal function, liver 
function 
b) ECG to exclude atrial fibrillation and recent cardiac ischaemia 
a) Blood pressure and heart rate 
b)  CT or (MRI) brain imaging 
2. Carotid studies 
a) Carotid imaging for plaque and flow on ipsilateral and contralateral side to symptoms and signs 
of presenting acute stroke syndrome. 
b) Imaging for cerebral microemboli by temporal trans-cranial Doppler [or by transorbital Doppler 
if the temporal bone window is unsuitable (2)]. 
c) Platelet-related studies 
a) Thromboxane assay in clotted whole blood. A 5ml blood sample will be collected into a glass 
tube and allowed to clot with the tube warmed to 37oC. Serum will then be removed and stored 
in a plain Eppendorf tube at -80oC until assay. Samples will be transferred on dry ice for assay in 
Professor Warner’s lab at the William Harvey Institute, QMUL. 
b) Thromboxane assay in urine. A 20ml sample of urine will be collected into a universal container 
and stored at -80oC until assay. Samples will be transferred on dry ice for assay in Professor 
Warner’s lab at the William Harvey Institute, QMUL. 
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c) Light transmission aggregometry.  
d) Response of platelets to aggregants. Platelet rich plasma (PRP) will be prepared by 
centrifugation.  
i) PRP aliquots will be added to wells in a 96 well plate (to be supplied by Professor Warner) 
containing increasing concentrations of multiple selective stimuli for platelet aggregation (3). 
After 15 minutes on a plate warmer with mixing at 1200 rpm, responses will be assessed on a 
plate reader. Dose responses to the above agents will then be prepared.  
ii) In selected patients, responses of PRP to standard stimuli will be assayed using a light 
transmission aggregometer.  
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